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Abstract		Trauma	is	a	leading	cause	of	death	worldwide	with	5.8	million	deaths	occurring	yearly.	Almost	40%	of	trauma	deaths	are	due	to	bleeding	and	occur	 in	the	first	few	 hours	 after	 injury.	 Of	 the	 remaining	 severely	 injured	 patients	 up	 to	 25%	develop	 a	 dysregulated	 immune	 response	 leading	 to	 multiple	 organ	 failure		(MOF).	 	 Despite	 improvements	 in	 trauma	 care,	 the	morbidity	 and	mortality	 of	this	 condition	 remains	 very	 high.	 Massive	 traumatic	 injury	 can	 overwhelm	endogenous	 homeostatic	 mechanisms	 even	 with	 prompt	 treatment.	 The	underlying	mechanisms	 driving	MOF	 are	 also	 not	 fully	 elucidated.	 As	 a	 result,	successful	therapies	for	trauma-related	MOF	are	lacking.			Trauma	 causes	 tissue	 damage	 that	 releases	 a	 large	 number	 of	 endogenous	damage-associated	molecular	patterns	(DAMPs).	Mitochondrial	DAMPs	released	in	trauma,	such	as	mitochondrial	DNA	(mtDNA),	could	help	to	explain	part	of	the	immune	 response	 in	 trauma	 given	 the	 structural	 similarities	 between	mitochondria	and	bacteria.	MtDNA,	like	bacterial	DNA,	contains	an	abundance	of	highly	 stimulatory	 unmethylated	 CpG	DNA	motifs	 that	 signal	 through	 Toll-like	receptor	(TLR)-9	to	produce	inflammation.	MtDNA	has	been	shown	to	be	highly	damaging	 when	 injected	 into	 healthy	 animals	 causing	 acute	 organ	 injury	 to	develop.	 Elevated	 circulating	 levels	 of	 mtDNA	 have	 been	 reported	 in	 trauma	patients	 but	 an	 association	 with	 clinically	 meaningful	 outcomes	 has	 not	 been	established	in	a	large	cohort.				
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The	first	aim	of	this	PhD	thesis	was	to	determine	whether	mtDNA	released	after	trauma	haemorrhage	 is	sufficient	 for	the	development	of	MOF.	Secondly,	 I	 then	aimed	to	determine	the	extent	of	mtDNA	release	with	varying	degrees	of	tissue	injury	 and	 haemorrhagic	 shock	 in	 a	 clinically	 relevant	 rodent	model.	 	My	 final	aim	was	to	determine	whether	neutralising	mtDNA	at	a	clinically	relevant	time	point	in	vivo	would	reduce	the	severity	of	organ	injury	in	this	model.																		
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Abbreviations	
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ERK	 Extracellular	–signal-related-kinase	FP	 Formyl(lated)	peptide	GAG	 Glycosaminoglycan	GAPDH	 Glyceraldehyde	3-phosphate	dehydrogenase	G-CSF	 Granulocyte	colony	stimulating	factor	Hb	 Haemoglobin	HDMBr	 Hexadimethrine	bromide	HMGB1	 High	mobility	group	box	1	protein	HLA	 Human	leukocyte	antigen	HR	 Heart	rate	HS	 Haemorrhagic	shock	HSP	 Heat-shock	protein	ICU	 Intensive	care	unit	IFI16	 Gamma	Interferon-inducible	protein	16	IFN	 Interferon	IL	 Interleukin	iNOS	 Inducible	nitric	oxide	synthase	ISS	 Injury	severity	score	LDH	 Lactate	dehydrogenase	LPS	 Lipopolysaccharide	MAP	 Mean	arterial	pressure	MAPK	 Mitogen-activated	protein	kinase	MOF	 Multiple	organ	failure	MODS	 Multiple	organ	dysfunction	syndrome	
	 12	
MPO	 Myeloperoxidase	MtDNA	 Mitochondrial	DNA	MyD88	 Myeloid	differentiation	factor	88	NaCl	 Sodium	Chloride		NAD	 Nicotinamide	adenine	dinucleotide	NASP	 Nucleic	acid	scavenging	polymer	ND	or	NADHD	 NADH	dehydrogenase	NDNA	 Nuclear	DNA	NET	 Neutrophil	extracellular	trap	NF-κB	 Nuclear	factor-κB	NLR	or	NLRP	 NOD-like	receptor	PAMAM-G3	 Polyamidoamine	dendrimer,	1,4-diaminobutane	core-PAMAM-G3	PAMP	 Pathogen-associated	molecular	pattern	PBS	 Phosphate	buffered	saline	PCR	 Polymerase	chain	reaction	pDC	 Plasmacytoid	dendritic	cell	PE	 Polyethylene	PRR	 Pattern	recognition	receptor	PRBC	 Packed	red	blood	cells	RAGE	 Receptor	for	advanced	glycation	end	products	RCT	 Randomised	controlled	trial	RNA	 Ribonucleic	acid	rRNA	 Ribosomal	RNA	
	 13	
ROS	 Reactive	oxygen	species	SIRS	 Systemic	inflammatory	response	syndrome	SOP	 Standard	operating	procedure	STAT	 Signal	transducer	and	activator	of	transcription	STING	 Stimulator	of	interferon	genes	Taq	 Thermus	aquaticus	TFAM	 Mitochondrial	transcription	factor	A	T-HS	 Trauma-Haemorrhagic	shock	TIR	 Toll-interleukin	1	receptor	TLR	 Toll-like	receptor	TNF-alpha	 Tumour	necrosis	factor-alpha	TOM	 Translocase	of	outer	mitochondrial	membrane	
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Measurements	and	units		bp	 Base	pair	°C	 Degree	celsius	h	 Hour	g	 Gram	HR	 Heart	Rate	IU	 International	unit	MAP	 Mean	arterial	pressure	mg	 Milligram	min	 Minute	μL	 Microlitre	mL	 Millilitre	mmHg	 Millimetres	of	mercury	μM	 Micromolar	mM	 Millimolar	OD	 Optical	density	%	 Percentage								
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Miscellaneous	terms		ANOVA	 Analysis	of	variance	e.g.	 For	example	i.e.	 That	is	i.p.	 Intraperitoneal	i.v.	 Intravenous	n	 Number	of	animals	SEM	 Standard	error	of	the	mean																	
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The	Scale	of	the	Problem	of	Trauma	Haemorrhage		
According	to	the	latest	data	from	the	World	Health	Organisation	(WHO),	trauma	accounts	 for	 10%	 of	 deaths	 and	 16%	 of	 disabilities	 worldwide	 (World	 Health	Organization,	2014).	It	is	the	leading	cause	of	death	globally	in	ages	1	to	44.	Road	traffic	accidents	account	for	the	majority	of	trauma	deaths	worldwide,	with	over	1	million	deaths	occurring	per	 year.	There	 is	 a	huge	preponderance	of	 trauma	related	 mortality	 in	 the	 developing	 world	 with	 90%	 of	 road	 traffic	 deaths	occurring	 in	 this	region.	This	disease	 is	also	associated	with	huge	 financial	and	societal	 burdens.	Global	 costs	 are	 estimated	 to	 exceed	US$500	billion	per	 year	and	this	is	likely	an	underestimate	due	to	loss	of	earnings	of	the	injured	and	their	families,	 medical	 expenses,	 insurance	 costs,	 etc.,	 not	 being	 taken	 into	 account	(Surgeons,	2012).		
“In	England,	it	is	estimated	that	there	are	at	least	20,000	cases	of	major	trauma	each	 year	 resulting	 in	 5,400	 deaths	 and	 many	 others	 resulting	 in	 permanent	disabilities	 requiring	 long-term	 care.	 There	 are	 around	 a	 further	 28,000	 cases	which,	 although	 not	meeting	 the	 precise	 definition	 of	major	 trauma,	would	 be	cared	 for	 in	 the	 same	 way.	 It	 is	 estimated	 that	 major	 trauma	 costs	 the	 NHS	between	 £0.3	 and	 £0.4	 billion	 a	 year	 in	 immediate	 treatment.	 The	 cost	 of	 any	subsequent	 hospital	 treatments,	 rehabilitation,	 home	 care	 support	 or	 informal	carer	costs	are	unknown.	The	estimate	of	annual	lost	economic	output	as	a	result	of	major	trauma	is	between	£3.3	billion	and	£3.7	billion”	(Morse	et	al.,	2010).	
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The	Trimodal	Death	Distribution	in	Trauma	Haemorrhage		Death	due	to	trauma	haemorrhage	occurs	in	one	of	three	time	periods	(Trunkey,	1983).	The	first	peak	(’immediate	deaths’)	occurs	within	seconds	to	minutes	of	the	 injury	 and	 accounts	 for	 30-40%	 of	 all	 deaths	 in	 the	 trauma	 cohort.	 Death	results	from	apnoea	due	to	severe	brain	or	high	spinal	cord	injury	or	rupture	of	the	 heart	 or	 great	 vessels.	 These	 deaths	 can	 be	 minimised	 only	 through	preventative	 measures	 such	 as	 improved	 road	 safety	 and	 the	 use	 of	 personal	protective	apparatus.	The	second	peak	(‘early	deaths’)	occurs	within	minutes	to	several	hours	after	injury	and	encompasses	the	so-called	‘golden	hour’	of	trauma.	This	 peak	 accounts	 for	 20-30%	 of	 trauma	 deaths.	 Rapid	 assessment	 and	resuscitation	during	this	period	to	identify	and	treat	the	causes	of	death	in	this	group,	 e.g.	 subdural	 and	 extradural	 haemorrhage,	 haemopneumothorax,	ruptured	spleen,	 liver	lacerations,	pelvic	fractures	and	other	injuries	associated	with	 large	 blood	 loss,	 can	 prevent	 early	 death.	 The	 third	 peak	 (‘late	 deaths’)	occurs	several	days	to	weeks	after	the	injury	and	is	generally	due	to	deaths	from	multiple	 organ	 failure	 and	 sepsis.	 This	 peak	 accounts	 for	 10-30%	 of	 trauma	deaths.			
Definitions	in	postinjury	multiple	organ	failure		There	are	four	different	scoring	systems	for	MOF:	Denver	MOF	score,	Knaus	MOF	score,	SOFA	score	and	Marshall	score.	The	most	frequently	used	and	validated	is	the	Denver	MOF	 score,	which	 is	 defined	 as	 two	 or	more	 organ	 systems	 failing	greater	 than	 48h	 after	 a	 significant	 injury	 to	 exclude	 reversible	 derangements	
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due	to	incomplete	resuscitation	(Dewar	et	al.,	2009).	Multiple	organ	dysfunction	syndrome	(MODS)	is	reversible	organ	dysfunction	within	the	first	48h	of	injury	as	 opposed	 to	 persistent	 MOF,	 and	 is	 common	 during	 resuscitation	 and	 often	resolves	during	the	first	48h	(Ciesla	et	al.,	2004).	Severe	trauma	is	defined	as	an	Injury	Severity	Score	(ISS)	greater	than	15	(Baker	et	al.,	1974).		
Changing	aetiology	of	postinjury	MOF			There	 is	evidence	 to	suggest	 that	 improvements	 in	resuscitation	strategies	and	ongoing	care	are	translating	into	better	outcomes	for	trauma	patients	(Sauaia	et	al.,	2014,	Schoeneberg	et	al.,	2014,	Fröhlich	et	al.,	2014).	These	strategies	have	largely	been	based	on	the	experience	of	the	U.S	Military	in	Iraq	and	Afghanistan	in	 dealing	 with	 traumatic	 injury	 over	 the	 last	 20	 years,	 which	 has	 steadily	transferred	 to	 civilian	 trauma	 practice	 (Glassberg	 et	 al.,	 2014,	 Haider	 et	 al.,	2015).	 Such	 damage-control	 resuscitation	 includes	 the	 use	 of	 permissive	hypotension	 (acceptance	of	 a	 lower	perfusion	pressure	during	 rapid	 control	of	bleeding),	 avoidance	of	 large	 volumes	of	 crystalloid	 or	 colloid,	 use	 of	 balanced	ratios	 of	 blood	 products	 during	 massive	 blood	 transfusion,	 damage	 control	surgery	 and	 ongoing	 ICU	 based	 resuscitation	 to	 reverse	 the	 physiologic	 insult	(Haider	 et	 al.,	 2015).	 Adjuncts	 such	 as	 topical	 haemostatic	 agents	 and	interventional	 radiological	 approaches	 are	 also	 becoming	 more	 commonplace	(Gruen	 et	 al.,	 2012).	Damage	 control	 surgery	was	 initially	practiced	 in	 the	 late	1980’s	as	an	effective	and	safe	way	of	dealing	with	abdominal	trauma	(Rotondo	et	al.,	1993).	The	same	techniques	were	found	to	be	beneficial	for	the	treatment	of	 pelvic	 and	 long	 bone	 fractures	 of	 multiply	 injured	 patients.	 Prolonged	
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definitive	surgery	in	critically	ill	patients	was	recognised	as	a	‘second	hit’	which	added	a	further	physiological	insult	and	worsened	outcomes	(Pape	et	al.,	1999).	In	critical	care,	the	use	of	low	tidal	volume	lung	protective	ventilation,	restrictive	blood	transfusion	and	restrictive	fluid	strategies	are	examples	of	the	increasingly	described	paradigm	of	‘less	is	more’	which	has	improved	overall	outcomes	over	the	last	15	years,	at	least	in	part,	by	reducing	iatrogenic	harm	(Marik,	2014).	It	is	unclear	to	what	extents	both	damage	control	resuscitation	and	bundled	critical	care	 strategies	 have	 made	 an	 impact	 on	 outcomes.	 	 There	 has	 been	 heavy	reliance	on	 retrospective	analysis	of	prospectively	 collected	observational	data	and	before-after	studies	 to	make	 the	case	 for	 their	use	 in	bundled	 trauma	care	(Cuschieri	et	al.,	2012,	Johansson	et	al.,	2014).			However,	 several	 prospective	 epidemiological	 studies	 have	 shown	 that	 the	overall	mortality	 of	 severe	 trauma	 and	 incidence	 of	 postinjury	MOF	 has	 fallen	over	 the	 last	 25	 years.	 Evidence	 for	 a	 decline	 in	 overall	 mortality	 has	accumulated	 over	 time.	 A	 large	 prospective	US	 study	 of	 1344	 severely	 injured	trauma	patients	cited	no	overall	change	in	mortality	over	the	period	from	1992	to	 2003,	 averaging	 8%	 over	 the	 study	 period	 (Ciesla,	 2005).	 However,	 a	 large	prospective	 German	 study	 over	 the	 period	 from	 1993	 to	 2005	 showed	 a	reduction	 in	 mortality	 from	 22.8%	 to	 18.7%	 (Ruchholtz	 et	 al.,	 2008).	 A	 more	recent	 US	 study	 of	 1643	 patients	 over	 the	 period	 2003	 to	 2010	 showed	 a	progressive	 decline	 in	mortality	 from	 23.9%	 to	 10.5%	 (The	 Inflammation	 and	Host	Response	to	Injury	Glue	Grant	Study	(Sauaia	et	al.,	2014)).			
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The	incidence	of	MOF	has	also	fallen	over	this	period.		The	adjusted	OR	in	1992	was	1.8	times	greater	than	 in	2002	with	a	25%	mean	overall	 incidence	(Ciesla,	2005).	 The	 incidence	was	 17%	 in	 2003-2004	 and	 decreased	 to	 9.8%	 in	 2009-2010	(Sauaia	et	al.,	2014)	with	a	 	mean	overall	 incidence	of	15%	(Dewar	et	al.,	2013).		The	rate	of	MOF-related	death	has	remained	largely	unchanged,	however,	hovering	between	24%	(Dewar	et	al.,	2013,	Ciesla,	2005)	and	30%	(Sauaia	et	al.,	2014).	Most	MOF-related	deaths	occur	within	the	first	week	of	injury	(Sauaia	et	al.,	2014,	Ciesla,	2005).		Direct	 comparison	 of	 the	 large	 numbers	 of	 studies	 is	 problematic	 due	 to	confounding	 factors	 such	as	 age,	 variable	degree	of	 traumatic	 injury,	degree	of	shock	 at	 presentation,	 preponderance	 of	 penetrating	 vs.	 blunt	 injury	 and	exclusion	 or	 inclusion	 of	 very	 high	 risk	 patients	 such	 as	 those	with	 significant	head	injuries	(Table	1.1).	Also,	different	scoring	systems	of	MOF	have	been	used	in	 different	 studies.	 In	 many	 studies,	 the	 definition	 and	 inclusion	 criteria	 of	severe	 trauma	vary	 considerably.	An	 ISS	 score	 greater	 than	15	 alone	has	been	the	only	inclusion	criterion	in	several	large	studies	and	this	has	been	criticised	as	being	 too	 limited	 and	with	poor	 correlation	 to	 outcome	 (Paffrath	 et	 al.,	 2014).		The	addition	of	more	comprehensive	entry	criteria	such	as	shock	variables,	blunt	vs.	 penetrating	 injury	 discriminators	 and	 inclusion/exclusion	 of	 isolated	 head	injury	still	fail	to	accurately	predict	the	most	serious	outcomes	such	as	MOF.	The	independent	 predictors	 for	 these	 outcomes	 have	 changed	 reflective	 of	 our	increasingly	 elderly	 and	 multiply	 co-morbid	 population	 (Dewar	 et	 al.,	 2013).	Furthermore,	 standard	 operating	 procedures	 (SOPs)	 within	 and	 between	different	 countries	 have	 been	 highly	 variable	 over	 time.	 Changes	 in	 patient	factors,	 injury	 factors	 and	 treatment	 factors	 have	 been	 cited	 to	 explain	 the	
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improvement	 or	 lack	of	 improvement	 in	 overall	mortality	 or	MOF	mortality	 in	severe	 trauma	over	 the	 last	20	years	 (see	Figure	1.1)(Dewar	et	al.,	2009).	 	For	example,	 the	 increasing	 incidence	 of	 severe	 trauma	 as	 a	 result	 of	 greater	numbers	 of	 road	 traffic	 accidents	 worldwide,	 increasing	 age	 of	 patients	 with	multiple	 co-morbidities	 and	 higher	 ISS	 at	 presentation	 are	 seemingly	 pitted	against	the	benefits	of	better	organised	trauma	systems,	improving	technology	to	stem	bleeding,	 better	 resuscitation,	 and	 bundled	 critical	 care	 that	 has	 reduced	the	 progression	 to	 MOF	 (Sauaia	 et	 al.,	 2014,	 Dewar	 et	 al.,	 2013,	 Dewar	 et	 al.,	2009,	 Ciesla,	 2005,	 Cuschieri	 et	 al.,	 2012,	 Johansson	 et	 al.,	 2014).	 Overall,	 it	appears	 that	 the	 latter	 factors	 are	 gaining	 ground	 to	 account	 for	 recent	improvements	in	outcomes.		
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 Fig.	1.1.	Multifactorial	aetiology	of	MOF.	The	complexity	of	the	aetiology	of	MOF	can	be	described	by	patient	factors,	injury	factors	and	treatment/second-hit	factors.	From	Dewar	et	al.	(2009)	
	
	
	
	
	
	 24	
Author,	year	
(Prosp/Retro)	
Study	
period	
Patient	
Numbers	
(n)	
Overall	
Mortality	
(%)	
MOF	
Incidence	
(%)	
MOF	
Mortality	
(%)	
Average	
ISS	
(Faist	et	al.,	1983)	(P)	 1978-82	 433	 18	 7.8	 56	
		
(Champion	et	al.,	1990)	(R)	 1982-87	 80,544	 9	 	 	
	
(Regel	et	al.,	1995)	(R)	
1972-81	 3406	 37	 7.9	 18.6	 	1982-91	 22	 12.4	 	
(Moore	et	al.,	1996)	(P)	 1990-94	 457	 8.3	 15	 36	
	25.1	
(Sauaia	et	al.,	1998)	(P)	 1991-95	 411	 8.5	 19	 37	
	
(Antonelli	et	al.,	1999)	(P)	 1995	 181	 19	 	 	
	
(Nast-Kolb,	2001)	
1975-80	(R)	 317	 29	 15	 85	 	1981-85	(R)	 308	 20	 14	 86	1986-90	(R)	 246	 18	 17	 60	 	1991-97	(P)	 368	 12	 11	 56	
1998-99	(P)	 122	 14	 12	 33	 	
(Gannon	et	al.,	2002)	(P)	 1996-97	 22,323	 7	 	 	
	14	
(Guenther	et	al.,	2003)	(P)	 1993-98	 3814	 26.2	 	 	
	27	
(Ciesla,	2005a)	(P)	 1992-2003	 1344	 8	 25	 26.5	
	29	
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Author,	year	
(Prosp/Retro)	 Study	period	
Patient	
Numbers	
(n)	
Overall	
Mortality	
(%)	
MOF	
Incidence	
(%)	
MOF	
Mortality	
(%)	
Average	
ISS	
(Aldrian	et	al.,	2007)		(P)	 1992-2002	 501	 	
1992=15	 	 		2002=0	
(Frink	et	al.,	2007)	(P)	 1997-2001	 143	 14	 16.8	 58	
	25	
(Ulvik	et	al.,	2007)	(P)	 1998-2002	 325	 16.9	 47	 	
	24	
(Ruchholtz	et	al.,	2008)	(P)	 1993-2005	
11,	013	
						1993=22.8	2005=18.7		
	 	 23.9	
(Füglistaler-Montali	et	al.,	2009)	(P)	
2001-05	 237	 22.8%	 	 	 	29.5	
(Brattström	et	al.,	2010)	(P)	
	2007-08		
	164	 10.4	 40.2	 	 	24	
(Dewar	et	al.,	2013)	(P)	 2005-10	
	140	 6	 15	 24	 	30	
(Schoeneberg	et	al.,	2014)	(P)	
	2010-12		
373	
	2010=32.5	2011=18.4	2012=19.3	
	2010=32.1	2011/12=17		
	 	26.8-30	
(Fröhlich	et	al.,	2014)	(P)		
	2002-11		 31,154	
2002=18.1	2011=15.3	 2002=24.6	2011=31.5	 2002=42.6	2011=33.3	 	
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Author,	year	
(Prosp/Retro)	 Study	period	
Patient	
Numbers	
(n)	
Overall	
Mortality	
(%)	
MOF	
Incidence	
(%)	
MOF	
Mortality	
(%)	
Average	
ISS	
	(Paffrath	et	al.,	2014)	(P)	
1993-2011	 	45,350		 21.6	 	 	
		
	(Sauaia	et	al.,	2014)		(P)	 2003-10	 1643	 15	
2003-04=17	2009-10=9.8	 03-04=33	09-10=36	 32	
(Lee	et	al.,	2015)	(R)	
	2010-12		 915	 18.8	 n/a	 n/a	
	25.1	
Table	1.1.	 Clinical	 studies	 of	 patients	with	 severe	 trauma.	 (P)	Prospectively	 collected	data;	 (R)	Retrospectively	collected	data;	ISS	injury	severity	score;	MOF	multiple	organ	failure.																
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Trauma	Admissions	to	the	Royal	London	Hospital	(RLH)	
	The	RLH	 is	a	 large	 teaching	hospital	based	 in	East	London	and	 is	part	of	Barts	Health	NHS	Trust.	It	is	one	of	four	Major	Trauma	Centres	in	London	and	is	home	to	 London’s	 Air	 Ambulance.	 The	 Trauma	 Sciences	 unit	 at	 the	 RLH	 initiated	 an	ambitious	 prospective	 observational	 study	 in	 2008	 called	 the	 Activation	 of	Coagulation	and	 Inflammation	 in	Trauma	(ACIT)	study	 (which	 is	 still	ongoing).	ACIT	serves	as	a	platform	on	which	standardised	enrollment	of	trauma	patients	presenting	to	the	ED	occurs	with	sequential	collection	of	blood	and	clinical	data.	This	 study	 has	 since	 been	 rolled	 out	 to	 other	 countries	 and	 provides	 a	 large	database	 that	 supports	multiple	 investigations	 into	 the	host	 response	 to	 injury	and	 treatment.	 Table	 1.2	 demonstrates	 demographic	 data,	 injury	 profiles	 and	outcomes	 for	 patients	 recruited	 into	 ACIT	 from	 2010	 to	 2015.	 Direct	 year-to-year	comparisons	are	problematic	due	to	the	evolving	enrollment	strategy	over	time.	Recently,	 there	has	been	a	greater	 focus	 in	 recruiting	more	of	 the	sickest	cohort	 of	 trauma	 patients.	 Table	 1.3	 demonstrates	 a	 deeper	 analysis	 of	 139	patients	 selected	 at	 random	 from	 the	 first	 367	 patients	 enrolled	 into	 ACIT	 in	2008-2009,	focusing	on	the	development	of	MOF.	In	agreement	with	much	of	the	literature,	 it	 shows	 that	 the	 risk	 of	 developing	MOF	 is	 higher	 in	 older	 patients	subjected	 to	 a	 blunt	 injury	 mechanism	 resulting	 in	 higher	 tissue	 injury	 and	shock.	MOF	itself	 is	shown	to	be	associated	with	higher	hospital	LOS,	 increased	incidence	of	nosocomial	infection	and	higher	28-day	mortality.				
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Parameter	
Year	
	
2010	
	
2011	 2012	 2013	 2014	 2015	ACIT	Patient	numbers		 	112		 129	 167	 214	 172	 148	Sex,	%	male		 79 87 84 79 83 76 Age,	years		 36	(23-50)	 33	(24-50)	 38	(26-52)	 35	(26-54)	 35	(24-53)	 37	(24-51)	ISS			 21	(10-29)	 17	(9-30)	 13	*	(5-27)	 13	**	(5-25)	 20	(9-29)	 20	(10-30)	Blunt,	%		 79	 76	 83	 80	 79	 78	MHP	Activation,	%		 33 18 ** 19 ** 18 ** 26 36 ED	Systolic	BP,	mmHg		 131	(106-150)	 127	(113-147)	 132	(116-149)	 136	(118-151)	 132	(111-148)	 126	(96-146)	ED	Lactate,	mmol/L		 2.3	(1.6-4.5)	 2.1	(1.3-3.5)	 2.3	(1.4-3.1)	 2.1	(1.4-3.3)	 2.2	(1.5-3.5)	 2.5	(1.5-4.3)	ED	Base	Excess		 -2.4	(-6.1,	-0.4)	 -1.3	*	(-4,	+1)	 -0.5	****	(-3.1,	+1.2)	 -0.4	****	(-3.1,	+1.6)	 -1.45	*	(-5.10.2)	 -2.2	(-6.1,+0.2)	Pre-ED	Clear	Fluids,	ml		 299	(+/-449)	 207	(+/-344)	 118	***	(+/-309)	 71	****	(+/-	247)	 151	*	(+/-	304)	 158	*	(+/-	310)	MOF,	%		 7.1	 23.2	***	 13.2		 13.6		 34	****	 34	****	Hospital	LOS,	Days		 13.5	(3.3-32.5)	 8	(3-29.5)	 6	**	(2-21)	 8	**	(1-19)	 10	4-30)	 11	(3-29)	28	Day	Mortality,	%		 11.6	 7.8	 8.4	 5.6	 14.5	 17.6	Table	1.2.	Demographic,	Injury	Characteristics	and	Outcomes	for	patients	recruited	into	the	ACIT	Prospective	 Observational	 Trial	 at	 the	 Royal	 London	Hospital	 2010-2015	 inclusive.	 	 A	 total	 of	10,685	 trauma	 activations	 occurred	 at	 the	 RLH	 during	 the	 period	 2010-2015	 inclusive.	 1036	patients	were	enrolled	into	the	ACIT	study	at	the	RLH	during	the	hours	of	08:00	and	22:00.	The	patient	or	next	of	kin	refused	consent	in	94	instances,	leaving	the	above	942	patients’	data	to	be	analysed	in	the	study.	This	does	not	represent	the	total	number	of	trauma	patients	presenting	to	the	RLH.	Furthermore,	the	recruitment	strategy	was	modified	over	time	to	capture	more	severely	injured	patients	 as	 can	be	 seen	by	 a	worsening	of	 physiological	 variables	 at	 presentation	over	time	 (bar	 2010	data)	 and	 an	 increase	 in	 the	 number	 of	 patients	 requiring	 an	 activation	 of	 the	MHP	(‘Code	red’).	ISS,	Injury	Severity	Score.	MHP,	MHP,	Major	Haemorrhage	Protocol	Activation	
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=	‘Code	Red’.	MOF,	Multiple	organ	failure,	defined	by	SOFA	score	>48	hours.	LOS,	Length	of	stay.	Averages	are	displayed	as	Median	values	(IQR)	except	for	Pre-ED	clear	fluid	volumes	represented	as	Mean	(+/-SD).	Appropriate	parametric	or	non-parametric	tests	are	applied	between	2010	data	and	other	columns.	*	p<0.05,	**	p<0.01,	***	p<0.001,	****	p<0.0001.		
 Control Died <48h NO MOFS MOFS p value 
Demographics      
n 16 11 85 27 - 
male (%) 75 73 82 93 0.03 
Age † 30 (24-40) 31 (24-45) 30 (22-44) 56 (33-67) < 0.01 
Injuries      
ISS † 4 (1-4) 30 (25-42) 12 (9-26) 29 (25-36) < 0.01 
Blunt (%) 88 91 26 96 < 0.01 
Time from injury (mins) 72 (65-92) 107 (96-114) 86 (73-107) 116 (104-120) < 0.01 
GCS at scene † 15 (15-15) 5 (3-11) 15 (14-15) 14 (9-15) < 0.01 
SBP in ED † 139 (123-150) 101 (87-136) 136 (117-150) 120 (96-148) 0.03 
BD in ED † 0.4 (-0.6 - 1.3) 8.0 (6.2-12.5) 2.0 (0.3-3.3) 5.0 (2.3-9.0) < 0.01 
Lactate in ED † 1.2 (0.9-2.1) 3.1 (2.3-9.5) 2.0 (1.4-3.0) 3.1 (1.4-4.5) 0.06 
Clear Fluids pre-ED † 0 (0-0) 1000 (375-2000) 0 (0-250) 500 (250-925) < 0.01 
AIS Head  † 0 (0-0) 3 (0-5) 0 (0-1) 2 (0-4) < 0.01 
AIS Face  † 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0.56 
AIS Thorax  † 0 (0-0) 4 (2-5) 2 (0-3) 4 (0-5) 0.01 
AIS Abdo & Pelvis  † 0 (0-0) 0 (0-1) 0 (0-0) 0 (0-2) 0.25 
AIS Extremity & Pelvis  † 0 (0-2) 1 (0-3) 2 (0-30) 3 (1-3) 0.08 
Immune response      
IL-6 pg/ml ‡ 21 (8-34) 590 (129-827) 70 (44-97) 434 (220-649) < 0.01 
Outcomes      
Length of stay † 4 (1-9) <48h 8 (3-20) 18 (10-27) < 0.01 
Acute Lung Injury <24h (%) 0 100 11 85 < 0.01 
Acute Lung Injury >48h (%) 0 - 1 93 < 0.01 
Mortality  (%) 0 100 0 22 < 0.01 
Infections (%) 0 - 8 67 < 0.01 
† median (IQR), ‡ mean (95% CI), ISS = Injury severity score, AIS = Abbreviated injury severity score, CSL = crystalloid fluid administered prior 
to blood draw. p value compares No MOFS and MOFS groups. 	Table	1.3.	Analysis	of	139	patients	according	to	the	presence	or	absence	of	MOF.	These	patients	were	picked	at	random	from	the	first	367	patients	recruited	into	the	ACIT	study	over	the	period	2008-2009.	 The	 ‘Control’	 group	 was	 arbitrarily	 defined	 as	 a	 low/minimal	 ISS	 with	 normal	physiological	parameters	on	admission	to	the	ED.	It	can	be	seen	that	the	development	of	MOF	is	preceded	by	a	high	ISS	(particularly	affecting	the	head	and	thorax)	and	the	presence	of	shock	on	arrival	to	the	ED.	It	is	also	more	common	in	the	elderly	and	in	the	presence	of	a	blunt	mechanism	of	 injury.	 The	 resultant	 outcomes	 in	 the	 presence	 of	 MOF	 are	 much	 worse,	 with	 longer	 LOS,	higher	rates	of	nosocomial	infection	and	higher	28-day	mortality.	
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Clinical	presentation	of	postinjury	MOF		The	 perfect	 storm	 of	 patient	 factors,	 injury	 factors	 and	 treatment	factors/potential	second	hits	as	outlined	in	Figure	1.1	can	lead	to	postinjury	MOF	in	up	to	25%	of	cases.		Isolated	overwhelming	tissue	injury	can	lead	to	MOF	but	more	commonly	there	is	a	combination	of	tissue	injury	and	haemorrhagic	shock.	Half	 of	 MOF	 cases	 occur	 within	 3	 days	 postinjury	 (Sauaia	 et	 al.,	 2014).	 Lung	failure	was	the	most	common	organ	failure	reported	in	up	to	99%	of	cases	at	a	median	of	Day	2	(IQR	2-3)	post	injury,	followed	by	cardiac	failure	at	Day	2	(IQR	2-4.5),	renal	failure	at	Day	3	(IQR	2-9)	and	then	liver	failure	at	Day	6	(IQR	4-9)	(Ciesla	et	al.,	2005).	The	presence	and	severity	of	lung	injury	has	been	shown	to	be	highly	associated	with	the	development	and	severity	of	MOF.	It	is	therefore	a	key	research	focus	in	the	treatment	of	postinjury	MOF.	Lung	failure	appears	to	be	decreasing	 in	 incidence	 over	 time	 (Sauaia	 et	 al.,	 2014)	 probably	 due	 to	 a	reduction	 in	 secondary	 lung	 injury	 as	 a	 result	 of	 more	 restrictive	 fluid	administration,	 lung	 protective	 ventilation	 and	 improved	 critical	 care	 overall	(Cuschieri	et	al.,	2012).			The	reasons	for	lung	failure	occurring	first	in	the	sequence	of	MOF	are	not	fully	elucidated.	Certainly,	ubiquitous	point	of	care	tests	(such	as	blood	gas	analysis)	allow	 frequent,	 sensitive,	 precise	 and	 timely	 diagnoses	 of	 respiratory	dysfunction	to	be	made.	However,	the	appearance	of	bilateral	infiltrates	on	chest	X-ray	 (CXR)	 is	 also	 required	 for	 the	 diagnosis	 of	 Acute	 Respiratory	 Distress	Syndrome	 (ARDS)(Ferguson	 et	 al.,	 2012).	Many	 clinical	 trauma	 studies	 do	 not	include	this	component	 in	 their	diagnosis	of	respiratory	 failure	and	rely	on	the	
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Pa02/Fi02	 ratio,	 which	 can	 result	 in	 a	 relative	 over	 diagnosis	 of	 lung	 failure.	Blood	pressure	 and	 cardiac	 output	monitoring	offer	 a	 similar,	 but	 less	precise,	diagnosis	 of	 cardiac	 dysfunction.	 Liver	 and	 renal	 function	 by	 comparison	 is	measured	intermittently,	often	daily,	with	nonlinear	associations	and	lag	times	of	the	 biomarkers	 with	 their	 corresponding	 organ	 dysfunctions.	 Aside	 from	diagnostic	difficulties,	 there	are	other	reasons	why	 lung	 failure	 is	postulated	to	occur	early	in	postinjury	MOF:			 1. The	highly	dense	capillary	network	of	the	lung	microcirculation	has	been	noted	 to	 be	 differently	 organised	 compared	 to	 other	 organs	 (Gil,	 2011)	and	therefore	may	be	more	susceptible	to	endothelial	damage	(Abrams	et	al.,	2013).		2. This	large	microvascular	circulation	contains	a	preponderance	of	immune	cells,	 largely	 neutrophils,	 carrying	 out	 surveillance	 of	 the	 air-lung	parenchymal	 interface	 to	 prevent	 inoculation	 of	 airborne	 pathogens	(Azad	et	al.,	2008).	During	severe	 trauma	and	haemorrhage,	 it	has	been	speculated	that	these	immune	cells	become	readily	primed	leading	to	the	development	of	a	local	unregulated	immune	response	and	resultant	lung	tissue	 damage,	 even	 in	 the	 absence	 of	 direct	 lung	 injury	 (remote	 organ	injury)	(Hazeldine	et	al.,	2014).	3. 	Trauma	 has	 been	 shown	 to	 induce	 the	 formation	 of	 neutrophil	extracellular	traps	(NETs),	which	are	composed	of	DNA	strands	attached	to	 a	 number	 of	 granules	 containing	 proteins	 with	 antimicrobial	properties.	 These	 form	 an	 extracellular	 matrix	 (Abrams	 et	 al.,	 2013,	Itagaki	 et	 al.,	 2015b,	 McIlroy	 et	 al.,	 2015).	 	 	 This	 process	 was	 initially	
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thought	 to	provide	antimicrobial	 killing	 independent	of	phagocytosis	by	delivering	 high	 local	 concentrations	 of	 antimicrobials,	 e.g.	 neutrophil	elastase	 and	 myeloperoxidase	 (Brinkmann,	 2004).	 	 However,	 in	 the	trauma	 setting,	 NET	 formation	 may	 increase	 the	 chance	 of	 neutrophils	becoming	 trapped	 in	 the	 lung	 microcirculation	 in	 particular,	 causing	microthrombosis	(Abrams	et	al.,	2013).		4. More	 recent	 animal	work	 has	 uncovered	 evidence	 that	 suggests	 that	 in	cases	of	blunt	chest	injury	leading	to	contusions,	neutrophils	are	diverted	to	 other	 sites	 of	 injury	 and	 away	 from	 the	 lungs,	 leaving	 the	 lungs	susceptible	 to	 pneumonia	 to	 further	 compound	 the	 initial	 direct	 lung	injury	 (Zhao	 et	 al.,	 2014,	 Haipeng	 et	 al.,	 2015).	 This	 mechanism	 may	partly	 explain	 the	well	 recognised	 ten-fold	 increased	 incidence	 in	 early	pneumonia	observed	clinically	in	trauma	patients	subjected	to	both	blunt	chest	and	abdominal	injuries	(Antonelli	et	al.,	1994).	5. Another	 postulated	 reason	 to	 explain	 lung	 susceptibility	 to	 injury,	somewhat	 paradoxically	 may	 be	 related	 to	 the	 high	 concentrations	 of	oxygen	in	lung	tissue	and	the	seeming	vulnerability	of	mtDNA	to	oxidative	damage	(compared	to	the	robustness	shown	by	nDNA).	MtDNA	is	known	to	 be	 between	 50	 and	 100	 times	 more	 sensitive	 to	 ROS-mediated	oxidative	 injury	 than	 nDNA.	 When	 cells	 or	 intact	 lung	 tissue	 are	challenged	 with	 ROS,	 mtDNA	 is	 extensively	 damaged	 but	 nDNA	 is	 not	(Schumacker	 et	 al.,	 2014).	 The	 reasons	 for	 this	 are	 unclear.	 Perhaps	mitochondria	act	 as	 the	 ‘canary	 in	 the	 coalmine’	 for	dangerous	 levels	of	oxidative	 injury	 which	 can	 then	 be	 promptly	 dealt	 with	 by	 triggering	localised	 mitochondria-mediated	 cell	 death	 to	 contain	 the	 insult.	 This	
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concept	 has	 been	 validated	 somewhat	 by	 the	 use	 of	 mitochondrially	targeted	 DNA	 repair	 protein,	 Ogg1,	 which	 acts	 to	 prevent	 oxidative	mtDNA	injury,	reduce	acute	lung	injury	and	improve	mortality	induced	by	Pseudomonas	lung	sepsis	in	rats	(Gorodnya	et	al.,	2011).			Approximately	 half	 of	 all	 late	 deaths	 are	 due	 to	 post	 injury	 MOF	 and	 these	patients	 have	 high	morbidity	with	 prolonged	 ICU	 stays	 (median	 LOS	 of	 18-19	days)	and	disproportionately	large	healthcare	costs	(Ciesla,	2005a,	Sauaia	et	al.,	2014).	MOF	onset	has	a	multimodal	distribution	suggestive	of	the	two-hit	model.	The	highest	peak	occurs	within	3	days	postinjury	(‘early	MOF’)	and	accounts	for	50%	of	 all	MOF.	 This	 group	 is	 responsible	 for	 25%	of	 the	 overall	MOF-related	mortality.	MOF	occurring	more	than	3	days	postinjury	(‘late	MOF’)	demonstrates	progressively	smaller	peaks	over	time	with	corresponding	lower	mortality	rates	(Sauaia	 et	 al.,	 2014).	 For	 example,	 MOF	 with	 onset	 at	 4-7	 days	 occurs	 in	approximately	25%	of	all	MOF	and	is	responsible	for	approximately	10%	of	the	overall	MOF	related	mortality.		MOF	with	onset	at	greater	than	7	days	occurs	in	approximately	25%	of	all	MOF	and	is	responsible	for	0%	of	the	overall	mortality	in	 the	 latest	 series.	 A	 septic	 second	 hit,	 most	 commonly	 ventilator	 associated	pneumonia,	 is	 generally	 required	 to	 progress	 to	 late	 MOF.	 The	 time	 interval	between	MOF	onset	also	follows	a	multimodal	distribution.	Approximately	60%	of	deaths	following	MOF	occur	within	2	days	of	the	diagnosis	and	80%	within	a	week	of	MOF	onset	(Sauaia	et	al.,	2014).				
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Overview	of	innate	and	acquired	immunity		Innate	immunity	enables	non-specific,	rapid	responses	to	protect	the	host	from	infection	 (or	 ‘damage’	 –	 the	 immune	 response	 to	necrotic	 tissue	has	 long	been	known)	that	may	not	have	been	previously	encountered	by	the	acquired	immune	system.	It	does	not	confer	long	lasting	protection.	It	is	an	ancient	evolutionarily	conserved	form	of	defense	and	its	sensors	are	encoded	in	the	germ-line	(Bianchi	and	Manfredi,	2009,	Majno	et	al.,	1960).			Acquired	immunity	is	dependent	on	antibody	formation	and	cytotoxic	T	cells	to	locate	 and	 destroy	 antigens	 in	 a	 highly	 specific	 manner.	 This	 process	 takes	several	 days	 to	 develop	 but	 long-term	 immunity	 to	 the	 same	 antigen	 ensues	(Bianchi	and	Manfredi,	2009).		
Pathophysiology	of	MOF		The	 systemic	 response	 to	 severe	 injury	 involves	 interactions	 across	 the	haemostatic,	 inflammatory,	 endocrine	 and	 neurological	 systems,	 aggravating	initial	 damage	 caused	 by	 shock	 and	 reperfusion	 (See	 Figure	 1.5).	 Endothelium	activated	by	exposure	to	cytokines	and	the	effects	of	complement	leads	to	loss	of	endothelial	 integrity,	 further	 inflammatory	 cell	 recruitment	 and	 adhesion,	increased	 vascular	 permeability	 and	 tissue	 oedema	 (Lord	 et	 al.,	 2014).	 Our	understanding	of	the	pathophysiology	of	the	MOF	syndrome	has	evolved	greatly	over	 the	 last	 thirty	 years	 from	 one	 based	 on	 presumed	 overwhelming	 early	infection	 (Fry	et	al.,	1980)	 to,	more	recently,	one	based	on	a	sterile	 innate	and	
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adaptive	 immune	 response	 to	 trauma	 leading	 to	 a	 dysregulated	 host	 immune	response	 and	 concurrent	 immune	 suppression,	 MOF	 and	 sepsis	 (Moore	 and	Moore,	1995,	Moore	et	 al.,	 2005,	Zhang	et	 al.,	 2010b,	Xiao	et	 al.,	 2011).	Earlier	study	 of	 inflammatory	phenotypes	 (Pape	 et	 al.,	 2007)	 has	 been	 superseded	by	sophisticated	 genomic	 studies	 of	 trauma,	 burns	 and	 septic	 populations.	 These	have	confirmed	that	the	immune	responses	to	these	varied	conditions	in	humans	are	 broadly	 similar	 and	 conform	 to	 this	 new	 paradigm	 (Xiao	 et	 al.,	 2011,	Davenport	et	al.,	2016,	Vincent,	2016,	van	Vught	et	al.,	2016,	Singer	et	al.,	2016).	Prior	 to	 the	 Glue	 Grant	 study	 15	 years	 ago,	 the	 generally	 accepted	 clinical	paradigm	 (Figure	 1.2	 left	 panel)	 described	 an	 initial	 phase	 of	 multiple-organ	dysfunction,	associated	with	a	systemic	inflammatory	response	syndrome	(SIRS)	followed	 by	 a	 compensatory	 response,	 termed	 the	 compensatory	 anti-	inflammatory	 response	 syndrome	 (CARS),	 in	 which	 phenotypic	 markers	 of	immunosuppression	could	be	demonstrated.	If	necrotic	tissues	remained	in	situ	or	 infections	occurred	(a	 ‘second	hit’),	 then	the	second	phase	of	multiple-organ	dysfunction,	CARS,	had	an	even	higher	rate	of	mortality.	However,	the	Glue	Grant	investigators	 found	 a	 different	 profile:	 an	 immediate	 genomic	 response	 that	triggered	up-regulation	of	the	innate	immune	response	and	a	down-regulation	of	the	 adaptive	 immune	 response.	 These	 transcriptional	 changes	 were	 more	marked	and	longer	lasting	in	the	complicated	patient	than	in	the	uncomplicated	patient.	The	benefits	and	risks	to	the	host	of	each	directional	change	are	likely	to	be	 complex	 and	 dynamic.	 For	 example,	 a	 primed	 innate	 immune	 system	 can	trigger	 excessive	 inflammatory	 cascades	 and	 greater	 local	 tissue	 damage	 but	with	the	benefit	of	increased	antimicrobial	defense.	Similarly,	suppression	of	the	adaptive	 immune	system	my	result	 in	greater	opportunistic	 infections	but	with	
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the	 benefit	 of	 suppression	 of	 trauma	 induced	 inflammation	 by	 limiting	 the	cellular	 immune	 response	 to	 tissue	 damage	 (which	 essentially	 produces	unprocessed	 self-antigens	 as	 a	 result	 of	 necrosis	 or	 severe	 cellular	 stress)	 and	the	 promotion	 of	 a	 natural	 healing	 response	 to	 restore	 immune	 homeostasis	(Stoecklein	et	al.,	2012).	It	is	likely	that	these	genomic	changes	translate	into	the	phenotypic	 changes	 of	 SIRS	 and	 CARS	 commonly	 seen	 in	 trauma	 critical	 care	patients.	Differences	 in	our	 traditional	understanding	of	 these	syndromes	have	emerged:	 the	 transcriptional	 responses	 leading	 to	 SIRS	 and	 CARS	 are	simultaneous,	 the	 CARS	 response	 is	 not	 a	 compensatory	 response,	 and	 the	transcriptional	 responses	 are	 persistent	 and	 do	 not	 come	 and	 go.	 This	 new	insight	 is	 important	 because	 these	 immune	 responses	 have	 been	 triggered	transcriptionally	 soon	 after	 injury.	 If	 an	 intervention	 intended	 to	 alter	components	 of	 the	 innate	 immune	 or	 the	 adaptive	 immune	 response	 is	administered,	then	it	is	most	likely	to	succeed	if	administered	as	soon	as	possible	after	injury.	
These	 studies	have	 also	highlighted,	 however,	 that	 there	 is	 poor	 correlation	 in	the	immune	responses	between	animals	and	humans.	Further	studies	should	be	able	 to	 better	 identify	 different	 phenotypes,	 leading	 to	 less	 heterogeneity	 in	randomised	 controlled	 trials	 of	 interventions	 and	 the	 delivery	 of	 increasingly	personalised	and	precise	treatment	(Vincent,	2016).				
	 37	
 
 
Figure	1.2.	(A)	Current	understanding	of	the	immune	response	after	trauma	describes	excessive	innate	 immune	 responses	 (as	manifested	by	 a	marked	pro-inflammatory	 response,	 termed	 the	Systemic	 Inflammatory	 Response	 Syndrome	 (SIRS))	 then	 followed	 by	 a	 period	 of	 suppressed	adaptive	immunity,	termed	Compensatory	Inflammatory	Response	Syndrome	(CARS).	A	2nd	hit	is	postulated	to	lead	to	further	magnified	‘hits’	and	‘counterhits’	leading	to	a	prolonged	complicated	outcome.	(B)	The	proposed	new	paradigm	involves	simultaneous	and	rapid	 induction	of	 innate	(both	 pro-	 and	 antiinflammatory	 genes)	 and	 suppression	 of	 adaptive	 immunity	 genes	 with	sustained	 responses	 of	 both.	 Complicated	 recoveries	 are	 delayed,	 resulting	 in	 a	 prolonged,	dysregulated	immune–inflammatory	state.	(Taken	from	(Xiao	et	al.,	2011)	
 			
Danger	theory	to	explain	the	immune	response	to	trauma		In	1994,	Matzinger	proposed	a	theory	labelled	‘danger	theory’	that	significantly	advanced	 our	 understanding	 of	 immune	 responses	 after	 both	 infections	 and	trauma.	It	postulated	that	immune	responses	are	caused	by	infectious	pathogens	(termed	pathogen	 associated	molecular	 patterns,	 PAMPs)	 as	well	 as	 danger	 or	alarm	signals	 (termed	damage	associated	molecular	patterns,	DAMPs)	released	from	the	body’s	own	cells	(See	figure	1.3).	 It	was	a	seismic	shift	 in	theory	from	the	 previous	 self-nonself	 theory	 which	 stated	 that	 only	 the	 presence	 of	
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genetically	 foreign	 material	 could	 stimulate	 an	 immune	 response	 (Matzinger,	1994).	Dedicated	pattern	 recognition	 receptors	 (PRRs)	 on	 innate	 and	 adaptive	immune	cells	recognise	either	PAMPs	or	DAMPs	leading	to	activation	of	antigen	presenting	 cells	 (APCs)	 and,	 crucially,	 provided	 the	 first	 definite	 evidence	 of	 a	link	 between	 innate	 immune	 activation	 and	 activation	 of	 specific	 adaptive	immune	responses	(Medzhitov	et	al.,	1997,	Kono	and	Rock,	2008,	Medzhitov	et	al.,	2011).	The	Toll-like	receptors	were	the	first	class	of	PRR	to	be	discovered	in	1994.	The	TLRs	remain	the	best	understood,	most	important	and	probably	most	potent	 of	 the	PRRs	 in	 propagating	 inflammation	 via	 chemotaxis,	 the	 release	 of	cytokines,	activation	of	complement,	antimicrobial	defenses	(neutrophil	elastase	release,	 reactive	 oxygen	 species	 (ROS)	 formation	 in	 neutrophils	 and	 NET	formation),	phagocytosis	and	adaptive	immune	cell	responses	(see	Figures	3	and	4).	Their	discovery	remains	one	of	 the	most	 remarkable	 in	 recent	decades	and	largely	validated	Janeway’s	earlier	pattern	recognition	theory	proposed	in	1989	(Janeway,	1989).	Remarkably,	both	PAMPs	and	DAMPs	appear	to	signal	through	broadly	 similar	 classes	 of	 PRR.	 This	 is	 probably	 due	 to	 common	 structural	elements	 to	 both	PAMPs	 and	DAMPs,	 namely,	 hydrophobic	 portions	 (‘hyppos’)	and	 the	 presence	 of	 nucleic	 acid,	 both	 of	 which	 are	 normally	 hidden	 within	healthy	cells.	The	expression	of	such	signals	doubtless	served	as	signs	of	damage	and	would	 have	 been	 very	 useful	 in	 early	 evolution	 and	 likely	 resulted	 in	 the	development	 of	 receptors	 for	 the	 ancient	 innate	 immune	 response	 (Seong	 and	Matzinger,	2004,	Matzinger,	2007).					
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Figure	 1.3.	 	 Discriminating	 between	 viable	cells,	necrosis	and	apoptosis.	The	hidden	self	model	 proposes	 that	 innate	 immune	 cells	have	 PRRs	 that	 detect	 DAMPs,	 which	 are	normally	 hidden	 in	 the	 interior	 of	 cells	 and	only	 revealed	after	necrosis.	This	model	 can	explain	 why	 live	 cells,	 which	 contain	 pre-existing	 danger	 signals,	 don’t	 stimulate	 the	innate	immune	system.	Necrotic	cells	always	lose	 membrane	 integrity	 and	 release	 their	intracellular	contents.	By	 contrast,	apoptotic	cells	 initially	 maintain	 membrane	 integrity.	However,	 if	 apoptotic	 cells	 are	 not	 rapidly	cleared,	 they	 undergo	 secondary	 necrosis	and	 become	 permeable.	 From	 Kono,	 Nat	Immunol	(2008)		
Figure	 1.4.	 Cell	 death	 and	inflammation.	 Necrotic	 cell	 death	releases	 intracellular	 DAMPs	 that	 are	recognised	by	 receptors	on	 leukocytes	stimulating	 the	 production	 of	 pro-inflammatory	 cytokines	 such	 as	 IL-1.	Other	 molecules	 that	 are	 exposed	 or	released	 from	 dead	 cells	 act	 on	extracellular	 components	 to	 generate	mediators	 or	 DAMPs	 that	 then	 trigger	the	 production	 of	 pro-inflammatory	cytokines	 by	 host	 cells.	 Inflammatory	mediators	 cause	 increased	 vascular	endothelium	 permeability	 and	 attract	neutrophils	 and	monocytes/macrophages.	 Soluble	(antibody)	 and	 cellular	 defenses	attempt	 to	 neutralise	 or	 contain	microorganisms	 if	 present.	 They	 also	clear	 dead	 cells	 and	 stimulate	 tissue	repair.	 From	 Kono,	 Nat	 Immunol	(2008)	
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Figure	 1.5.	 Activation	 of	 the	 immune	 system	after	 trauma	 and	 tissue	damage,	 accompanied	by	increased	susceptibility	to	infection.	 	Tissue	damage	leads	to	the	release	of	DAMPs	that	triggers	an	inflammatory	response	in	the	absence	of	infection.	Infection	is	associated	with	exposure	of	the	immune	system	to	a	range	of	non-self	molecules,	collectively	referred	to	as	PAMPs.	PAMPs	and	DAMPs	 stimulate	 cells	 of	 the	 innate	 immune	 system	 and	 complement,	 which	 can	 lead	 to	endothelial	and	organ	damage,	and	immunoparesis.	Organ	damage	and	sepsis	lead	to	the	release	of	further	DAMPs	and	exposure	to	further	PAMPs,	respectively,	resulting	in	a	vicious	cycle,	with	continued	inflammation	and	immune	activation.	From	Lord,	Lancet	(2014)	
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Important	sensors	of	the	innate	immune	system	recognising	PAMPs		
1. Toll-like	receptors		Ten	functional	TLRs	have	been	identified	in	humans,	twelve	in	mice	and	thirteen	in	rodents	(Table	1.5)	(Beutler	and	Rehli,	2002).	TLRs	are	type	I	transmembrane	proteins	with	ectodomains	containing	 leucine-rich	repeats	 (LRRs)	 that	mediate	the	recognition	of	PAMPs	and	DAMPs,	transmembrane	domains	and	intracellular	Toll-interleukin	 1	 (IL-1)	 receptor	 (TIR)	 domains	 required	 for	 downstream	signalling	 (Kawai	 and	 Akira,	 2011).	 When	 activated,	 TLRs	 recruit	 adapter	molecules	 within	 the	 cytoplasm	 of	 cells	 in	 order	 to	 propagate	 a	 signal.	 Four	adapter	molecules	have	been	identified:		1. Myeloid	differentiation	factor	88	(MyD88)		2. TIR	domain	containing	adaptor	protein	(TIRAP,	also	called	Mal)		3. TIR	domain	containing	adapter	inducing	interferon	β	(TRIF)	and		4. TRAM	(toll-like	receptor	4	adaptor	protein).			However,	TLR	signalling	generally	falls	into	two	distinct	signaling	pathways,	the	MyD88-dependent	 and	 TRIF-dependent	 pathway.	 MyD88	 is	 used	 by	 all	 TLRs	except	 TLR3	 and	 activates	 transcription	 factor	 NF-kB	 and	 mitogen-activated	protein	kinases	(MAPKs)	to	induce	inflammatory	cytokines	such	as	IL-6	and	IL-12	(Akira	et	al.,	2006).	Both	NF-kB	and	MAPKs	are	 inactive	 in	their	base	 forms	and	 require	phosphorylation	 steps	 for	activation,	 e.g.	NF-kB	 is	 complexed	with	its	 inhibitor,	 IkB,	 in	 its	 inactive	 form	in	 the	cytoplasm,	awaiting	dissociation	by	the	 phosphorylation	 and	 degradation	 of	 IkB.	 NF-kB	 then	 translocates	 to	 the	
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nucleus	 to	upregulate	proinflammatory	genes.	TRIF	 is	used	by	TLR3	and	TLR4	and	 leads	 to	 the	 activation	 of	 transcription	 factors	 IRF3	 and	 NF-kB	 with	 the	subsequent	 release	 of	 interferon	 and	 cytokines.	 TRAM	 and	 TIRAP	 are	 sorting	adaptors	that	recruit	TRIF	to	TLR4	and	MyD88	to	TLR2	and	TLR4,	respectively	(Kawai	and	Akira,	2010).		TLR1,	 TLR2,	 TLR4,	 TLR5,	 TLR6,	 and	 TLR10	 are	 located	 on	 the	 cell	membrane	surface,	 where	 they	 recognise	 known	 ligands	 corresponding	 to	 evolutionarily	conserved	 portions	 of	 pathogens	 (PAMPs).	 TLR3,	 TLR7,	 TLR8	 and	 TLR9	 are	located	 in	 intracellular	vesicles	such	as	endosomes,	endoplasmic	reticulum	and	lysosomes	where	they	recognise	nucleic	acids.	PAMPs	acting	at	TLRs	as	well	as	other	 PRRs	 are	 relatively	well	 characterised	 (see	 Table	 1.4).	 However,	 DAMPs	that	 act	 as	 ligands	 at	 TLRs	 and	 other	 PRRs	 are	much	 less	 well	 described	 and	understood	(Manson	et	al.,	2011).	
	Table	 1.4.	 PAMP	 detection	 by	 TLRs	 and	 other	 PRRs.	 Intact	 microbial	 pathogens	 are	 usually	composed	of	a	number	of	PAMPs,	which	activate	multiple	PRRs.	Moreover,	different	PRRs	may	recognise	the	same	PAMP.	From	Kawai,	Immunity	(2011)	
	
	 43	
	
Receptor	
Expression	 Ligand	 Ligand	
Location	
Adapter	 Location	
Humans	 Rats	 Mice	
TLR1	 Y	 Y	 Y	 Lipopeptides	 Bacterial	lipoprotein	 MyD88		MAL	 Cell	surface	
TLR2	 Y	 Y	 Y	 Lipopeptides	 Bacterial	peptidoglycans		 MyD88	MAL	 Cell	surface	Lipoteichoic	acid	 Gram	+ve	bacteria	HSP70	 Host	cells	
TLR3	
	 Y	 Y	 Y	 dsRNA	 Viruses	 TRIF	 Endosomes	
TLR4	 Y	 Y	 Y	 LPS	 Gram	–ve	bacteria	 MyD88	MAL	TRIF	TRAM	
Cell	surface	Glycocalyx	fragments	 Host	cells	HSPs,	HMGB1	 Host	cells	
TLR5	
	 Y	 Y	 Y	 Profilin	 Toxoplasma	gondii	 MyD88	 Cell	surface	Flagellin	 Flagellated	bacteria	
TLR6	 Y	 Y	 Y	 Lipopeptides	 Mycoplasma	 MyD88	MAL	 Cell	surface	
TLR7	
	 Y	 Y	 Y	 ssRNA	 RNA	Viruses	 MyD88	 Endosomes	
TLR8	 Y	 Y	 Y	 ssRNA	 RNA	Viruses	Bacterial	RNA	 MyD88	 Endosomes	
TLR9	 Y	 Y	 Y	 Unmethylated	CpG	DNA	ODN	DNA	
Bacterial	and	viral	DNA,	mtDNA	Immune	complex	DNA		
MyD88	 Endosomes	
TLR10	
	 Y	 Y	 N	*	 Unknown	 Influenza	virus	 MyD88	 Cell	surface	
TLR11	 N	*	 Y	 Y	 Profilin		 Toxoplasma	gondii	 MyD88	 Endosomes	Unknown	 Uropathogenic	bacteria	
TLR12	
	 N	 Y	 Y	 Profilin	 Toxoplasma	gondii	 MyD88	 Endosomes	
TLR13	 N	 Y	 Y	 23S	Bacterial	rRNA	sequence:	CGGAAAGACC	 Bacteria	esp.	Group	B	Strep	 MyD88	TAK-1	 Endosomes		Table	1.5.	Human	and	Rodent/Murine	Toll-like	receptors.	*Pseudogene:	TLR10/11	gene	present	in	mice/humans	but	 functional	TLR10/11	 is	not	expressed	due	to	the	presence	of	stop	codons.	ODN,	Oligodeoxynucleotide.			
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2. Non	Toll-like	receptors	that	recognise	PAMPs	
PRRs	other	than	TLRs	are	also	involved	in	PAMP	recognition	(Table	1.2)(Kawai	and	Akira,	2011):	
2.1. C-type	lectin	receptors	(CLRs)	are	membrane-bound	proteins	comprising	one	 or	 more	 C-type	 lectin-like	 domains	 which	 recognise	 fungal	 and	bacterial	PAMPs	2.2. NOD-like	receptors	(NLRs)	are	cytosolic	proteins	that	respond	to	PAMPs	and	result	in	inflammation.	Subsets	of	NLR,	NLRP1	(NALP1)	and	NLRP3	(NALP3),	 can	 form	 the	 inflammasome	 complex	 which,	 when	 activated,	results	in	caspase-1	activity	and	release	of	IL-1b	and	IL-18.	2.3. RIG-I-like	 receptors	 (RLRs),	 for	 example	 RIG-I,	 sense	 RNA	 in	 the	cytoplasm	and	results	in	Type	I	interferon	production.	2.4. Other	 receptor	 proteins	 that	 sense	 cytosolic	 DNA.	 DNA-dependent	activator	 of	 IFN-regulatory	 factors	 (DAI),	 Interferon-inducible	 protein	also	 known	 as	 absent	 in	 melanoma	 2	 (AIM2)	 and	 interferon-gamma	inducible	 protein	 16	 (IFI-16)	 are	 cytosolic	 dsDNA	 sensors	 and	 largely	induce	 type	 I	 IFN	 production.	 AIM2	 recognises	 dsDNA	 and	 promotes	assembly	of	the	inflammasome	which	induces	the	secretion	of	IL-1β	and	IL-18	(Kawai	and	Akira,	2011).					
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Trauma-induced	DAMPs		Traumatic	injury	can	lead	to	a	range	of	injury	from	cell	stress	(which	causes	the	active	 release	 of	 DAMPs	 from	 cells),	 apoptosis	 (which	 may	 lead	 to	 secondary	necrosis	 if	cellular	homeostasis	 is	overwhelmed)	and	frank	necrosis,	which	can	lead	 to	 the	 passive	 release	 of	 DAMPs	 (Medzhitov,	 2008,	 Timmermans	 et	 al.,	2016a).	 All	 three	 processes	 have	 the	 potential	 to	 release	 large	 amounts	 of	heterogeneous	endogenous	material	into	the	extracellular	space	(Kono	and	Rock,	2008).	 They	may	 or	may	 not	 act	 as	 DAMPs.	 Strict	 criteria	 for	molecules	 to	 be	genuine	 DAMPs	 have	 been	 proposed	 but	 relatively	 few	molecules	 accepted	 as	DAMPs	fulfill	all	these	criteria	(Kono	and	Rock,	2008,	Timmermans	et	al.,	2016a):		 1. The	molecule	is	released	rapidly	after	an	acute	event	2. The	 purified	 molecule	 should	 have	 immune-inflammatory	 activity	 at	relevant	pathophysiological	concentrations,	ideally	in	vivo	3. Its	 biological	 activity	 should	not	 be	 due	 to	 contaminants	 in	 the	purified	sample,	for	example,	bacteria,	endotoxin	or	other	proteins	4. Selective	 blockade	 of	 the	 DAMP	 should	 inhibit	 the	 biological	 activity	 of	dead	cells	in	in	vitro	and	in	vivo	tests	5. The	molecule	has	chemotactic	and	APC-activating	effects			The	 above	 strict	 criteria	 for	DAMP	 classification	 have	 resulted	 in	 complex	 and	contradictory	findings	coming	to	light	in	this	field.		
	 46	
	
Examples	of	trauma-induced	DAMPs		Hypoxia,	acidosis	and	shock	often	accompany	traumatic	injury	clinically	and	lead	to	a	range	of	insults	to	cells	from	mild	stress	to	frank	necrosis	(Harris	and	Raucci,	2006).	A	large	number	of	potential	DAMPs	have	been	detected	in	ex	vivo	cellular	models.	 This	 is	 a	 reasonable	 first	 experimental	 approach	 but	 often	 the	mechanism	 of	 cellular	 injury	 is	 poorly	 related	 to	 clinical	 traumatic	 injury.	 The	number	of	DAMPs	confirmed	in	in	vivo	models	is	significantly	smaller	(Manson	et	al.,	2011).	 	This	 is	due	to	the	greater	expense,	 technical	difficulty	and	ethical	concerns	associated	with	conducting	such	experiments,	especially	in	the	field	of	trauma	research.	Therefore,	there	is	a	highly	relevant	and	urgent	research	need	for	 clinically	 relevant	 animals	 models	 of	 trauma	 to	 further	 elucidate	 DAMP	immunology	 given	 the	 inherent	 difficulties	 of	 conducting	 such	 research	 in	humans.	 It	 is	 hoped	 that	 this	 research	 will	 deliver	 therapeutics	 to	 target	upstream	DAMP	signalling	to	limit	the	initial	‘critical	trauma	burden’	that	occurs	in	severe	trauma	haemorrhage.				1. High-mobility	 group	 box	 protein	 1	 (HMGB1)	 is	 a	 non-histone	 intracellular	nuclear	 DNA	 binding	 protein	 important	 in	 chromatin	 remodeling	 which	 is	released	 following	 trauma	 or	 actively	 secreted	 from	 severely	 stressed	 cells	(Venereau	et	al.,	2013).	HMGB1	has	been	detected	in	trauma	patients’	blood	and	correlates	well	with	injury	severity	and	adverse	outcomes	(Cohen	et	al.,	2009).	HMGB1	signals	through	TLR4	as	well	as	TLR2,	TLR9	and	the	receptor	for	 advanced	 glycation	 end	 products	 (RAGE),	 a	 non-PRR	 DAMP	 specific	
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receptor	 expressed	 abundantly	 in	 the	 lung	 in	 particular.	 RAGE	 recognises	highly	charged	molecules	including	HMBG1,	TFAM	and	glycoproteins	through	heparan	 sulphate-type	 charge	 interactions,	 rather	 than	 specific	 pattern	recognition.	It	is	a	cell	membrane	receptor	and	transports	antigens	internally	for	interaction	with	a	number	of	potential	damage	sensors,	e.g.	TLR9	(Julian	et	 al.,	 2013).	 Advanced	 glycation	 end	 products	 result	 from	 non-enzymatic	glycation	 and	 oxidation	 of	 proteins	 and	 lipids	 under	 conditions	 of	 high	oxidant	stress	(Chen	and	Nuñez,	2010).	Highly	purified	HMGB1	has,	however,	conferred	 low	 biological	 activity	 in	 some	 series	 (Tian	 et	 al.,	 2007,	 Tsan,	2011).	Other	studies	suggest	that	the	different	observed	activities	of	HMGB1	may	be	related	to	the	co-presence	of	certain	chemokines,	to	the	subsequent	binding	 of	 HMGB1	 to	 nDNA	 and/or	 to	 the	 variable	 redox	 state	 of	 HMGB1	itself	to	enable	immunostimulatory	activity	of	these	complexes	to	occur	(Tian	et	al.,	2007,	Bianchi,	2009,	Venereau	et	al.,	2013,	Magna	and	Pisetsky,	2016).	These	factors	explain	its	effects	in	vivo	but	HMGB1	does	not	fulfill	the	strict	criteria	to	be	classified	as	a	DAMP	in	isolation	(Bianchi,	2009).		2. Histones	are	highly	evolutionarily	conserved	small	polycationic	nuclear	basic	proteins	 that	 condense	DNA	 into	 units	 called	 nucleosomes	 (Freeman	 et	 al.,	2013).	Histones	also	play	a	major	 role	 in	gene	 regulation	with	active	genes	being	 less	 bound	 to	 histones.	 Histones	 provide	 protection	 from	 injury	 to	nuclear	DNA.	Histones	 are	 not	 associated	with	mtDNA	and	 this,	 along	with	the	close	proximity	of	mtDNA	to	cellular	ROS	generation,	is	part	of	the	reason	why	 mtDNA	 is	 more	 vulnerable	 to	 damage	 (Marín-García,	 2016).	Extracellular	histones	are	 found	 in	 trauma	 (Kutcher	et	 al.,	 2012,	Abrams	et	
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al.,	2013)	and	correlate	with	injury	severity	and	poor	outcomes.	They	act	as	bona	fide	DAMPs	due	to	their	affinity	for	phospholipid	components	of	the	cell	membrane	resulting	in	endothelial	disruption,	microvascular	thrombosis	and	inflammation	 (Freeman	 et	 al.,	 2013,	 Abrams	 et	 al.,	 2013).	 	 Extracellular	histone	has	been	shown	to	 interact	with	multiple	receptors	 including	TLR2,	TLR4	and	TLR9	and	through	activation	of	the	NLRP3	inflammasome	(Chen	et	al.,	2014).		3. Heat-shock	 proteins	 (HSPs)	 are	 produced	 by	 cells	 in	 response	 to	 a	 wide	variety	 of	 stressors	 (Wallin	 et	 al.,	 2002).	 HSP70	 has	 been	 found	 to	 be	persistently	elevated	in	a	large	series	of	trauma	patients	(Timmermans	et	al.,	2016b).	 HSPs	 have	 been	 shown	 to	 mediate	 the	 early	 adverse	 effects	 of	trauma	in	terms	of	acute	lung	injury	and	cardiovascular	instability	(Pespeni	et	 al.,	 2005,	 Stoecklein	 et	 al.,	 2012).	 Signalling	 has	 been	 identified	 as	 being	through	 TLR2,	 TLR4	 and	 RAGE.	 However,	 similar	 controversies	 as	 with	HMGB1	 exist	 as	 to	 the	 importance	 of	 HSPs	 as	 DAMPs.	 Previous	 work	 has	indicated	 that	 the	 immune	 effects	 of	HSPs	might	 be	due	 to	 the	presence	 of	contaminants	 such	 as	 endotoxin	 introduced	during	 the	purification	process	(Kono	and	Rock,	2008).			4. S100	 proteins	 are	 a	 family	 of	 small	 proteins	 that	 bind	 calcium	 and	 are	involved	in	a	wide	variety	of	processes	such	as	protein	phosphorylation,	Ca2+	homeostasis,	 and	 the	 inflammatory	 response.	One	of	 the	best-characterised	members	 is	 S100B,	which	 is	 found	 in	neural	 tissue	 and	 correlates	with	 the	degree	 of	 traumatic	 brain	 injury	 in	 humans	 (Leclerc	 et	 al.,	 2009,	Vos	 et	 al.,	
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2010).	S100B	signals	via	RAGE.		5. Components	of	 the	endothelial	glycocalyx.	This	 is	a	negatively	charged	anti-adherent,	 anticoagulant	 layer	 that	 coats	 and	 protects	 the	 endothelium	 and	maintains	 its	 barrier	 function.	 It	 is	 comprised	 of	 a	 proteoglycan	 backbone	consisting	 mostly	 of	 syndecan-1	 and	 glypican	 from	 which	 long	glycosaminoglycan	 (GAGs)	 side	 chains	 branch.	 GAGs	 consist	 mostly	 of	heparan	 sulphate,	 as	 well	 as	 chondroitin	 sulphate,	 dermatan	 sulphate,	keratin	 sulphate	 and	 hyaluronic	 acid	 (Alphonsus	 and	 Rodseth,	 2014).	Shedding	of	 these	anticoagulant	 glycocalyx	 constituents	 into	 the	 circulation	has	 been	 recorded	 in	 severe	 human	 trauma	 and	 is	 associated	 with	 mild	systemic	 heparin-like	 effects	 that	 might	 explain	 the	 early	 acute	 traumatic	coagulopathy	 that	 occurs	 (Ostrowski	 and	 Johansson,	 2012,	 Rahbar	 et	 al.,	2015).	 Damage	 to	 the	 glycocalyx	 reveals	 the	 underlying	 endothelium	 cell	adhesion	 molecules	 and	 promotes	 a	 vigorous	 inflammatory	 response	 with	leukocyte	 rolling	 and	 adhesion	 (Becker	 et	 al.,	 2010).	Heparan	 sulphate	 and	hyaluronic	 acid	 fragments,	 in	 particular,	 have	 been	 shown	 to	 have	 pro-inflammatory	 effects	 signalling	 through	 CD44,	 TLR2,	 TLR4	 and	 RAGE.	 This	lends	support	to	their	classification	as	extracellular	DAMPs	(Kono	and	Rock,	2008,	Julian	et	al.,	2013).		6. Mitochondrial	DAMPs	have	recently	been	 identified	as	 important	mediators	of	the	innate	immune	response	to	trauma	(Zhang	et	al.,	2010b).	This	is	likely	due	 to	 the	 structural	 similarities	 between	mitochondria	 and	 bacteria	 given	their	shared	ancient	origin,	as	per	the	endosymbiont	theory.		
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Endosymbiont	 theory	 -	 Ancient	 aerobic	 archeabacteria	 internalised	 by	 alpha-
proteobacteria	becoming	energy	producing	organelles	of	the	eukaryote	cell		The	 first	 living	 organisms	 that	 appeared	 on	 Earth	 3.7	 billion	 years	 ago	 were	single	celled	microbes.	These	organisms	were	classified	as	prokaryotes	(lacking	a	nucleus)	and	were	obligate	anaerobes,	as	oxygen	did	not	significantly	form	in	the	atmosphere	until	2	billion	years	ago,	reaching	current	levels	1.5	billion	years	ago.	 During	 this	 period,	 the	 first	 aerobic	 microbes	 emerged	 (likely	 an	 alpha-proteobacteria	 ancestor)	 and	 became	 engulfed	 but	 not	 destroyed	 by	 larger	anaerobic	microbes	(likely	an	ancestor	of	archeabacteria)	 to	produce	a	state	of	mutual	symbiosis	over	geologic	time	(de	Duve,	1996).	 	The	engulfed	organisms	benefited	 from	 the	 physical	 shelter	 of	 the	 larger	 organism.	 The	 engulfing	organism	 benefitted	 from	 the	 organelle’s	 ability	 to	 utilise	 oxygen	 and	 detoxify	harmful	compounds	created	by	the	rising	levels	of	atmospheric	oxygen	–	the	so-called	oxygen	holocaust.	Over	the	following	billion	years,	 the	precursor	aerobic	eukaryotic	organisms	(with	nucleus)	of	all	modern	animal,	plant	and	fungal	 life	developed.	 The	 endosymbiont	 theory	 similarly	 explains	 the	 emergence	 of	photosynthetic	 chloroplasts	 from	 ancient	 cyanobacteria	 whose	 ability	 to	generate	oxygen	brought	about	the	oxygen	holocaust	in	the	first	place	(de	Duve,	1996,	 Dyall,	 2004).	 Modern	 mitochondrial	 DNA	 shares	 many	 similarities	 with	bacterial	DNA	including	size,	circular	structure,	lack	of	association	with	histones	and	high	frequency	of	unmethylated	CpG	repeats	(>60%	frequency).	A	cytosine	nucleotide	 followed	 by	 a	 guanine	 nucleotide	 separated	 by	 one	 phosphate	 is	
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expected	 to	 occur	 by	 random	 chance	 with	 a	 frequency	 of	 4.4%	 in	 the	 human	genome.	 (By	 contrast,	 nuclear	 DNA	 has	 a	 CpG	 repeat	 frequency	 of	 only	 1%	representing	 so-called	 ‘CpG	 suppression’.)	 This	 provides	 the	 most	 compelling	evidence	of	the	endosymbiont	theory.	Further	support	is	suggested	by	the	facts	that	 both	mitochondria	 and	bacteria	 reproduce	 clonally	 and	not	 sexually,	 both	produce	 their	 own	 proteins	 with	 formyl	 methionine	 at	 their	 N	 terminus	 and	antibiotics	 that	 inhibit	 protein	 synthesis	 in	 bacteria	 are	 also	 effective	 against	mitochondria	 (Hubbard	 et	 al.,	 2004).	 The	 complete	 human	 mitochondrial	genome	was	sequenced	in	1981	(Anderson	et	al.,	1981).	It	is	16,569	base	pairs	in	length	and	contains	only	37	genes	coding	 for	2	ribosomal	RNAs	(12S	and	16S),	22	transfer	RNAs	and	13	formylated	proteins	–	all	subunits	of	enzyme	complexes	I,	 III,	 IV	 and	 V	 of	 the	 oxidative	 phosphorylation	 system	 embedded	 in	 the	mitochondrial	 inner	 membrane	 (7	 subunits	 of	 NADH	 dehydrogenase,	Cytochrome	 B,	 3	 subunits	 of	 Cytochrome	 oxidase	 c	 and	 2	 subunits	 of	 ATP	synthase	respectively).		A	human	mitochondrion	can	contain	up	to	ten	copies	of	its	 genome	 and	 cells	 can	 contain	 hundreds	 of	mitochondria.	 Mitochondria	 are	now	dependent	on	nuclear	gene	products	for	the	majority	of	their	structure	and	function	(Taanman,	1999).		
6.1. MtDNA	signalling	through	the	TLR9	pathway	in	trauma		
6.1.1. Clinical	studies	
	TLR9	 is	 the	 only	 known	 PRR	 for	 mtDNA	 and	 is	 found	 in	 a	 wide	 variety	 of	immune	 and	 non-immune	 cells	 including	 neutrophils,	 macrophages,	 dendritic	
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cells,	 hepatocytes,	 cardiomyocytes,	 neurones	 and	 endothelium.	 TLR9	 has	 been	shown	 to	 be	 a	 key	 driver	 of	 the	 inflammatory	 response	 after	 trauma	haemorrhage	(Zhang	et	al.,	2010b,	Zhang	et	al.,	2010a,	Gill	et	al.,	2011).	
MtDNA	 has	 been	 detected	 in	 trauma	 patients’	 blood	 in	 several	 studies	 and	correlates	 with	 initial	 injury	 severity	 as	 measured	 by	 ISS	 (Lam	 et	 al.,	 2004a,	Zhang	et	al.,	2010b,	Simmons	et	al.,	2013,	Gu	et	al.,	2013,	Yamanouchi	et	al.,	2013,	Khubutia,	2013,	Prikhodko	et	al.,	2015,	McIlroy	et	al.,	2015,	Itagaki	et	al.,	2015b,	Timmermans	 et	 al.,	 2016b).	 However,	 the	 small	 numbers	 of	 highly	heterogeneous	patients	 (bar	 the	 last	 study,	n=38,	15,	14,	86,	37,	25,	34,	35,	15	and	 166	 respectively)	 examined	 in	 these	 studies	 has	 meant	 that	 strong	correlations	of	mtDNA	levels	to	degree	of	shock	and	later	sequelae	such	as	MOF,	sepsis	 and	 mortality	 cannot	 be	 conclusively	 stated.	 The	 latest	 study	 by	Timmermans	 et	 al.	 (2016b)	 reported	 a	 relatively	 modest	 rise	 in	 mtDNA	 in	trauma	patients	(the	smallest	relative	rise	of	all	the	series	reported	here)	and	a	far	 larger	 rise	 in	nDNA	 levels.	Both	mtDNA	and	nDNA	were	 found	 to	 correlate	weakly	with	subsequent	susceptibility	to	infection	within	the	following	28	days	in	 this	 study.	 However,	 this	 was	 associated	 with	 increased	 survival	 overall.	NDNA	was	found	to	correlate	strongly	with	suppression	of	monocyte	HLA-DRA	mRNA	expression,	 indicating	a	generalised	immune	suppressed	state.	However,	no	 such	 correlation	 was	 found	 with	 mtDNA.	 Overall,	 firm	 conclusions	 and	causation	 cannot	 be	made	 from	 this	medium	 sized	 study.	 However,	 it	 appears	mtDNA	and	nDNA	are	associated	with	different	phenotypic	responses	in	the	post	trauma	patient.		
Composition	of	mtDNA	released	has	rarely	been	examined.	One	study	reported	a	
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preponderance	 of	 mtDNA	 in	 human	 trauma	 plasma	 corresponding	 to	 a	 gene	coding	 for	 the	 mitochondrial	 formyl	 peptide	 NADH	 dehydrogenase	 subunit	 6	(ND6)	and	suggested	this	was	associated	with	a	worse	outcome	(Simmons	et	al.,	2013).	 Interestingly,	 a	 rat	model	 of	 haemorrhagic	 shock	 showed	 an	 increased	concentration	 of	 this	 formyl	 peptide	 in	 plasma	with	 an	 associated	 lung	 injury	(see	later	section	on	formyl	peptides)(Wenceslau	et	al.,	2015).		
Two	studies	(Simmons	et	al.,	2013,	Yamanouchi	et	al.,	2013)	showed	some	utility	in	 correlating	 mtDNA	 with	 SIRS	 but	 this	 phenotypic	 description	 does	 not	conform	 to	 the	 current	understanding	of	 the	 immune	 response	 to	 injury,	 lacks	specificity	and	has	been	superseded	already	by	new	criteria	in	sepsis	(Shankar-Hari	et	al.,	2015,	Singer	et	al.,	2016).		
Different	mtDNA	extraction	techniques	and	lack	of	comparable	quantification	of	mtDNA	 concentrations	 across	 the	 studies	 has	 also	 limited	 their	 objective	comparison.	 Indeed,	 the	 range	 of	 mtDNA	 concentration	 in	 human	 trauma	 has	been	 reported	 to	 be	 as	 low	 as	 0.87ng/ml	 (Gu	 et	 al.,	 2013)	 and	 as	 high	 as	2.7μg/ml	 (Zhang	 et	 al.,	 2010b).	 There	 has	 also	 been	 a	 lack	 of	 relevant	 animal	models	 of	 trauma	 haemorrhage	 with	 only	 a	 handful	 of	 published	 studies	investigating	DNA	release	directly	or	indirectly	(Zhang	et	al.,	2010b,	Zhang	et	al.,	2010a,	Gill	et	al.,	2011,	Sodhi	et	al.,	2011).	None	of	these	studies	has	elucidated	how	 mtDNA	 correlates	 with	 varying	 tissue	 trauma	 and/or	 shock,	 surgical	interventions	 or	 the	 development	 of	 other	 outcomes	 such	 as	 sepsis,	 MOF	 and	survival.	 	 This	 is	 reflected	 in	 the	 lack	 of	 experimental	 and	 clinical	 therapeutic	interventions	 targeting	 mtDNA.	 Clearly,	 larger	 human	 studies	 and	 relevant	animals	studies	are	needed	to	address	these	issues.	
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Passive	release	of	a	huge	number	of	DAMPs	due	to	cell	rupture	and	necrosis	 is	expected	in	trauma.	Approximately	40%	of	the	new	peptides	that	appear	in	the	bloodstream	 have	 been	 demonstrated	 to	 be	 self-antigens	 (Tompkins,	 2015).	MtDNA	appears	soon	after	clinical	trauma	in	the	circulation	and	peaks	at	around	24	hours	after	 trauma	(Zhang	et	al.,	2010a,	Yamanouchi	et	al.,	2013,	Gan	et	al.,	2015b,	Lam	et	al.,	2004a).	MtDNA	correlates	with	markers	of	necrotic	cell	death	in	 trauma	 such	 as	 creatine	 kinase,	 supporting	 direct	 cell	 injury	 and	hypoperfusion	 of	 skeletal	 muscle	 as	 a	 mechanism	 of	 mtDNA	 release	 in	 the	immediate	post	trauma	phase	(Yamanouchi	et	al.,	2013).	However,	a	later	rise	in	mtDNA	 occurred	 at	 around	 3	 days	 in	 trauma	 patients	 (McIlroy	 et	 al.,	 2015).	There	 were	 no	 discernible	 correlations	 between	 plasma	 mtDNA	 levels	 and	markers	of	cell	necrosis	such	as	CK,	AST	and	LDH	at	this	stage.	Furthermore,	as	there	 was	 no	 associated	 rise	 in	 nDNA,	 this	 delayed	 rise	 in	 mtDNA	 has	 been	attributed	to	NETosis	(McIlroy	et	al.,	2015,	Itagaki	et	al.,	2015b).		
In	health,	plasma	nucleases	 rapidly	metabolise	DNA,	as	evidenced	by	 the	 rapid	decline	over	the	first	hour	 in	mtDNA	plasma	levels	after	an	 injection	of	mtDNA	into	a	healthy	animal	 (Zhang	et	al.,	2010a,	He	et	al.,	2015).	Hence,	 a	persistent	mtDNA	level	can	indicate	either	nuclease	impairment	or	ongoing	mtDNA	release.	Overall,	 the	mechanisms	of	 the	release	and	degradation	of	mtDNA	are	 far	 from	fully	elucidated.	
6.1.2. In	vivo	studies		
Seminal	work	undertaken	by	Hauser	 (Zhang	 et	 al.,	 2010b)	 revealed	 that	when	healthy	 rats	 were	 intravenously	 injected	with	 a	mitochondrial	 debris	 de	 novo	remote	moderate	acute	lung	injury	and	acute	liver	injury	developed	(Zhang	et	al.,	
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2010b,	 Hauser	 et	 al.,	 2010,	 Zhang	 et	 al.,	 2010a).	 This	 mitochondrial	 debris	inoculation	 was	 intended	 to	 simulate	 traumatic	 injury,	 mitochondrial	fragmentation	and	release	of	multiple	mitochondrial	DAMPs	into	the	circulation	at	 physiological	 concentrations.	 They	 confirmed	 that	 both	 mtDNA	 and	 formyl	peptides	 were	 involved	 in	 activating	 neutrophils	 via	 TLR9	 and	 FPR-1,	respectively,	 through	 the	 p38	 MAPK	 pathway.	 Such	 systemically	 primed	neutrophils,	 it	 is	 postulated,	 cause	 neutrophil	mediated	 local	 acute	 lung	 injury	due	 to	 its	 inherent	 susceptibility	 to	 injury	 (discussed	 earlier).	 Later	 studies	demonstrated	 that	 intravenous	 injections	 of	 purified	mtDNA	 alone,	 generating	physiological	 concentrations	of	 circulating	mtDNA	 found	 in	 trauma,	 resulted	 in	remote	de	novo	acute	lung	injury	in	healthy	animals	(Zhang	et	al.,	2014a,	He	et	al.,	2015,	Gan	et	al.,	2015a,	Wei	et	al.,	2015)	and	direct	acute	 lung	 injury	when	instilled	directly	into	the	trachea	(Gu	et	al.,	2015b).	The	mtDNA	source	(whether	extracted	 from	 fresh	mitochondria	or	generated	with	PCR	(Collins,	2004,	He	et	al.,	 2015)),	mtDNA	purity,	 lengths	 of	 the	 resultant	mtDNA	 fragments	 and	 total	amounts	 administered	 were	 not	 always	 described	 and	 varied	 considerably	 in	these	studies.	Therefore,	direct	comparisons	are	problematic.	 	 In	a	perfused	rat	lung	 study,	 exogenous	 purified	mtDNA	was	 shown	 to	 cause	 direct	 lung	 tissue	oxidative	 mtDNA	 damage	 and	 increased	 pulmonary	 endothelial	 permeability,	leading	to	acute	lung	injury	and	further	release	of	mtDNA,	leading	to	further	lung	injury	propagation	 in	a	 feed-forward	cycle	(Figure	1.6,	 (Kuck	et	al.,	2015).	This	could	 explain	 why	 severely	 injured	 trauma	 patients	 often	 progress	 to	 MOF	despite	 initial	 resuscitation	 and	 surgery,	 which	 fails	 to	 address	 the	 initial	triggering	 event.	 Clearly,	 limiting	 the	 initial	 circulating	 mtDNA	 load	 and	preventing	 oxidative	 mtDNA	 damage	 in	 this	 proposed	 feed-forward	 cycle	 are	
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potential	novel	avenues	for	further	research.	
6.1.3.		 In	vitro	studies:		
MtDNA-TLR9-p38	 MAPK	 (neutrophil)	 and	 mtDNA-TLR9-NF-kB	 (macrophage)	
pathways	
	Cellular	 studies	 have	 demonstrated	 that	 mtDNA	 activates	 neutrophils	 and	alveolar	macrophages	by	binding	to	TLR9,	activating	p38	MAPK	and	inducing	the	prototypical	neutrophil	responses	(degranulation	of	MMP-8,	MPO	and	neutrophil	elastase,	 ROS	 generation	 and	 formation	 of	 IL-8)	 and	 prototypical	 macrophage	responses	(IL-1beta,	IL-6	and	TNF-alpha	release)	(Zhang	et	al.,	2010b,	Gu	et	al.,	2015a,	Wei	et	al.,	2015).	Similarly,	mtDNA	activates	the	TLR9-NF-kB	pathway	in	macrophages	leading	to	IL-6,	IL-10	and	TNF-alpha	release	(Zhang	et	al.,	2014a).		
However,	many	inconsistencies	are	found	in	the	literature,	which	is	unsurprising	given	 the	 complexity	 and	 redundancies	 involved.	 For	 example,	 other	 studies	have	 found	 no	 evidence	 of	 neutrophil	 activation	 at	 all	 when	 challenged	 with		‘highly’	purified	mtDNA	 (Prikhodko	et	 al.,	 2015)	or	only	when	challenged	with	extremely	 high	 concentrations	 of	mtDNA	 (Hazeldine	 et	 al.,	 2015).	MtDNA	was	shown	 to	 increase	 neutrophil	 chemotaxis	 (Wei	 et	 al.,	 2015)	 but	 another	 study	showed	a	decrease	in	chemotaxis	with	subsequent	septic	challenge	(Zhang	et	al.,	2010b).	Other	groups	have	shown	that	mtDNA	has	inflammatory	effects	only	as	part	of	a	mix	of	mitochondrial	DAMPs,	especially	with	formyl	peptides	and	TFAM	(Crouser	et	al.,	2009,	Julian	et	al.,	2013).	The	effects	of	mtDNA	appear	to	be	cell-	and	 tissue-specific	 (Shintani	 et	 al.,	 2013).	 Clearly,	 further	 work	 is	 needed	 to	elucidate	these	mechanisms.		
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MtDNA-endothelial	interactions	
	Purified	mtDNA	is	rapidly	taken	up	by	endothelial	cells	to	co-localise	with	TLR9	in	 the	 endosomal	 compartments	 (Sun	 et	 al.,	 2013).	 Purified	mtDNA-neutrophil	interactions	have	been	shown	to	increase	endothelial	cell	permeability	and	may	help	to	explain	the	early	endothelial	dysfunction	in	trauma	that	forms	the	basis	for	later	organ	dysfunction	(Sun	et	al.,	2013).	
Nuclear	DNA	(nDNA)	release	in	trauma	
	In	 trauma,	 an	 expected	 rise	 in	 circulating	 nDNA	 levels	 occurs	 secondary	 to	necrotic	 cell	 death	 and	 cell	 rupture.	 NDNA	 correlates	with	 injury	 severity	 (Lo,	2000)	but	mostly	fails	to	correlate	with	adverse	outcomes	in	humans	in	trauma	and	 perioperatively	 (McIlroy	 et	 al.,	 2015),	 with	 the	 exception	 of	 one	 study	correlating	 nDNA	 levels	 with	 immunosuppression	 and	 increased	 sepsis	 post	trauma	 (Timmermans	 et	 al.,	 2016b).	 However,	 acute	 lung	 injury	 or	 systemic	inflammation	was	not	evident	with	inoculations	of	purified	nDNA	in	all	the	above	in	vivo	studies	cited	earlier,	where	equivalent	doses	of	mtDNA	were	inoculated	with	 injurious	 effect.	 NDNA	 is	 generally	 considered	 to	 be	 inert	 due	 its	 low	frequency	 of	 unmethylated	 CpG	 repeats	 and	 hence	 weak	 activity	 at	 TLR9	(Hemmi	et	al.,	2000).	Hence,	interest	in	nDNA	as	a	therapeutic	target	in	trauma	has	 been	 limited	 given	 its	 low	 inflammatory	 potential.	 However,	 circulating	nDNA	 can	 bind	 to	 other	 proteins,	 such	 as	 HMGB1,	 to	 form	 complexes	 with	immunogenic	 properties,	 most	 evident	 in	 studies	 of	 chronic	 autoimmune	diseases	 (Tian	 et	 al.,	 2007,	 Pisetsky	 et	 al.,	 2012,	 Magna	 and	 Pisetsky,	 2016).	However,	 this	 has	 not	 yet	 been	demonstrated	 clinically	 or	 in	 vivo	 in	 the	 acute	trauma	setting.	
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Figure.	1.6.	Proposed	feed-forward	cycle	linking	oxidative	mtDNA	damage	and	DAMP	formation	to	 injury	 propagation.	 Oxidant	 stress	 induced	 by	 infection,	 trauma,	 or	 ischemia-reperfusion	injury	 to	 leads	 to	 a	positive	 feedback	 cycle	of	 further	oxidative	mtDNA	damage,	mtDNA	DAMP	formation,	 and	 regenerative	mtDNA	 damage	 in	 a	 feed-forward	 cycle	 resulting	 in	 inflammation	and	tissue	damage.	If	valid,	the	model	explains	why	treatment	of	the	initial	 insult,	regardless	of	its	 specific	 etiology,	 often	 fails	 to	 prevent	 propagation	 of	 the	 insult	 to	 distant	 organs	 and	 the	occurrence	 of	 delayed	 organ	 dysfunction.	 Both	 inhibition	 (A)	 of	 oxidative	mtDNA	 damage	 and	enhanced	degradation	 (B)	 of	mtDNA	DAMPs	would	 be	 expected	 to	 impede	 injury	 progression.	From	Kuck,	Am	J	Physiol	Lung	Cell	Mol	Physiol	(2015)		
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6.1.4.	MtDNA	and	NLRP3	inflammasome	activation	
Haemorrhagic	 shock	 and	 reperfusion	 injury	 are	 associated	 with	 a	 global	oxidative	 stress	 injury	 (Kentner	 et	 al.,	 2002)	which	 is	mediated	 by	 the	 innate	immune	 system	 and	 the	 TLRs	 in	 particular	 (Gill	 et	 al.,	 2010).	 The	 NLRP3	inflammasome	is	a	key	cytosolic	sensing	platform	which	is	activated	by	hypoxia	and	 a	wide	 range	 of	 necrotic	 cell	 products	 (Iyer	 et	 al.,	 2009b).	 This	 ultimately	leads	 to	 caspase-1	 activation	 and	 the	 maturation	 of	 the	 proinflammatory	cytokines	IL-1beta	and	IL-18.	There	is	increasing	evidence	implicating	oxidative	damage	to	mtDNA	with	 the	subsequent	activation	of	 the	NLRP3	 inflammasome	pathway	(Nakahira	et	al.,	2010,	Zhou	et	al.,	2010,	Shimada	et	al.,	2012,	Ding	et	al.,	2014).	 Persistent	 cellular	 stress	 results	 in	 damage	 to	 mitochondria	 which	manifests	 as	 harmful	 mitochondrial	 ROS	 production,	 oxidation	 of	 mtDNA,	activation	of	the	NLRP3	inflammasome	and	loss	of	mitochondrial	integrity	with	translocation	 of	mtDNA	 to	 the	 cytoplasm	and	 cell-autonomous	 canonical	 TLR9	dependent	 inflammation	 (Nakahira	 et	 al.,	 2010,	 Oka	 et	 al.,	 2012).	 	 This	 is	normally	 prevented	 by	 mitophagy	 processes,	 which	 act	 to	 remove	 ROS-generating	 mitochondria	 and	 cytosolic	 mtDNA.	 Failure	 of	 mitophagy	 in	persistent	 or	 overwhelming	 cellular	 stress	 leads	 to	 further	 ROS	 generation,	oxidation	 of	mtDNA,	 further	 translocation	 of	mtDNA	 into	 the	 cytoplasm	 and	 a	feed-forward	 cycle	 leading	 which	 can	 result	 in	 cellular	 apoptosis	 (Kepp	 et	 al.,	Shimada	 et	 al.,	 2012).	 	 Pyroptosis	 (programmed	 cell	 death	 not	 related	 to	apoptosis)	or	necrosis	can	also	occur	in	overwhelming	cell	stress	with	resultant	expulsion	 of	 mtDNA	 extracellularly	 to	 propagate	 the	 process	 to	 nearby	 cells	(Schroder	and	Tschopp,	2010,	Wei	et	al.,	2015).	This	is	compatible	with	the	feed-
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forward	 concept	 proposed	 by	 Kuck	 et	 al.	 (2015).	 Administration	 of	 a	 mtROS	specific	 antioxidant	 therapy	 in	 a	 septic	 mouse	model	 demonstrated	 a	 marked	improvement	in	mtDNA	damage	and	decreased	translocation	into	the	cytoplasm	and	reduced	apoptotic	cell	death	(Yao	et	al.,	2015).	The	antioxidant	Tempol	has	also	been	used	successfully	in	a	rodent	model	of	haemorrhagic	shock	to	improve	short-term	survival	(Kentner	et	al.,	2002).	
Other	inflammasomes	that	also	recognise	dsDNA	are	the	PRRs	AIM2	(Absent	in	melanoma	 2)	 and	 IFI16	 (gamma	 Interferon-inducible	 protein	 16).	 Their	recognition	of	bacterial	and	viral	dsDNA	is	best	studied	(Xiao,	2015).	The	DNA-dependent	activator	of	IFN-regulatory	factors	(DAI)	receptor	is	another	cytosolic	DNA	receptor	 that	produces	 type	 I	 interferon	responses	(Takaoka	et	al.,	2007).	Viral	 cell	 stress	 leading	 to	 loss	 of	 stabilising	TFAM	 in	mtDNA,	 leads	 to	mtDNA	fragmentation	 and	 activation	 of	 the	 STING	 (Stimulator	 of	 interferon	 genes)	pathway	to	generate	innate	antiviral	responses	(West	et	al.,	2015).		
No	data	exists	regarding	the	activation	of	these	sensors	by	mtDNA	in	trauma	per	se	but	 clearly,	 there	 are	 a	 large	number	of	 non-TLR9	 receptors	 through	which	mtDNA	 could	 act	 in	 this	 setting.	 It	 is	 mtDNA,	 as	 opposed	 to	 nDNA,	 which	 is	released	into	the	cytoplasm	after	cell	stress	to	play	an	important	part	 in	sterile	inflammatory	diseases	such	as	trauma	and	acute	liver	failure	as	well	as	chronic	inflammatory	 conditions	 such	 as	 atherosclerotic	 heart	 failure	 and	 rheumatoid	arthritis	(Fang	et	al.,	2015).		
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6.1.5.	NET	formation	in	trauma	leading	to	mtDNA	release	
NET	 formation	 is	 an	 important	 component	 of	 innate	 immunity	 and	 provides	potent	 antibacterial	 killing.	 ‘Traditional’	 NETs	 are	 comprised	 of	 nuclear	 DNA,	histones	 and	 other	 granular	 antimicrobial	 proteins	 and	 are	 associated	 with	controlled	 neutrophil	 death	 (Brinkmann,	 2004).	 	 However,	 NETs	 comprised	 of	pure	mtDNA	 have	 been	 recorded	 in	 trauma	 patients’	 blood	 appearing	 several	days	 postoperatively	 (McIlroy	 et	 al.,	 2014).	 Trauma	 NET	 formation	 was	 not	associated	 with	 neutrophil	 necrosis	 or	 a	 rise	 in	 circulating	 nDNA	 levels.	 This	resulted	 in	a	secondary	circulating	peak	of	plasma	mtDNA	levels	at	around	3-5	days	post	surgery	 (McIlroy	et	al.,	2015).	Elderly	 trauma	patients	demonstrated	fewer	circulating	NETs	than	young	trauma	patients	in	another	study	(Itagaki	et	al.,	2015b).	Intriguingly,	ROS	production	and	mtDNA	were	found	to	stimulate	the	production	 of	 NETs	 in	 human	 neutrophils,	 which	 potentially	 sets	 up	 another	feed-forward	cycle	mechanism	of	 injury	(Itagaki	et	al.,	2015b).	The	significance	of	 these	 observations	 is	 unclear	 but	 potentially	 NETs	 may	 have	 prognostic	importance	 for	 later	 adverse	 outcomes,	 such	 as	 the	 development	 of	opportunistic	 infections.	 Other	 leukocytes	 have	 also	 been	 shown	 to	 release	mtDNA	in	their	extracellular	traps	without	cell	death	in	response	to	infection,	for	example,	eosinophils,	EETs,	(Yousefi	et	al.,	2008)	and	basophils,	BETs	(Yousefi	et	al.,	2015),	but	their	release	in	the	trauma	population	is	unknown.		
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6.2. Formyl	peptide	as	a	trauma	DAMP	
N-Formylated	peptides	(FPs)	are	only	present	in	bacteria	and	mitochondria	and	provide	 further	 evidence	 of	 their	 shared	 ancient	 heritage.	 Both	 bacterial	 and	mitochondrial	 FPs	 have	 been	 long	 identified	 as	 powerful	 chemoattractants	 for	circulating	 leukocytes	 (Schiffmann	 et	 al.,	 1975,	 Carp,	 1982).	 In	 humans,	 the	formyl	peptide	receptor	(FPR1)	exists	with	 its	two	homologues,	 formyl	peptide	receptor-like	1		(FPRL1)	and	formyl	receptor-like	2	(FPRL2).	The	nomenclature	has	changed	recently	to	FPR1,	FPR2	and	FPR3,	correspondingly.		These	receptors	are	highly	 expressed	on	neutrophils	 and	monocytes	 as	well	 as	 in	 endothelium,	spleen,	 lung,	 liver	 and	 skeletal	 muscle.	 FPRs	 function	 to	 mediate	 chemotaxis	(Wenceslau	et	al.,	2015).	
More	 recently,	mitochondrial	 FPs	 have	 been	 identified	 as	 important	DAMPs	 in	sterile	 necrotic	 cell	 death	 by	 the	 ability	 to	 stimulate	 potent	 innate	 immune	responses	via	FPRs	(Crouser	et	al.,	2009).	Necrotic	cells	have	also	been	shown	to	generate	 intravascular	 formyl	 peptide	 signals	 to	 direct	 neutrophil	 chemotaxis	(McDonald	et	al.,	2010).	
Mitochondrial	FPs	intravenously	injected	as	part	of	a	mixed	mitochondrial	debris	into	 healthy	 rats	 caused	 acute	 lung	 injury	 (Zhang	 et	 al.,	 2010b,	 Hauser	 et	 al.,	2010).	More	 recently,	 infusion	of	 synthetic	mitochondrial	FPs	 into	healthy	 rats	was	 shown	 to	 induce	 hypotension,	 increased	 vascular	 permeability,	hyperthermia,	 increased	 coagulation	 and	 acute	 lung	 injury	 (Wenceslau	 et	 al.,	2015).	 Direct	 intra-tracheal	 FP	 challenge	 also	 demonstrated	 neutrophil	activation,	 neutrophil	 elastase	 release	 and	 increased	 iNOS	 expression	 in	 lung	tissue	 (Wenceslau	 et	 al.,	 2016).	 In	 vitro	 studies	 have	 confirmed	 that	
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mitochondrial	FPs	activate	neutrophils	via	FPR1	and	FPRL-1	to	produce	robust	neutrophil	 responses	 such	 as	 neutrophil	 degranulation,	 ROS	 generation,	chemotaxis	and	 IL-8	secretion,	and	simultaneous	activation	of	 the	p38/p44/42	MAPK	 (Zhang	 et	 al.,	 2010b,	 Raoof	 et	 al.,	 2010,	 Hauser	 et	 al.,	 2010)	 and	extracellular-signal-related-kinase	 1/2	 (ERK1/2)	 MAPK	 signalling	 pathways	(Hazeldine	et	al.,	2015,	Wenceslau	et	al.,	2015).		
As	 discussed	 earlier	 in	 the	 section	 on	 mtDNA	 release	 in	 trauma,	 these	experiments	suggest	that	the	mitochondrial	DAMPs,	FP	and	mtDNA,	systemically	prime	 neutrophils,	 which	 then	 mediate	 the	 local	 acute	 lung	 injury,	 an	 organ	susceptible	to	damage	because	of	the	inherent	structural	and	functional	 factors	discussed	 previously.	 Beyond	 the	 acute	 stage	 of	 neutrophil	 activation,	neutrophils	 appear	 to	 be	 more	 exhausted,	 less	 responsive	 to	 subsequent	stimulation	and	this	may	be	associated	with	increased	host	susceptibility	to	new	infection	 (Zhang	 et	 al.,	 2010b,	 Hazeldine	 et	 al.,	 2015).	 MtDAMP-induced	endotoxin	 tolerance	 has	 been	 demonstrated	 in	 monocytes	 but	 has	 not	 yet	conclusively	been	demonstrated	in	neutrophils	(Fernández-Ruiz	et	al.,	2014).	
It	 should	 be	 noted	 that	 that	 the	 direct	 measurement	 of	 endogenous	mitochondrial	 FPs	 in	 vivo	 has	 proved	 extremely	 challenging.	 Endogenous	mitochondrial	 FPs	 have	 been	mostly	 implicated	 in	 the	 above	 innate	 signalling	pathways	with	the	use	of	synthetic	or	endogenous	FP	challenges	and	functional	FPR	blockade	in	vitro	(neutrophil	FPR1	antibodies	or	cyclosporine	H)	and	in	vivo	(FPR1-/-knockout	 mice	 studies)(Zhang	 et	 al.,	 2010b,	 McDonald	 et	 al.,	 2010).	Currently,	 only	 chemically	 synthesised	 mitochondrial	 FPs	 have	 been	 used	experimentally	 to	 confirm	 neutrophil	 activation	 (Rabiet	 et	 al.,	 2005)	 or	 to	
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generate	 a	 response	 in	 vivo,	 e.g.	 hypotension	 and	 increased	 vascular	permeability	(Wenceslau	et	al.,	2015).	Importantly,	this	group	has	also	measured	a	 raised	 plasma	 concentration	 of	 one	 endogenous	 formyl	 peptide,	 NADH	dehydrogenase	 6	 (ND6)	 with	 ELISA,	 in	 rats	 subjected	 to	 haemorrhagic	 shock,	and	correlated	it	to	the	development	of	severe	acute	lung	injury.	This	appears	to	be	the	first	ever	in	measurement	of	an	endogenous	formylated	peptide	without	the	use	of	complex	mass	spectrometry	techniques	(Walker	et	al.,	2009,	Carroll	et	al.,	 2006).	 The	 authors	 then	 proceeded	 to	 demonstrate	 endogenous	mitochondrial	 FP	 release	 into	 the	 circulation	 of	 trauma	 patients.	 Significantly	higher	levels	of	FPs	in	trauma	patients	were	associated	with	the	development	of	SIRS	 or	 sepsis.	 Overall,	 their	 findings	 suggest	 that	 higher	 levels	 of	 FPs	may	 be	correlated	with	 the	 development	 of	 persistent,	 dysregulated	 inflammation,	ALI	and	 MOF,	 which	 is	 found	 in	 patients	 with	 SIRS	 and	 sepsis	 (Wenceslau	 et	 al.,	2016).	 Interestingly,	another	study	has	showed	a	preponderance	of	 the	mtDNA	coding	 for	 ND6	 in	 trauma	 patients’	 plasma	 in	 a	 small	 series	 of	 14	 patients	(Simmons	et	al.,	2013).	These	findings	warrant	further	study.		
Novel	 N-formylated	 neutrophil-activating	 peptide	 fragments	 derived	 from	mitochondrial	FPs	(so-called	‘cryptides’)	including	cytochrome	B	(mitocryptide-2	(MCT-2)),	COX1	and	ND4-ND6	have	been	discovered	previously	 (Marutani	et	al.,	 2015).	 This	 group	 has	 also	 found	 evidence	 that	 some	 non-FP	 fragments	derived	 from	mitochondria	 (i.e.	 non	 formylated	 cryptides	 encoded	 by	 nuclear	DNA)	are	also	able	to	activate	neutrophils.	
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6.3. ATP	as	a	trauma	DAMP	
As	organelles	 responsible	 for	producing	 the	majority	of	 the	ATP	under	aerobic	conditions,	mitochondria	 are	 an	 abundant	 source	 of	 ATP	 that	 can	 be	 liberated	into	the	extracellular	space	following	cell	stress,	apoptosis	or	necrosis	(Krysko	et	al.,	2011).	Powerful	ecto-ATPases	rapidly	degrade	extracellular	ATP	(Willart	and	Lambrecht,	2009).	Elevated	 levels	have	not	been	measured	clinically	 in	 trauma	but	there	is	compelling	experimental	cellular	evidence	which	supports	its	role	as	a	DAMP.	Extracellular	ATP	 from	cell	necrosis,	acting	 through	 its	purinergic	cell	surface	 receptor,	 P2X7,	 on	 leukocytes,	 platelets,	 APCs,	 lung	 and	 other	 tissues,	was	 found	 to	 be	 partially	 responsible	 for	 the	 activation	 of	 the	 NLRP3	inflammasome	 (Iyer	 et	 al.,	 2009b).	 This	 effect	 on	 the	 inflammasome	 is	 likely	mediated	via	generation	of	mitochondrial	ROS,	the	common	mediator	for	a	wide	range	of	stimuli	(Yu	et	al.,	2014).		It	was	further	suggested	that	the	source	of	the	ATP	might	be	 intact	 respiring	mitochondria	 released	 from	necrotic	 cells	 rather	than	passively	released	ATP	from	cell	breakdown	(Iyer	et	al.,	2009b).	In	a	mouse	model	of	focal	hepatic	necrosis	using	real	time	intravital	microscopy,	neutrophil	activation	and	endothelial	adherence	to	necrotic	areas,	but	not	chemotaxis,	was	found	to	be	entirely	ATP	dependent	(McDonald	et	al.,	2010).	
	
	
6.4. TFAM	as	a	trauma	DAMP	
Mitochondrial	 transcription	 factor	 A	 is	 a	 member	 of	 the	 high-mobility	 group	(HMG)	 of	 DNA-binding	 proteins	 that	 are	 involved	 in	 mtDNA	 replication	 and	
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transcription	 (Iyer	 et	 al.,	 2009a).	 TFAM	 is	 concentrated	 therefore	 in	mitochondria	 and	when	 released	 in	 necrosis	 is	 highly	 associated	with	mtDNA	(Crouser	et	al.,	2009).	TFAM	is	homologous	to	HMGB1	and	its	relationship	with	nuclear	 DNA.	 It	 has	 been	 detected	 in	 the	 plasma	 of	 rats	 subjected	 to	haemorrhagic	shock.	A	recombinant	intravenous	injection	of	TFAM	into	healthy	rats	 caused	 systemic	 release	 of	 TNF-alpha	 and	 IL-6	 and	 acute	 lung	 injury	 as	evidenced	 by	 increased	 neutrophil	 infiltration	 as	 measured	 by	 MPO	 in	 lung	(Chaung	 et	 al.,	 2012,	 Julian	 et	 al.,	 2012,	 Julian	 et	 al.,	 2013).	 TFAM-mtDNA	complexes	 released	 from	 necrotic	 cells	 were	 shown	 to	 augment	 mtDNA	mediated	TNF-alpha	release	from	plasmacytoid	dendritic	cells		(pDCs)	via	RAGE	and	 TLR9	 interactions,	 respectively	 (Julian	 et	 al.,	 2012,	 Julian	 et	 al.,	 2013).	Plasmacytoid	DCs	 are	 specialist	APCs	which	 recognise	 CpG	DNA	via	TLR7/8/9	and	are	able	to	produce	large	amounts	of	Type	I	interferon,	as	well	as	TNF-alpha	to	generate	 ’bystander’	activation	of	 local	macrophages.	Subsequent	endosomal	acidification	 and	 activation	 of	 the	 PI3K	 and	NF-kB	 pathways	 occur	 to	 produce	canonical	 inflammation.	 TFAM-RAGE-dependent	 signalling	 is	 not	 unexpected	given	 TFAM’s	 similarity	 to	 HMGB1.	 TFAM	 alone	 failed	 to	 generate	 TNF-alpha	release	from	pDCs	in	this	model,	in	contrast	with	TFAM	challenge	in	healthy	rats	(Chaung	et	al.,	2012),	although	an	effective	dose	comparison	is	difficult	between	the	two	studies.	TFAM	has	been	shown	to	augment	the	inflammatory	activity	of	formyl	 peptides	 by	 promoting	 release	 of	 IL-8	 from	 monocytes	 in	 one	 study	(Crouser	 et	 al.,	 2009)	 but	 failed	 to	 demonstrate	 an	 augmented	 TNF-alpha	response	in	pDCs	(Julian	et	al.,	2013).		
Overall,	these	findings	suggest	that	the	mitochondrial	DAMPs,	mtDNA	and	TFAM,	
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are	 able	 to	 prime	 neutrophils	 and	 a	 number	 of	 APCs,	 including	 pDCs	 and	monocytes,	 which	 is	 likely	 to	 be	 important	 in	 the	 pathogenesis	 of	 acute	 lung	injury	and	MOF	in	the	context	of	sterile	inflammation	(Schumacker	et	al.,	2014).	TFAM	 remains	 an	 important	 target	 for	 further	 DAMP	 research	 given	 its	 close	association	with	mtDNA	when	liberated	from	dead	cells.		
	
6.5. Cytochrome	c	as	a	trauma	DAMP	
Cytochrome	 c	 (Cyt	 c)	 is	 located	 in	 the	 mitochondrial	 intermembrane	 and	intercristae	 spaces	 where	 it	 is	 closely	 associated	 with	 cardiolipin.	 	 During	mitochondrial	 injury,	 Cyt	 c	 can	 escape	 and	 participate	 in	 cell	 death	 processes,	notably	apoptosis	with	subsequent	caspase	activation	(Garrido	et	al.,	2006).	This	process	 has	 been	 reported	 in	 experimental	 traumatic	 brain	 injury	 (Büki	 et	 al.,	2000,	 Sullivan	 et	 al.,	 2002)	 and	 in	 cold	 induced	 brain	 injury	 in	mice	 and	 rats	(Morita-Fujimura	 et	 al.,	 1999).	 One	 ongoing	 clinical	 trial	 is	 investigating	 the	utility	 of	 Cyt	 c	 as	 a	 biomarker	 in	 trauma	 (ClinicalTrials.gov	 Identifier:	NCT02440373).					
6.6. Cardiolipin	as	a	trauma	DAMP	
Cardiolipin	 is	 a	 mitochondrial	 phospholipid	 that	 resides	 in	 the	 inner	mitochondrial	membrane	as	well	as	in	bacterial	membranes.	It	constitutes	up	to	
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15%	 of	 the	 phospholipid	 content	 in	 the	 heart,	 for	 example,	 where	 it	 is	 most	concentrated.	 Cardiolipin	 is	 closely	 associated	with	 cytochrome	 c	 at	 the	 outer	leaflet	 of	 the	 mitochondrial	 inner	 membrane,	 and	 cardiolipin	 peroxidation	 is	vital	 for	 cytochrome	 c	 dissociation	 from	 the	 mitochondrial	 inner	 membrane	(Morita	 and	Terada,	 2015).	During	 periods	 of	mitochondrial	 stress,	 cardiolipin	translocates	 to	 the	 outer	 mitochondrial	 membrane	 and	 interacts	 with	 and	activates	 the	 NLRP3	 inflammasome.	 This	 process	 has	 been	 shown	 to	 be	 both	independent	and	dependent	on	ROS	generation	(Iyer	et	al.,	2013).	Cardiolipin	is	therefore	 potentially	 a	 DAMP.	 However,	 there	 is	 no	 known	 study	 of	 elevated	cardiolipin	 levels	 in	 the	 circulation	 in	 clinical	 or	 experimental	 trauma.	 This	 is	likely	 due	 to	 the	 technical	 challenges	 of	 measuring	 phospholipid	 in	 animal	tissues	and	 fluids	 (Morita	and	Terada,	2015).	Mitochondrial	 rupture	 leading	 to	immediate	 mitochondrial	 ROS	 formation	 and	 cardiolipin	 oxidation	 has	 been	detected,	 however,	 on	 electron	 microscopy	 in	 a	 stretch-type	 injury	 of	 rat	neurones	to	simulate	neurotrauma	(Ji	et	al.,	2012).	
	
Pharmacological	 interventions	 to	modulate	 the	dysregulated	 immune	response	 in	
trauma	haemorrhage	
Unfortunately	 there	 has	 been	 little	 progress	 to	 date	 in	 the	 development	 of	 a	successful	drug	to	modulate	the	dysregulated	immune	response	in	trauma.	Most	trials,	except	CRASH	2	(CRASH	2	Collaborators	et	al.,	2010),	have	included	small	numbers	 of	 patients	 inextricably	 linked	 to	 significant	 heterogeneity	 and	resultant	wide	confidence	intervals	in	results	(Lord	et	al.,	2014).	Their	principles	of	proposed	benefit	have	often	relied	on	outdated	understanding	of	the	complex	
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immune	response	to	this	disease.	As	a	result,	the	therapeutic	targets	have	been	either	 non-selective	 (broad	 immunosuppression	 which	 is	 unlikely	 to	 be	beneficial	for	everyone	at	all	time	points)	or	too	downstream	in	focus	(blocking	one	 receptor	 which	 is	 unlikely	 to	 succeed	 given	 the	 inherent	 complexity	 and	redundancy	in	the	immune	system).	Fortunately,	there	has	been	recent	progress	especially	 in	 the	 field	of	 immune	signalling,	genomics,	and	transcriptomics	 that	has	 brought	 new	 understanding	 and	 offers	 new	 potential	 for	 successful	treatments.	In	particular,	the	genomics	analysis	of	the	Glue	Grant	investigators	in	trauma	 (Xiao	 et	 al.,	 2011)	 and	 similar	 analyses	 from	 septic	 patients	 have	highlighted	many	of	the	commonalities	of	the	immune	response	to	a	wide	range	of	 pathologies	 (Davenport	 et	 al.,	 2016,	 Tompkins,	 2015).	 	 This	 should	 lead	 to	improved	 phenotypic	 classification	 of	 patients	 and	 more	 personalised	enrollment	 into	 RCTs,	 e.g.	 not	 enrolling	 a	 patient	 with	 pronounced	 innate	immune	 suppression	 into	 an	 immunosuppressive	 steroid	 arm.	 Unfortunately,	this	 scenario	 and	 others	 like	 it	 has	 undoubtedly	 occurred	 on	 many	 occasions	perhaps	 partially	 explaining	 the	 lack	 of	 benefit	 of	 trials	 such	 as	 the	 CORTICUS	study	which	investigated	the	use	of	steroids	in	sepsis	(Sprung	et	al.,	2008).	
Mitochondrial	DAMPs	are	a	logical	target	for	therapeutic	intervention	given	their	powerful	upstream	modulation	of	both	 innate	and	acquired	 immune	responses	in	trauma.	
1. Potential	 therapeutic	 angles	 include	 the	 scavenging,	 neutralisation	 or	degradation	of	DAMPs	as	soon	as	possible	after	severe	injury	with	agents	that	ideally	have	minimal	effects	on	 immune	signalling.	For	example,	 removal	of	HMGB1	with	a	haemoperfusion	adsorption	column	was	demonstrated	in	a	rat	
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liver	 model	 of	 ischaemia-reperfusion	 injury	 and	 was	 associated	 with	increased	survival	(Yamamoto	et	al.,	2010).	Nucleic	acid	scavenging	polymers	were	shown	to	prevent	fatal	liver	injury	caused	by	damaging	CpG	DNA	in	an	acute	toxic	shock	model	in	mice	(Lee	et	al.,	2011).		2. Another	 potential	 approach	 is	 the	 targeting	 of	 upstream	 cell	 stress	 signals,	e.g.	 inhibition	 of	 mitochondrial	 ROS	 or	 oxidative	 mtDNA	 damage.	 This	approach	is	inherently	riskier	as	it	risks	the	effects	of	systemically	targeting	oxidative	 injury	 but	 has	 been	 used	 with	 some	 success	 experimentally.	 For	example,	 the	 mitochondrial	 targeted	 antioxidant	 vitamin	 E,	 Mito-Vit–E,	reduced	 mitochondrial	 ROS,	 stabilised	 mtDNA,	 reduced	 inflammation	 and	improved	cardiac	performance	in	a	rodent	model	of	sepsis	(Yao	et	al.,	2015).		3. An	example	of	an	approach	unlikely	to	succeed	is	the	use	of	a	TLR	antagonist	such	 as	 the	 TLR4	 antagonist,	 eritoran,	 which	 failed	 to	 deliver	 organ	protection	after	injury	in	a	rodent	model	of	trauma	haemorrhage	(Korff	et	al.,	2013).	 TLR4,	 in	 particular,	 mediates	 multiple	 diverse	 ligands	 and	 the	 TLR	family	of	receptors	have	a	high	degree	of	redundancy	and	complexity.		4. Similarly,	 therapies	 to	 blindly	 augment	 immunity,	 for	 example,	 with	granulocyte	 colony	 stimulating	 factor	 and	 interferon-gamma,	 have	 been	broadly	unsuccessful	because	they	are	as	flawed	in	principle	and	approach	as	broad	immunosuppression	for	the	same	disease	(Lord	et	al.,	2014).		
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Summary		Trauma	is	a	common	and	important	disease.	There	have	been	improvements	in	mortality	and	morbidity	over	the	last	decade	largely	due	to	better	resuscitation,	damage	 control	 principles	 and	 improved	 bundled	 critical	 care	 strategies.	 The	underlying	 immunopathology	 remains	 poorly	 understood	 with	 no	 successful	pharmacological	intervention	in	use	currently.	There	have	been	recent	strides	in	our	understanding	of	the	underlying	immune	mechanisms,	which	offers	hope	for	new	therapies.	In	particular,	mitochondrial	DAMP	immune	signalling	provides	a	logical	and	potent	target	for	further	research.	Relevant	animal	models	of	trauma	haemorrhage	are	a	research	priority,	in	parallel	with	further	human	study.		
Main	Hypotheses		
	1. MtDNA	 release	 after	 trauma	 haemorrhage	 is	 important	 for	 the	development	of	remote	acute	lung	injury	and	subsequent	MOF.		2. The	 extent	 of	 mtDNA	 release	 varies	 with	 degrees	 of	 tissue	 injury	 and	haemorrhagic	shock.	3. Neutralising	 mtDNA	 with	 the	 nucleic	 acid	 scavenging	 polymer,	Hexadimethrine	 bromide,	 at	 a	 clinically	 relevant	 time	 point	 in	 vivo	 can	reduce	the	severity	of	organ	injury	and	improve	outcomes.			
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			Figure	above.	Summary	of	known	and	proposed	pathways	in	sterile	 inflammation	as	a	result	of	trauma,	 shock,	 hypoxia	 or	 ischaemia-reperfusion	 I	 (IR)	 injury.	 Liberated	 extracellular	mitochondrial	 DAMPs	 such	 as	mtDNA,	 formyl	 peptides	 (FP),	 TFAM,	ATP,	 Cardiolipin	 (CL),	 and	Cytochrome	 C	 (CYTO	 C)	 activate	 inflammation	 via	 TLR9,	 FPR,	 RAGE,	 P2X7	 and	 the	 NLRP3	Inflammasome	 in	 innate	 immune	 cells	 and	 non-immune	 cells	 such	 as	 endothelium	 and	 organ	parenchyma.	 Activation	 of	macrophages	 (the	 primary	 sentinel	 cells	 that	 sense	 cell	 death)	 and	neutrophils	 (the	 ‘first	 responders’)	 leads	 to	 localised	 and	 systemic	 inflammation	 which	 can	progress	 to	 remote	 organ	 injury,	MODS/MOF	 and	 the	 further	 liberation	 of	 DAMPs.	 Circulating	monocytes	 and	 plasmacytoid	 dendritic	 cells	 also	 respond	 to	 DAMPs	 and	 augment	 the	 main	neutrophil	 and	 macrophage	 responses.	 Macrophage	 activation	 via	 both	 MAPK	 and	 NF-kB	pathways	 lead	 to	 the	 prototypical	 cytokine	 responses	 which	 further	 augments	 other	 innate	immune	 cell	 activity	 and	 also	 causes	 localised	 inflammation	 to	 endothelium	 and	 parenchyma.	Neutrophil	 activation	 via	 MAPK	 pathways	 induces	 wide-ranging	 antibacterial	 and	 anti-inflammatory	 responses,	 e.g.	 degranulation	 of	 proteases	 such	 as	 neutrophil	 elastase	 (NE),	myeloperoxidase	 (MPO)	 and	 matrix	 metalloprotease	 (MMP),	 NETosis,	 increased	 neutrophil	chemotaxis	 to	 necrotic	 cells	 and	 marked	 cytokine	 production,	 neutrophil	 adhesion	 to	endothelium	 and	 neutrophil	 extravasation.	 MtDNA	 fragments	 also	 directly	 cause	 increased	endothelial	 permeability	 and	 also	 further	 activate	 neutrophil-endothelial	 interactions	 (not	shown	in	figure).	These	 lead	to	endothelial	disruption,	 fluid	 leak	and	oedema	locally,	as	well	as	systemically,	 part	 explaining	 the	 remote	 acute	 organ	 dysfunction	 the	 frequently	 occurs	 in	severe/prolonged	 insults.	 	 A	 persistent	 or	 vigorous	 inflammatory	 response	 can	 also	 lead	 to	exhaustion	of	these	immune	cells	and	resultant	immunosuppression	with	increased	nosocomial	sepsis	later	on.	Mitochondria	are	important	sensors	of	the	cell’s	health	–	increased	stress/injury	leads	to	increased	mitochondrial	ROS		(mROS)	formation	and	loss	of	mitochondrial	integrity	with	translocation	of	mtDNA,	CL,	Cyto	C	and	ATP	to	the	cytosol	where	they	can	interact	with	TLR9	in	endosomes	and/or	the	NLPR3	Inflammasome	in	innate	immune	cells	such	as	macrophages.	The	NLRP3	inflammasome	is	a	cytosolic	PRR	which	recognises	a	broad	range	of	cell	death	products	and	signals	via	the	common	pathway	of	mitochondrial	stress	and	mitochondrial	ROS	production.	With	 intact	 homeostasis,	 mitophagy	 acts	 to	 remove	 stressed	 or	 injured	 ROS	 producing	mitochondria	 and	 cytosolic	 mtDNA	 (and	 other	 cytosolic	 mitochondrial	 DAMPs)	 to	 limit	inflammation.	 With	 persistent	 and/or	 severe	 insults,	 mitophagy	 is	 overwhelmed	 and	 a	dysregulated	 pathophysiological	 inflammation	 results.	 Non-mitochondrial	 DAMPs	 and	 PAMPs	signal	 through	 different	 receptors	 such	 as	 TLR2	 and	 TLR4,	 but	 there	 is	 considerable	 overlap	between	sterile	and	infectious	signalling.		
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CHAPTER	II	
	
DEVELOPMENT	OF	A	TRAUMA	
HAEMORRHAGE	MODEL	OF	ORGAN	
DYSFUNCTION	
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Aims	
	 1. To	develop	a	rodent	model	of	trauma	haemorrhage	to	enable:		 a. Measurement	 of	 the	 release	 of	mitochondrial	 DAMPs	 (and	 other	DAMPs)	 and	 establish	 their	 relationship	 to	 degree	 of	 traumatic	injury	and	shock	sustained,	resultant	MOF	and	survival		b. Development	of	a	consistent	end	point	of	MOF		c. Therapeutic	 interventions	 in	 this	 model	 to	 target	 the	 resultant	MOF	as	a	matter	of	research	priority	and	unmet	need			
Introduction		Despite	 the	 recently	 voiced	 concerns	 regarding	 the	 translatability	 of	 findings	from	 animal	 models	 to	 humans	 (Seok	 et	 al.,	 2013,	 Leist	 and	 Hartung,	 2013),	animal	models	 still	 have	 an	 important	 role	 to	 play	 in	 the	 advancement	 of	 our	understanding	 of	 the	 host	 response	 to	 injury,	 as	 well	 as	 for	 testing	 novel	therapeutics	 and	generating	 further	hypotheses	 (Osuchowski	 et	 al.,	 2014).	The	selection	of	species,	degree	and	duration	of	insult	should	be	carefully	considered	and	tailored	to	relevant	clinical	questions.			
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Choice	of	Animal		Mice,	 rats,	 rabbits,	 guinea	 pigs,	 dogs,	 sheep	 and	 baboons	 have	 been	 used	previously	to	model	trauma	haemorrhage	(Hauser,	2005).	It	should	also	be	noted	that	 the	 two	 species	 in	 current	 use	 in	 Professor	Thiemermann’s	 laboratory	 on	my	 arrival	were	 the	mouse	 and	 rat.	Mice	 in	 particular	 have	 a	 greater	 array	 of	immune	 assays	 and	 genetic	 knockout	 models	 available,	 but	 this	 situation	 is	improving	steadily	for	the	rodent.	The	different	responses	to	trauma	and	sepsis	between	 rodents	 and	 humans	 should	 be	 highlighted.	 They	 include	 different	cardiovascular	 responses	 to	 haemorrhage	 (bradycardia	 in	 small	mammals	 and	tachycardia	 in	 large	 mammals)	 and	 differential	 gene	 expression	 and	 immune	responses	 to	 similar	 levels	 of	 infection	 (postulated	 to	 be	 due	 to	 ‘the	 hygiene	hypothesis’	 (Seok	 et	 al.,	 2013))	 and	 trauma	 (Valparaiso	 et	 al.,	 2015).	 I	 have	focused	on	rodent	models	of	 trauma	haemorrhage	 in	my	research	because	 this	species	 offers	 the	 best	 compromise	 of	 level	 of	 technical	 ability	 required,	 cost,	availability,	 ease	 of	 care,	 availability	 of	 immune	 assays	 and	 fewer	 ethical	 and	regulatory	hurdles.	Furthermore,	I	 limited	the	traumatic	insults	to	non-thoracic	and	non-traumatic	brain	injuries.	This	is	because	I	was	particularly	interested	in	the	role	of	 trauma	related	mitochondrial	DAMPs	 in	 the	development	of	 remote	organ	 injury,	 particularly	 in	 the	 lung.	 Furthermore,	 head	 injuries	 are	 often	excluded	from	clinical	trials	due	to	their	increased	heterogeneity	and	complexity	of	immune	responses.	This	latter	point	is	well	demonstrated	when	one	considers	the	 impressively	 large	 CRASH-2	 trial	 which	 found	 that	 tranexamic	 acid	 (TXA)	reduced	 bleeding	 and	 mortality	 in	 trauma	 patients,	 but	 those	 with	 traumatic	
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brain	 injuries	 (TBI)	were	 excluded	 from	enrollment	 (CRASH	2	 collaborators	 et	al.,	2010).		
	
Duration	of	Trauma	Haemorrhage	Model		Most	commonly,	acute,	non-recovery	models	(1-6	hours	duration)	are	employed	primarily	 for	 cost	 and	 ethical	 reasons.	 Recovery	models,	 involving	waking	 the	animal	 from	 anaesthesia	 with	 repaired	 traumatic	 injuries	 and	 a	 postoperative	period	 of	 monitoring	 or	 critical	 care,	 are	 uncommon	 in	 the	 UK.	 The	 existing	animal	license	in	Professor	Thiemermann’s	laboratory	precludes	this	use	of	this	level	of	severity	and	duration.			
Type	of	Anaesthesia		The	 common	 routes	 of	 administration	 of	 anaesthesia	 include	 inhalation	 (e.g.	continuous	 isoflurane),	 or	 injectable	 (e.g.	 intravascular	 or	 intraperitoneal	delivered	barbiturates,	such	as	thiopentone,	or	ketamine).	The	route	and	type	of	anesthesia	 will	 be	 determined	 by	 available	 equipment,	 expertise	 and	experimental	endpoints.	 	 I	 favoured	the	injectable	anaesthetic	thiopentone	as	it	was	commonly	 in	use	with	rodent	models	 in	the	 laboratory	and	it	also	allowed	multiple	animals	to	be	used	simultaneously.				
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Traumatic	injury		Experimentally,	 the	 combination	 of	 traumatic	 injury	 and	 haemorrhagic	 shock	much	more	 closely	mirrors	 the	 clinical	 scenario	 and	 therefore	 its	 use	 is	more	likely	to	mirror	the	clinical	pathobiology	of	trauma	haemorrhage	(Valparaiso	et	al.,	2015).	The	addition	of	traumatic	injury	to	haemorrhagic	shock	has	long	been	appreciated	 to	 further	 cause	 immune	 depression	 compared	 to	 little	 or	 no	immune	 depression	 with	 traumatic	 injury	 per	 se.	 This	 phenomenon	 has	 been	linked	 to	 later	 MOF	 and	 sepsis	 in	 multiply	 injured	 humans	 (Wichmann	 et	 al.,	1996,	Wichmann	et	al.,	1998).		In	order	to	assess	the	degree	to	which	trauma	or	shock	 contributes	 to	 the	 host	 immune	 response,	 organ	 function	 and	 survival,	most	models	 incorporate	an	 initial	 traumatic	 injury	(which	can	be	scaled	up	to	increase	severity)	followed	by	bleeding	from	an	intravascular	catheter	following	either	a	fixed	pressure	or	fixed	volume	protocol	(which	can	also	be	scaled	up	as	required).	Table	2.1	summarises	the	recently	published	rodent	models	of	trauma	haemorrhage.	It	is	clear	from	this	table	that	most	of	the	included	models	do	not	have	 an	 endpoint	 of	 MOF,	 or	 if	 the	 model	 does	 indeed	 develop	 MOF,	 data	regarding	this	is	not	provided.	Most	commonly,	lung	injury	is	the	main	reported	endpoint;	 occasionally,	 it	 is	 lung	 injury	 in	 conjunction	 with	 another	 organ	dysfunction.	Clearly,	the	development	of	a	model	of	trauma	haemorrhage	leading	to	MOF	is	an	important	and	unmet	research	need.				
	 79	
Study	
	
	
	
Trauma	
	
	
	
Haemorrhage	 Reperfusion	(Duration)	 End	points	
(Hirano	et	al.,	2005)	 Laparotomy	 MAP	40mmHg	for	20	min			
n/a	(1	h)	 Liver	ischaemia,	Renal	neutrophil	infiltration	(Masuno	et	al.,	2006)	 Laparotomy	 MAP	30mmHg	for	45	min	(most	severe)			
½	shed	blood,	4x	shed	blood	vol	w	NS	(2h)	 Neutrophil	activation	by	post	shock	mesenteric	lymph	(Gonzalez	et	al.,	2002,	Gonzalez	et	al.,	2001)	 Laparotomy	 MAP	40mmHg	for	30	min			
½	shed	blood,	2x	shed	blood	vol	w	RL	(2h)	 Neutrophil	activation	by	post	shock	mesenteric	lymph	(Gonzalez	et	al.,	2001)	 Laparotomy	 MAP	40mmHg	for	30	min			
½	shed	blood,	2x	shed	blood	vol	w	RL	(2h)	 Neutrophil	activation	by	post	shock	mesenteric	lymph	(Lee	et	al.,	2008)	 Laparotomy	 MAP	30-40mmHg	for	90	min			
100%	shed	blood	(3h)	 Lung	injury	Ca2+	inhibition		(Rupani	et	al.,	2007)	 Laparotomy	 MAP	30-40mmHg	for	90	min			
100%	shed	blood	(3h)	 Gut	permeability			(Fujiyoshi	et	al.,	2005)	 Laparotomy	 MAP	30-40mmHg	for	90	min			
3x	shed	blood	vol	w	RL	(or	sm.	vol	HTS)	(3h)		
Gut	permeability	Lung	injury	Neutrophil	activation	(Lee	et	al.,	2005)	 Laparotomy	 MAP	30-40mmHg	for	90	min			
100%	shed	blood	(3h)	 Lung	injury	Neutrophil	activation	(Lee	et	al.,	2004)	 Laparotomy	 MAP	30-40mmHg	for	90	min			
100%	shed	blood	(3h)	 Lung	injury	Neutrophil	activation	(Deitch	et	al.,	2003,	Sambol	et	al.,	2000)	 Laparotomy	 MAP	30-40mmHg	for	90	min	 3x	shed	blood	vol	w	RL		(or	sm.	vol	HTS)	(3h)		
Neutrophil	activation	by	post	shock	mesenteric	lymph	
(Sambol	et	al.,	2000)	 Laparotomy	 MAP	30-40mmHg	for	90	min			
3x	shed	blood	vol	w	RL	(3h)	 Lung	injury	Mesenteric	lymph	diversion	(Kilicoglu	et	al.,	2006)	 Laparotomy	Splenectomy	Omentectomy	 MAP	40mmHg	for	60	min	 100%	shed	blood	1x	shed	blood	vol	w	RL	(2h)		
Lung	injury	
(Zhang	et	al.,	2010a)	 Laparotomy	 MAP	30-40mmHg	for	90	min			
100%	shed	blood	(3h	to	7	days)		 Plasma	mtDNA	levels	(Frith	and	Brohi,	2010)	 Laparotomy	Bilateral	tibia/fibula	fractures			
MAP	40-50mmHg	for	70	min			
No	resus	(0h)	 Coagulopathy	
(Darlington	et	al.,	2013)	 Laparotomy	Crush	injury	to	small	bowel,	liver,		Rt	leg	muscle	Rt	femur	fracture		
MAP	40mmHg	until	40%	loss	EBV	 No	resus	(4h)	 Coagulopathy	Kidney	injury	
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	Table	2.1.	Studies	of	rodent	trauma	haemorrhage.	MAP,	Mean	arterial	pressure.	EBV,	Estimated	blood	volume	(65ml/kg	for	rats).	HS,	Haemorrhagic	shock.	NS,	Normal	saline.	RL,	Ringer’s	lactate	solution.	HTS,	Hypertonic	saline	solution.		
(Bumann	et	al.,	2003)	 Tibial	fracture	 Fixed	volume	12ml/kg			 12ml/kg	colloid			 Fracture	healing	at	4	weeks		(Pelinka	et	al.,	2004)	 Bilateral	femur	fractures	 MAP	30-35mmHg	until	40%	shed	blood	vol	given	as	RL;	then	MAP	40-45mmHg	for	40	min		
Variable	vol	RL	(1h)	 Release	of	neuron-specific	enolase	in	plasma	(Liu	et	al.,	2004)	 Rt	femur	fracture	 MAP	45mmHg	for	60	min	 1-3x	shed	blood	vol	w	RL	(2h)		
Lung	injury	Survival	
(Guan	et	al.,	2002)	 Multiple	fractures	(femur,	tibia,	humerus)	 MAP	40mmHg	for	60	min	 100%	shed	blood	+4ml	NS	(6-24h)		
Apoptosis	of	multiple	organs	
(Sato	et	al.,	2012)	 Laparotomy	 Fixed	volume	25%	EBV	 No	resus	(5h)			
Liver	injury	
(Nishi	et	al.,	2013)	 Tail	amputation	 Fixed	vol	35%	EBV	(15min)	Uncontrolled	HS	via	tail	amputation	+	4-33ml	RL	(45min)	
Tail	ligated	1/3	shed	blood	(10min)	+7ml	RL		(30	min)		
Coagulopathy	vs	degree	of	fluid	resuscitation	
(Morgan	et	al.,	2015)	 Tail-cut	(4	cm)	or		Liver	punch	biopsy	or		Liver	laceration	or		Spleen	transection			
Uncontrolled	HS	15-28%	loss	EBV	(30min)	 No	resus	(48h)	 Survival	
(Park	et	al.,	2013)	 Laparotomy	Splenic	injury	 Uncontrolled	HS	for	60	min				
Variable	NS	and	blood,	splenectomy	(1h)	
Coagulopathy	vs	hypothermia	Survival	to	48h	
(Krausz	et	al.,	2003)	 Laparotomy	Massive	splenic	crush	injury	 Uncontrolled	HS	25-30%	loss	EBV			
No	resus	(4h)	 Reproductive	cycle	of	female	vs	survival	(Bayram	et	al.,	2012)	 Laparotomy	Massive	liver	injury	 Uncontrolled	HS	50-70%	loss	EBV			
Variable	vol	RL	(90min)	 Survival	study	of	terlipressin	vs	RL	vs	control	(Gan	et	al.,	2015a,	Zhao	et	al.,	2014)	 Unilateral	femur	fracture	 No	haemorrhage				
-	(up	to	72h)	 Lung	injury	
(Zhao	et	al.,	2014)	 Unilateral	haemorrhagic	pulmonary	contusion		
No	haemorrhage			 -	(16h)	 Lung	injury	(Wang	et	al.,	2013)	 Whole	body	blunt	trauma	Noble-Collip	drum	 No	haemorrhage				
-	(12h)	 Myocardial	injury	
(Gierer	et	al.,	2008)	 Leg	soft	tissue	trauma	by	pneumatically	driven	impact	device	 No	haemorrhage	(Delayed	LPS	at	6h)			
-	(24h)		 Skeletal	muscle	microcirculation	(Gorbunov	et	al.,	2004)	 Global	Blast	injury	 No	haemorrhage			 -	(24h)			
Lung	injury	
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Traumatic	Injury	–	Midline	Laparotomy		This	is	the	commonest	form	of	inflicted	soft	tissue	injury	reported	in	the	rodent	and	comprises	a	midline	2.5-4.0cm	incision	subsequently	repaired	with	sutures	or	staples	 in	one	or	 two	 layers.	This	model	has	been	 in	use	 for	 the	 last	 twenty	years	in	combination	with	a	fixed	pressure	haemorrhage	and	was	pioneered	by	the	 groups	 lead	 by	 Deitch	 and	 Moore	 (Hauser,	 2005,	 Valparaiso	 et	 al.,	 2015,	Tsukamoto	 and	 Pape,	 2009).	 	 Early	 work	 by	 Chaudry	 suggested	 that	 the	contribution	of	laparotomy	to	early	cellular	immune	depression	was	minimal	in	addition	 to	 haemorrhagic	 shock	 (Schmand	 et	 al.,	 1994).	 However,	 this	 finding	was	 later	 rebuffed	 by	work	 from	 the	 same	 group	who	 found	 that	 the	 immune	depression	 was	 significant	 and	 comparable	 to	 leg	 fracture	 (Wichmann	 et	 al.,	1998).	Intentional	or	accidental	bowel	manipulation	during	laparotomy	has	been	suggested	 as	 a	 driver	 for	 increased	 inflammation,	 remote	 organ	 injury	 and	increased	model	severity	(Hu,	1992,	Thomas	et	al.,	2005,	Atkins	et	al.,	2013).		
Peripheral	Traumatic	injury	–	Closed	Long	bone	fractures		Femur,	Tibia	 and	Fibula	 fracture:	Numerous	 studies	have	 included	 this	 type	of	injury.	 In	 a	 typical	 rodent	 of	 350g	 the	 femur	 is	 fairly	 robust	 and	 cannot	 be	reliably	be	fractured	manually.	Several	techniques	have	been	described:		1. Manual	methods	(more	appropriate	for	bones	other	than	the	femur	in	the	rat)	(Bonnarens	and	Einhorn,	1984,	Frith	et	al.,	2010)	
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2. 3	 point	 bending	 technique	 using	modified	 surgical	 forceps	 (Guan	 et	 al.,	2002,	Pelinka	et	al.,	2004).	3. Blunt	 guillotine	 device	 driven	 by	 a	 dropped	 500g	 weight	 to	 produce	minimal	 soft	 tissue	 injury	 and	 transverse	 femur/tibia	 fracture	(Bonnarens	and	Einhorn,	1984,	An	et	al.,	1994).	4. Modified	3	point	impact	device:	six	stainless	steel	balls	weighing	65g	each	stacked	together	in	a	tube	3	feet	above	the	mid-femur	(suspended	across	two	 aluminium	 stands)	 and	 then	 dropped	 onto	 a	 rounded	 aluminium	blade	(Darlington	et	al.,	2013).	5. Open	 femur	 fracture	 techniques	have	 also	been	described	 in	 the	 rodent	(Frink	et	al.,	2011).		
Peripheral	Traumatic	injury	-	Muscle	Crush	Injury		Various	methods	have	been	described	in	the	literature	to	induce	limb	soft	tissue	injury	 in	 the	 rodent,	 usually	 consisting	 of	 direct	 injury	 to	 the	 hind	 limbs.	 For	example,	a	 large	surgical	haemostat	forceps	has	been	used	to	clamp	the	muscle	of	 the	 leg	 repeatedly	 (Darlington	 et	 al.,	 2013)	 and	 a	 computer	 controlled	pneumatic	impact	device	has	been	used	(Gierer	et	al.,	2008).			
Traumatic	Injury	–	Chest	Injury		Direct	methods	have	been	used	whereby	a	unilateral	haemorrhagic	pulmonary	contusion	 results	 from	 the	 firing	of	 a	modified	 stapler	against	 the	 lateral	 chest	wall.	 	This	recreates	the	force	generated	when	a	70-kg	man	is	 involved	in	a	car	
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collision	 at	 20mph	 (Zhao	 et	 al.,	 2014).	 Low-pressure	 shock	waves	 to	 simulate	blast	injury	with	resultant	acute	lung	injury	has	also	been	reported	(Gorbunov	et	al.,	2004).			
Haemorrhage	–	Fixed	Pressure,	Fixed	Volume	or	Uncontrolled	Bleeding			Fixed	 pressure	 bleeding	 protocols	 involve	 the	 withdrawal	 of	 blood,	 rapidly	 at	first,	 to	 a	 low	 pressure	 target,	 commonly	 a	 MAP	 of	 30-40mmHg,	 where	 it	 is	maintained	for	the	duration	of	the	ischaemic	period,	either	by	further	removal	or	reinfusion	of	(shed)	blood.	Clearly,	a	variable	volume	of	blood	can	be	removed	to	achieve	 this	 pressure	 target.	 This	 volume	 is	 further	 altered	 depending	 on	 the	type	and	depth	of	anaesthesia,	and	the	severity	of	traumatic	insult.	This	model	is	not	 representative	 of	 the	 clinical	 scenario.	 Furthermore,	 resuscitation	 with	iatrogenically	harmful	fluid	and/or	anticoagulated	blood	is	often	required.			Fixed-volume	 haemorrhage	 protocols	 allow	 for	 an	 assessment	 of	 the	 normal	compensation	mechanisms	 to	 be	made	 at	 the	 expense	 of	 a	 variable	 degree	 of	hypotension.	 The	 normal	 compensation	 mechanisms	 per	 se	 can	 be	 highly	variable,	too.		Uncontrolled	 haemorrhage	 protocols	 are	 the	 most	 clinically	 realistic	 but	 are	highly	 complex	 with	 a	 high	 degree	 of	 variability	 and	 therefore	 require	 higher	numbers.	 Ethical	 problems	 can	 arise	 due	 to	 the	 increased	 numbers	 of	 animals	required	(van	Zyl	et	al.,	2015).			
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Methods		
Ethics	Statement		All	 experiments	 were	 carried	 out	 using	 male	 Wistar	 rats	 (Charles	 River,	 UK)	weighing	 between	 280	 and	 350g.	 Animals	 received	 a	 standard	 diet	 and	 free	access	 to	water	 during	 a	 seven-day	 adaptation	 period	 after	 transport	 into	 the	laboratory	 from	 the	 supplier.	 This	 was	 performed	 in	 accordance	 with	 Home	Office	Guidance	in	the	Operation	of	the	Animals	(Scientific	Procedures)	Act	1986	and	 the	 Guiding	 Principles	 in	 the	 Care	 and	 Use	 of	 Animals	 published	 by	 the	American	Physiological	Society.			
Anaesthesia		All	 animals	were	anaesthetised	using	 intraperitoneal	 injections	 (i.p.)	of	 sodium	thiopentone,	 a	 barbiturate	 anaesthetic	 agent,	 at	 a	 dose	 of	 120mg/kg	 (Merial	Animal	 Health,	 UK).	 Small	 supplementary	 injections	 of	 thiopentone	 were	administered	intravenously	during	the	course	of	the	experiment	as	required.		
Temperature	Control		Animals	were	then	placed	supine	onto	a	thermostatically	controlled	heating	mat	(Harvard	Apparatus,	 UK).	 Body	 temperature	was	maintained	 at	 38+/-1°C	with	temperature	 feedback	 via	 a	 rectal	 temperature	 probe	 connected	 to	 the	
	 85	
homeothermic	 blanket.	 Desk	 lamps	 provided	 extra	 heat	 as	 required	 during	particularly	hypothermic	phases	such	as	controlled	haemorrhage.		
Airway	and	Ventilation		Airway	 patency	 and	 spontaneous	 respiration	was	 facilitated	 by	 a	 tracheotomy	and	 insertion	 of	 2cm	 length	 of	 polyethylene	 tubing	 (I.D.	 1.67mm,	 Portex,	 UK)	approximately	5mm	into	the	trachea	where	it	was	secured	with	nylon	sutures.			
Arterial	Catheterisation		The	left	carotid	artery	was	cannulated	under	direct	vision	with	PE50	tubing	(I.D.	0.58mm,	 Portex,	 UK)	 and	 attached	 to	 a	 pressure	 transducer	 (AD	 Instruments,	UK)	 and	 connected	 to	 a	 data	 acquisition	 system	 (Powerlab	 8/35,	 AD	Instruments,	UK)	 for	 the	measurement	 of	mean	 arterial	 blood	pressure	 (MAP)	and	heart	rate	(HR).	The	arterial	catheter	was	primed	with	heparinised	saline	at	a	concentration	of	50IU/ml	to	prevent	clot	formation.		
Venous	Catheterisation		The	right	jugular	vein	was	cannulated	under	direct	vision	with	PE25	tubing	(I.D.	0.40mm,	Portex,	UK)	for	the	administration	of	fluid,	blood	or	therapeutic	agent.	After	baseline	instrumentation	was	completed,	animals	were	allowed	to	stabilise	for	15	minutes	before	the	next	phase	commenced.			
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Induced	Traumatic	Injury		 1. Closed	lower	limb	midshaft	fractures.	One	or	both	tibias	and	fibulas	were	fractured	manually,	taking	care	not	to	break	the	overlying	skin	and	tissue.	2. 4cm	midline	 laparotomy.	 After	 hair	 removal	 and	 skin	 sterilisation	with	70%	 isopropyl	 alcohol	 wipes	 (Molnlycke	 Healthcare,	 UK),	 a	 careful	midline	incision	was	made	without	bowel	manipulation.	The	wound	was	closed	 within	 5	 minutes	 in	 one	 layer	 with	 interrupted	 surgical	 4/0	sutures	(Prolene,	Ethicon,	UK).	3. Bilateral	 lower	 limb	muscle	 crush.	Haemostatic	 forceps	were	 applied	 to	the	upper	musculature	of	each	lower	limb	and	clamped	down	maximally	for	10	seconds.		4. Limb	 fracture	 haematoma,	 intraperitoneal	 haematoma	 and	 laparotomy	wound	haematoma	were	excluded	at	necropsy.		
Haemorrhagic	Shock	(Baseline	model)		Blood	was	withdrawn	via	the	carotid	artery	catheter	to	reduce	the	MAP	to	35+/-5mmHg	within	10	minutes,	at	a	rate	no	faster	than	1ml	blood	per	minute.	MAP	was	maintained	at	35+/-5mmHg	for	90	minutes	by	withdrawal	or	re-injection	of	heparinised	 shed	 blood.	 Animals	 were	 excluded	 if	 the	 volume	 of	 re-injected	blood	exceeded	10%	of	the	total	blood	withdrawn.	Blood	was	withdrawn	into	a	syringe	containing	heparin	at	a	concentration	of	100IU/ml	and	was	stored	at	4°C	until	it	was	rewarmed	to	room	temp	5	minutes	before	resuscitation	and	50%	of	this	volume	was	reinjected	 into	the	animal	over	10	minutes.	This	was	 followed	
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by	 a	 20ml/kg	 bolus	 of	 Hartmann’s	 solution	 (Baxter	 Healthcare,	 UK)	 over	 10	minutes,	followed	by	an	infusion	of	1.5ml/kg/	hr	for	4	hours.		
Point	of	Care	(POC)	tests		
Lactate	measurement.		A	20μl	blood	sample	was	withdrawn	and	used	for	lactate	measurement	(Accutrend,	Roche,	UK)	
Blood	gas	 analysis.	 A	 100μl	 blood	 sample	was	 aspirated	 into	 a	 heparin-coated	(heparin	fully	expelled)	syringe	for	blood	gas	analysis	(Radiometer,	UK).	
	
Plasma	preparation	
Terminal	 blood	was	 collected	 into	EDTA	 containing	 tubes	 (3	 x	 1.3ml,	 Sarstedt,	UK),	 gently	 inverted	 3	 times	 and	 immediately	 centrifuged	 at	 1600g	 for	 15	minutes	 at	 4°C	 and	 then	 again	 at	 16,000g	 for	 another	 15	 minutes	 at	 4°C		(Eppendorf	 cooled	 centrifuge	 Model	 5417R).	 200μl	 aliquots	 of	 plasma	 were	made	 in	 0.5ml	 tubes	 (Eppendorf,	 UK)	 and	 flash	 frozen	 in	 liquid	 nitrogen	 and	stored	at	-80°C	for	later	analysis.		
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Biochemical	Organ	Function	Analysis		Plasma	samples	were	sent	to	a	contract	laboratory	(Vetlab	Services,	Sussex,	UK)	for	 analysis	 within	 24	 h	 for	 urea,	 creatinine,	 alanine	 aminotransferase	 (ALT),	aspartate	 aminotransferase	 (AST)	 and	 creatine	 kinase	 (CK).	 Renal	 dysfunction	was	 quantified	 by	 the	 rise	 in	 urea	 (a	 marker	 of	 pre-renal	 renal	 impairment	and/or	increased	catabolism)	and	creatinine		(a	marker	of	impaired	glomerular	filtration	 rate	 (GFR)	 (Chatterjee	 and	 Thiemermann,	 2003).	 Liver	 injury	 was	quantified	by	a	rise	in	ALT	(a	specific	marker	of	parenchymal	damage)	and	also	in	AST	(a	non-specific	marker	of	liver	injury,	which	is	also	raised	in	myocardial,	renal	and	muscle	necrosis)	(Gill	et	al.,	2011).	Muscle	injury	was	quantified	by	a	rise	 in	 CK,	 which	 is	 also	 elevated	 in	 cardiac	 muscle	 injury	 and	 brain	 injury	(Strecker	et	al.,	1999).		
Plasma	Cytokine	Analysis		Commercial	colorimetric	rat	ELISA	kits	for	the	measurement	of	plasma	IL-1β,	IL-6	and	TNF-α	were	used	(R&D	Systems,	UK).	Rat	HMGB1	(MyBioSource,	USA)	and	TFAM	 (Cusabio,	 Japan)	ELISA	kits	were	 also	used.	 Plasma	dilutions	were	none	(neat)	for	all	ELISA	kits	except	IL-6	(1:2	dilution).		
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Lung	Myeloperoxidase	(MPO)	Activity	
	Performed	 in	 association	 with	 Prof.	 Massimo	 Collino,	 Department	 of	 Drug	Science	 and	 Technology,	 Turin	 University,	 Italy.	 MPO	 activity,	 used	 as	 an	indicator	of	leukocyte	accumulation	into	the	lung,	was	determined	as	previously	described	 (Collino	 et	 al.,	 2011).	 Briefly,	 samples	 were	 homogenised	 and	centrifuged	for	30	min	at	13,000g	at	4°C.	An	aliquot	of	the	supernatant	was	then	allowed	 to	 react	 with	 a	 solution	 of	 1.6	mM	 tetramethylbenzidine	 and	 0.1	mM	H2O2.	The	rate	of	change	in	absorbance	was	measured	spectrophotometrically	at	460	nm.	MPO	activity	was	defined	as	the	quantity	of	enzyme	degrading	1	µmol	of	peroxide	per	min	at	37°C	and	was	expressed	in	milliunits	per	gram	of	wet	tissue.	All	compounds	from	Sigma,	Missouri,	USA.		
Statistical	Analysis	
All	 statistical	 analyses	 were	 performed	 using	 Graphpad	 Prism	 version	 6.	Parametric	 data	 was	 analysed	 using	 student’s	 t	 test;	 multiple	 groups	 using	ANOVA	 with	 Dunnett’s/	 Tukey’s	 comparisons	 as	 appropriate.	 Non-parametric	data	 was	 analysed	 using	 Chi-square	 tests.	 Mean	 values	 with	 SEM	 quoted	throughout	unless	otherwise	stated.			
			
	
	
	 90	
Model	development	and	Results		
Existing	 model	 of	 rodent	 haemorrhagic	 shock	 in	 Professor	 Thiemermann’s	
laboratory		A	 highly	 validated	 and	well-published	model	was	 in	use	 on	my	 arrival	 at	 Prof.	Thiemermann’s	laboratory	(Patel	et	al.,	2011,	Nandra	et	al.,	2012,	Nandra	et	al.,	2013).	 It	 comprised	 of	 haemorrhagic	 shock	 induced	by	 the	 removal	 of	 arterial	blood	to	maintain	a	MAP	of	35mmHg	(+/-5mmHg)	over	90	minutes.	During	the	compensation	period,	shed	heparinised	blood	was	returned	(up	to	a	maximum	of	10%	of	the	total	volume	of	shed	blood)	as	necessary	to	maintain	the	MAP	in	this	range.	These	experiments	resulted	in	approximately	50%	of	the	total	circulatory	blood	volume	of	each	animal	being	removed	over	90	minutes,	with	the	majority	of	 blood	 being	 removed	 within	 60	 minutes.	 Subsequently,	 resuscitation	comprised	 of	 a	 combination	 of	 crystalloid	 (20ml/kg	Hartmann’s	 solution),	 half	the	 volume	 of	 shed	 blood	 and	 commencement	 of	 a	 low	 dose	 crystalloid	 fluid	infusion	 (Hartmann’s	 solution	 at	 1.5ml/kg/hr)	 over	 the	 4-hour	 resuscitation	period.	Animals	were	euthanased	at	the	end	of	this	5.5	hour	experiment.	Multiple	organ	failure	was	evident	on	examination	of	serum	and	tissues,	with	an	overall	mortality	reported	of	17%,	indicating	a	moderately	lethal	model.			
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Model	1:	The	addition	of	 traumatic	 injury	and	elimination	of	crystalloid	 from	the	
baseline	haemorrhagic	shock	model		
Survival	study		The	addition	of	a	severe	traumatic	insult,	consisting	of	bilateral	lower	limb	(tibia	and	fibula)	fractures	and	4cm	midline	laparotomy,	to	the	existing	haemorrhagic	shock	 model	 produced	 a	 100%	 experimental	 mortality	 rate	 (Group	 C).	 The	animals	 exhibited	 signs	 of	 severe	 injury	 in	 the	middle	 of	 the	 experiments	 and	then	 succumbed.	 The	 haemorrhagic	 shock	 phase	was	 therefore	 adjusted	 to	 be	less	 severe	 to	 accommodate	 this.	 Table	 2.2	 describes	 the	 sequential	modifications	 made	 to	 the	 existing	 baseline	 model.	 It	 was	 felt	 that	 the	 large	crystalloid	 element	 of	 the	 existing	 resuscitation	 protocol	 was	 not	 realistic	 of	current	 clinical	 practice	 where	 an	 avoidance	 of	 such	 fluid	 is	 recommended	(Johansson	 et	 al.,	 2014).	 An	 emphasis	 on	 balanced	 blood	 product	 use	 in	 the	hyperacute	 stage	 of	 bleeding	with	 a	 1:1:1	 ratio	 for	Platelets:FFP:PRBCs	 is	 now	advocated,	 whereby	 lost	 blood	 is	 essentially	 replaced	 with	 whole	 blood		(Holcomb	 et	 al.,	 2015).	 Thus,	 I	 removed	 all	 crystalloid	 use	 in	 the	 next	 model	iteration	 (Group	 D)	 and	 used	 100%	 of	 the	 shed	 blood	 for	 resuscitation	 of	 the	animal	with	a	resultant	experimental	mortality	of	9%	compared	to	the	previous	model’s	23%.	Following	this,	 the	experiment	was	repeated	with	the	addition	of	the	 standard	 traumatic	 injury	 which	 produced	 a	 serious	 injury	 overall	 with	 a	mortality	 rate	of	 60%	 (Group	E).	After	 ten	 animals	were	used,	 it	 became	 clear	that	 the	haemodynamic	 status	 of	 the	 four	 survivors	was	poor	 and	 that	 further	experiments	were	deemed	futile	and	unlikely	to	significantly	increase	the	rate	of	
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overall	survival	in	this	study.	This	model	clearly	was	not	going	to	be	a	practical	model	of	MOF	with	which	to	continue.	A	similar	but	less	severe	model	developed	by	Deitch	incorporating	laparotomy	alone	with	haemorrhagic	shock	of	MAP	30-40mmHg	 for	 90	minutes	 and	 resuscitation	with	 shed	 blood	has	 documented	 a	mortality	of	up	 to	25%	(Rupani	et	al.,	2007).	The	 following	 iteration	(Group	F)	involved	the	standard	traumatic	injury,	a	reduced	shock	time	of	60	minutes	and	100%	 shed	 blood	 resuscitation	 and	 resulted	 in	 an	 experimental	 mortality	 of	33%.								
	Table	2.2.	Characteristics	of	various	model	iterations	from	the	existing	baseline	model	onwards			
	
Grp	 Descriptor	
	
	
Trauma	
Phase	
	
Shock	
Phase	
Resuscitat’n	
Phase	 Resus	time	(h)	 Tot	time	
(h)	
Numbers	
	
Mortality	
(%)	
Maintenance	
	 Fluids	
Start	 Finish	
A	 Trauma	only			
B/l	limb	fractures	+	Laparotomy	 Nil	 Nil	 -		 5.75	 10	 10	 0		1.5ml/kg/h	
B	
	
	
	
Baseline	H/S	Model	 Nil	 MAP	35mmHg	90	min	 ½	shed	blood	+	CSL	20ml/kg	 4		 5.75	 13	 10	 23	1.5ml/kg/h	
C	 Baseline	H/S	Model	+	Trauma	 B/l	limb	fractures	+	Laparotomy	 MAP	35mmHg	90	min	 ½	shed	blood	+	CSL	20ml/kg	 4		 5.75	 8	 0	 100		1.5ml/kg/h	
D	
	
	
	
Modified	Resus			
Nil	 MAP	35mmHg	90	min	 100%	shed	blood	 4		 5.75	 11	 10	 9	Nil	
E	
	
	
	
Trauma	+	Modified	Resus	 B/l	limb	fractures	+	Laparotomy	 MAP	35mmHg	90	min	 100%	shed	blood	 4		 5.75	 10	 4	 60	Nil	
F	 Modified	Shock+	Resus+	Trauma	
B/l	limb	fractures	+	Laparotomy	 MAP	35mmHg	60	min	 100%	shed	blood	 5		 6.25	 15	 10	 33	Nil	
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Haemodynamic	Effects		Figure	 2.1	 depicts	 the	 haemodynamic	 profiles	 of	 all	 groups.	 	 All	 groups	 had	similar	values	for	MAP	and	HR	at	baseline.	In	animals	subjected	to	haemorrhage,	resuscitation	with	blood	and/or	crystalloid	resulted	 in	a	rapid	 increase	 in	MAP	from	 approximately	 35mmHg	 to	 between	 100+/-6mmHg	 and	 118+/-5mmHg,	followed	by	a	gradual	decline	 in	MAP	over	the	course	of	the	experiment.	There	were	no	significant	differences	in	MAP	between	the	shocked	groups	throughout	the	study,	except	for	at	time	90	minutes,	reflecting	a	different	bleeding	time	of	60	and	 90	minutes	 between	 some	 of	 the	 groups.	 Both	 the	 rate	 of	 decline	 of	MAP	during	the	reperfusion	phase	and	the	absolute	decline	were	highly	correlated	to	the	 severity	 of	 organ	 dysfunction	 and	 overall	 survival.	 For	 example,	 the	correlation	between	survival	and	final	MAP	was	r=0.90,	p=0.001.			No	significant	differences	in	HR	were	observed	at	any	time	point	between	any	of	the	groups.	There	was	a	small	non-significant	gradual	rise	in	HR	in	the	sham	and	trauma	 only	 groups	 from	 a	 baseline	 range	 of	 398+/-10	 to	 409+/-11	 beats	 per	minute	to	a	final	range	of	420+/-16	to	429+/-16	beats	per	minute	at	the	end	of	the	experiment	(means	+/-SEM	values).	The	surviving	shock	groups	experienced	small	but	non-significant	drops	in	HR	during	their	haemorrhage	phases,	followed	by	 a	 small	 but	 again	 non-significant	 overshoot	 in	HR	 after	 resuscitation.	 Close	observation	 of	 the	 HR	 during	 the	 bleeding	 and	 resuscitation	 phases	 revealed	important	clues	as	to	the	severity	and	lethality	of	the	model.	For	example,	during	the	first	60	minutes	of	haemorrhage,	the	addition	of	trauma	appeared	to	result	in	further	 depression	 of	 the	 HR	 compared	 to	 bleeding	 without	 trauma.	 Also,	 the	
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reduction	 in	 ischaemic	 time	 from	 90	 minutes	 to	 60	 minutes	 minimised	 the	depression	 in	 HR	 during	 this	 phase.	 The	 small	 n	 numbers	 involved	 in	combination	 with	 highly	 variable	 physiological	 responses	 to	 trauma	haemorrhage	precluded	detection	of	statistical	differences.	However,	the	lowest	HR	during	bleeding	and	HR	at	the	end	of	the	experiment	were	highly	correlated	to	experimental	mortality,	e.g.	r=0.97,	p=0.0062	for	final	HR.		 	
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Figure	 2.1.	 	Haemodynamic	 data	 for	 baseline	 and	modified	models.	 Sham	group,	 instrumented	rats,	 n=5,	 blue.	 Group	 A,	 Trauma	 only:	 Bilateral	 lower	 limb	 fractures	 and	 4cm	 midline	laparotomy,	 resutured,	 n=10,	magenta.	Group	B,	Baseline	H/S	Model:	 90	min	at	35mmHg	 then	resuscitation	 with	½	 volume	 shed	 blood	 over	 10	 min	 and	 20ml/kg	 Hartmann’s	 over	 50	 min,	n=10,	red.	Group	C,	Trauma	+	baseline	H/S	Model:	Bilateral	limb	fractures,	midline	laparotomy,	90	 min	 shock,	 MAP	 35mmHg,	 then	 resuscitation	 with	 ½	 volume	 shed	 blood	 and	 20ml/kg	Hartmann’s,	purple,	no	survivors	>4h.	Group	D,	90	min	H/S	+	100%	shed	blood:	Shock	for	90	min	MAP	35mmHg,	return	of	all	shed	blood	over	10	min,	n=10,	green.	Group	E,	Trauma	+	90	min	H/S	+	100%	shed	blood:	Bilateral	 lower	 limb	 fractures	plus	midline	 laparotomy,	 resutured,	90	min	H/S	at	35mmHg,	return	of	all	shed	blood	over	10	min,	n=4,	magenta.	Group	F,	Trauma	+	60	min	H/S	+	100%	shed	blood:	Bilateral	 lower	 limb	 fractures	plus	midline	 laparotomy,	 resutured,	60	min	H/S	at	35mmHg,	return	of	all	shed	blood	over	10	min,	n=10,	orange.	*	Denotes	p<0.05	for	all	shock	groups	vs	sham,	 t	 test.	Non-surviving	Group	C	excluded	 from	analysis.	Mean	values	with	SEM	error	bars	shown.						
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		Figure	2.2.	Heart	rate	data	for	all	models.	Mean	values	shown	only	for	clarity;	There	were	no	significant	differences	exist	in	HR	either	between	any	model	at	any	given	time	point	or	between	any	two	time	points	of	the	same	model,	p>0.05,	Two	way	ANOVA/Tukey’s.											
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Haemorrhage	 Phase	 –	 Haemoglobin	 (Hb)	 concentrations	 and	 blood	 volumes	
removed			The	 Hb	 level	 of	 both	 the	 sham	 and	 trauma	 only	 groups	 at	 90	 minutes	 were	similar	at	13.61	(+/-	0.44)	g/l	and	13.67	(+/-	0.29)	g/l	respectively	(mean	values	+/-SEM)(Figure	2.3).	The	Hb	levels	of	Groups	B	and	D	taken	at	90	minutes	 just	before	 resuscitation	 were	 also	 similar,	 8.4	 (+/-1.9)	 g/l	 and	 8.5	 (+/-1.3)	 g/l,	respectively	 (p<0.01	 vs	 sham/trauma	 Hb	 levels,	 t	 test).	 This	 is	 not	 surprising	given	these	groups	underwent	the	same	bleeding	protocol	–	90	minutes	at	a	MAP	of	35mmHg.	Assuming	a	drop	in	value	from	a	presumed	baseline	of	13.6g/l	this	implies	 a	 total	 blood	 volume	 removal	 of	 approximately	 40%	 for	 both	 groups.	However,	the	actual	recorded	blood	volumes	removed	were	11.06	(+/-0.24)	ml	and	11.69	(+/-	0.2)	ml,	respectively.	Assuming	a	total	circulating	blood	volume	of	65ml/kg	in	the	rat	and	a	mean	animal	weight	of	345	(+/-7)	g	for	this	experiment,	this	 implies	 a	49.3%	and	52.1%	removal	of	blood	volume,	 respectively.	This	 is	consistent	 with	 published	 data	 for	 the	 existing	 model.	 	 The	 application	 of	traumatic	 injury	 before	 the	 bleeding	 phases	 in	 Groups	 E	 and	 F	 generated	relatively	 greater	 subsequent	 haemodynamic	 disturbance	 such	 that	 less	 blood	could	be	removed	during	this	phase.	9.5	(+/-0.4)	ml	and	9.0	(+/-0.5)	ml	of	blood,	was	 withdrawn	 in	 groups	 E	 and	 F,	 respectively.	 This	 represents	 a	 42.4%	 and	40.6%	 loss	 of	 circulating	 volume,	 respectively	 (p<0.001	 vs.	 loss	 of	 volume	 in	groups	B	and	D,	t	test).	Thus,	the	trends	in	Hb	and	blood	volume	removed	mirror	each	other	reasonably	well.				
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		Figure	2.3.	Haemorrhage	phase	parameters.	Hb	values	taken	at	90	minutes	(60	min	for	Group	F)	for	 Groups	 Sham,	 A,	 B,	 D,	 E,	 F:	 13.61(+/-0.44)	 g/l,	 13.67(+/-0.29)	 g/l,	 8.406(+/-0.48)	 g/l,	8.543(+/-0.28)	g/l,	10.79(+/-0.59)	g/l,	10.71(+/-0.52)	g/l.	*	denotes	p<0.05	vs	sham,	**	denotes	p<0.01	vs.	sham.	The	haemorrhagic	shock	groups	experienced	a	fall	in	Hb	of	approximately	40%;	trauma	 plus	 haemorrhagic	 shock	 group	 experienced	 a	 fall	 in	 Hb	 of	 approximately	 20%.	 Total	volume	of	blood	withdrawn	in	Groups	B,	D,	E,	F:	11.06(+/-0.24)	ml,	11.69(+/-0.16)	ml,	9.536(+/-0.44)	 ml,	 9.0(+/-0.5)	 ml.	 **	 denotes	 p<0.01	 for	 trauma	 shock	 groups	 vs	 shock	 alone.	Haemorrhagic	 shock	 groups	 experienced	 approximately	 50/%	 reduction	 in	 circulating	 blood	volume	cf.	 to	approximately	40%	for	trauma	plus	haemorrhagic	shock	groups.	Lactate	 levels	at	the	end	of	haemorrhage	for	Groups	Sham	(control),	A	(control),	B,	D,	E,	F:	1.89(+/-0.14)	mmol/l,	2.085(+/-0.11)	 mmol/l,	 8.090(+/-0.43)	 mmol/l,	 9.25(+/-0.58)	 mmol/l,	 9.09(+/-0.59)	 mmol/l,	7.788(+/-0.39)	mmol/l.	**	denotes	p<0.01	vs	sham.	Mean	+/-SEM	values	used	throughout.	
Sham   A B D E F
0
5
10
15
H
b 
(g
/d
l)
End Bleed Hb
Sham   A B D E F
0
2
4
6
8
10
12
La
ct
at
e 
(m
m
ol
/L
)
End Bleed Lactate Sham  
Group A Trauma only
Group B Baseline HS Model
Group D 90min HS + Shed blood resus
Group E Trauma + 90min HS + 
Shed blood resus
Group F Trauma + 60min HS +
Shed blood resus
**	 **	
*	 *	
**	
**	 **	
**	
B D E F
0
2
4
6
8
10
12
B
lo
od
 v
ol
um
e 
(m
l)
Total blood volume removed
**	 **	
	 99	
Haemorrhage	Phase	–	Lactate			Lactate	levels	in	the	sham	and	trauma	only	groups	were	1.89	(+/-0.14)	mmol/l	and	 2.09	 (+/-0.11)	 mmol/l,	 respectively	 (p>0.05).	 The	 haemorrhagic	 shock	groups	 B	 and	D	 and	 the	 trauma	 plus	 haemorrhagic	 groups	 E	 and	 F	 generated	similar	considerably	raised	lactate	concentrations	just	before	their	resuscitation	phases:	 	 8.1	 (+/-	 0.43),	 9.3(+/-0.58),	 9.1	 (+/-	 0.59)	 and	 7.8	 (+/-	 0.39)	mmol/l,	respectively	(all	p<0.01	vs	sham/trauma	but	p>0.05	amongst	all	shock	groups,	t	test).	 There	 was	 a	 non-significant	 trend	 (p=0.10)	 to	 possibly	 support	 the	observed	difference	in	lactate	between	groups	E	and	F	(9.1	vs	7.8mmol/l)	given	the	 fact	 that	 group	 E	 experienced	 90	minutes	 ischaemic	 time	 compared	 to	 60	minutes	for	group	F.				
Organ	dysfunction		As	can	be	seen	in	Figure	2.4,	replication	of	the	existing	baseline	model	(Group	B)	generated	 moderate	 multiple	 organ	 failure	 as	 evidenced	 by	 elevated	 plasma	levels	 of	 urea,	 creatinine,	 AST,	 ALT	 and	 CK.	 Traumatic	 injury	 alone	 (Group	 A)	resulted	in	a	similar	haemodynamic	profile	and	not	significantly	different	organ	function	scores	as	compared	to	sham,	except	for	a	significant	rise	in	CK	(p<0.05,	t	test),	 a	 not	 unexpected	 finding.	 Resuscitation	 with	 100%	 of	 the	 shed	 blood	volume	 after	 the	 standard	H/S	 period	 and	 no	 crystalloid	 use	 at	 all	 (Group	D),	resulted	 in	 non-significant	 attenuation	 of	 all	 organ	 function	 markers.	Subsequently,	trauma	followed	by	a	90-minute	ischaemic	phase	and	then	100%	
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shed	 blood	 resuscitation	 (Group	 E)	 resulted	 in	 a	 severe	 MOF	 picture.	 Finally,	traumatic	 injury	 followed	 by	 a	 shortened	 haemorrhagic	 shock	 period	 of	 60	minutes	and	then	resuscitation	with	shed	blood,	yielded	a	somewhat	attenuated	pattern	of	MOF,	with	a	resultant	improved	survival	rate	as	compared	to	group	E.		Lung	MPO	was	 the	most	 sensitive	marker	of	organ	 injury	 related	 to	 increasing	traumatic	 injury	 and/or	 shock,	 followed	 by	 renal	 dysfunction	 and	 then	 liver	dysfunction.	This	correlates	with	the	progression	of	organ	dysfunction	found	in	clinical	postinjury	MOF	(Ciesla	et	al.,	2005).															
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														Figure	 2.4.	 Organ	 injury	 plasma	 and	 lung	 biomarkers	 in	 various	 models	 of	 (trauma)	haemorrhage.	Naïve	group,	uninstrumented	rats,	n=5,	black.	Sham	group,	instrumented	rats,	n=5,	blue.	 Group	 A,	 Trauma	 only:	 Bilateral	 lower	 limb	 fractures	 and	 4cm	 midline	 laparotomy,	resutured,	 cyan.	 Group	 B,	 Baseline	 H/S	Model:	 90	min	 at	 35mmHg	 then	 resuscitation	with	½	volume	shed	blood	over	10	min	and	20ml/kg	Hartmann’s	over	50	min,	red.	Group	D,	90	min	H/S	+	100%	shed	blood:	Shock	for	90	min	MAP	35mmHg,	return	of	all	shed	blood	over	10	min,	green.	Group	E,	Trauma	+	90	min	H/S		+	100%	shed	blood:	Bilateral	lower	limb	fractures	plus	midline	laparotomy,	resutured,	90	min	H/S	at	35mmHg,	return	of	all	shed	blood	over	10	min,	magenta.	Group	F,	Trauma	+	60	min	H/S	+	100%	shed	blood:	Bilateral	 lower	limb	fractures	plus	midline	laparotomy,	resutured,	60	min	H/S	at	35mmHg,	return	of	all	shed	blood	over	10	min,	orange.	*	denotes	p<0.05	 for	all	 shock	groups	vs	sham	(CK)	or	naïve	(MPO),	 t	 test.	§	denotes	p<0.001	vs	sham	(CK)	or	naïve	(MPO),	t	test	
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Model	2:	The	development	of	a	heparin-free	model	of	trauma	haemorrhage		The	models	described	above,	in	common	with	much	of	the	literature,	included	a	traumatic	 insult	 in	 combination	 with	 haemorrhage	 to	 generate	 ischaemic	 cell	stress,	apoptotic	and	necrotic	cell	death	with	resultant	MOF.	Resuscitation	was	with	heparinised	shed	blood,	which	poses	particular	challenges	and	problems	as	a	direct	result	of	the	systemic	heparinisation	of	the	animal.		
Heparin	problems		 1. Administration	of	heparin	to	an	animal	subjected	to	trauma	haemorrhage	results	 in	 a	model	 that	 is	 not	 clinically	 relevant.	 Increased	uncontrolled	bleeding	is	clearly	a	confounder.		2. Heparin	 is	 known	 to	 have	 anti-inflammatory	 properties	 by	 virtue	 of	 its	charge	 chemistry,	 as	 opposed	 to	 its	 direct	 anticoagulant	 activity.	 	 It	 is	 a	small	negatively	charged	molecule,	with	similar	properties	to	the	heparin	sulphate	 related	 components	 of	 the	 endothelial	 glycocalyx.	 Binding	 of	these	 endogenous	 molecules	 to	 RAGE	 is	 required	 for	 RAGE	 dependent	inflammatory	 signalling.	 Heparin	 has	 been	 shown	 to	 be	 a	 competitive	inhibitor	 of	 RAGE-TFAM	 mediated	 signalling	 and	 hence	 it	 reduces	endosomal	mtDNA-TLR9	dependent	inflammation	(Julian	et	al.,	2013).			 	
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3. Heparin	has	been	shown	to	also	have	deleterious	effects	on	inflammation	by	 directly	 promoting	 the	 release	 of	 toxic	 lipases	 from	 liver	 and	 fatty	tissue.	This	effect	was	not	related	to	the	charge	chemistry	of	heparin	(Qin	et	al.,	2011).		4. Other	 groups,	 however,	 have	 reported	 protective	 effects	 related	 to	heparinisation	 in	 animal	models	 of	 haemorrhagic	 shock.	 Early	work	 by	Rana	 et	 al.	 (1992)	 and	 Wang	 et	 al.	 (1990)	 reported	 increased	microvascular	 patency	 in	 heparinised	 animals	 subjected	 to	 severe	haemorrhagic	 shock.	 Subsequently,	 another	 group	 demonstrated	 that	heparin	 could	 displace	 myeloperoxidase	 (MPO)	 from	 vascular	endothelium	 and,	 furthermore,	 prevent	 MPO	 binding	 to	 vascular	endothelium,	 resulting	 in	 improved	 microvascular	 flow	 (Baldus	 et	 al.,	2006).			5. Heparin	has	also	been	reported	to	afford	lung	protection	in	aspiration	by	blocking	 the	 harmful	 effects	 of	 polycationic	 histones,	 again	 through	electrostatic	interactions	(Zhang	et	al.,	2014b).		 6. Heparin	 is	 known	 to	 be	 a	 powerful	 inhibitor	 of	 the	 chemical	 reactions	involved	 in	 PCR	 (García	 et	 al.,	 2002).	 Several	 groups	 have	 reported	successfully	 be	 able	 to	 measure	 plasma	 mtDNA	 from	 such	 heparinised	trauma	shock	models	(Zhang	et	al.,	2010b,	Zhang	et	al.,	2010a).	However,	other	groups	and	myself	 included	have	repeatedly	failed	to	demonstrate	consistent	 amplification	 of	 mtDNA	 from	 the	 models	 described	 above	
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(Chapter	3).	Therefore,	the	development	of	a	heparin-free	model	became	a	priority.			
Strategies	to	avoid	heparin	use	in	models	of	trauma	haemorrhage		 1. The	obvious	solution	is	to	use	a	blood-free	resuscitation	model,	 i.e.	pure	crystalloid.	 However,	 such	 models	 generally	 use	 large	 volumes	 of	crystalloid,	 generally	 2-3	 times	 the	 shed	 blood	 volume	 to	 maintain	perfusion	and	survival	(Wang	et	al.,	1990,	Rana	et	al.,	1992,	Mollen	et	al.,	2008).	 This	 paradigm	 is	 no	 longer	 reflective	 of	modern	 clinical	 practice	and	is	known	to	be	iatrogenically	harmful	(Marik,	2014).			2. Chaudry	et	al.	developed	a	heparin-free	model	with	the	use	of	a	tapered	catheter,	which	was	reported	as	being	less	thrombogenic	than	a	squared-off	 catheter	 tip,	 in	 combination	 with	 laparotomy	 involving	 bowel	manipulation	(Wang	et	al.,	1993).	It	has	been	suggested	that	the	addition	of	 trauma	 in	 these	models,	 e.g.	 laparotomy	with	 bowel	manipulation	 in	particular,	may	account	for	the	coagulopathic	state	seen	and	subsequent	lack	of	heparin	requirement.	This	trauma-induced	coagulopathy	has	been	postulated	to	be	due	to	a	combination	of	activation	of	protein	C	(Chesebro	et	al.,	2009),	systemic	auto-heparinisation	by	shedding	of	the	endothelial	glycocalyx	components	(Ostrowski	and	Johansson,	2012)	and	degradation	of	Weibel-Palade	bodies	from	the	endothelium	in	severe	injury	(Maegele	et	 al.,	 2014).	 To	 corroborate	 this,	 animal	models	 of	 pure	 haemorrhagic	shock	tend	not	to	develop	a	significant	coagulopathy,	and	in	fact,	become	
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hypercoagulable	 (Atkins	 et	 al.,	 2013).	 	 Clinically,	 acute	 traumatic	coagulopathy	 is	 more	 likely	 in	 severely	 injured	 patients	 suffering	 a	combination	of	tissue	injury	and	shock	(Maegele	et	al.,	2014).		 3. Alternate	 anticoagulation	 systems	 have	 been	 developed	 based	 on	commonly	 used	 regional	 citrate	 anticoagulation	 systems	 used	 in	 renal	replacement	devices	 for	 the	critically	 ill.	Atkins	et	al.	have	modified	 this	approach	 for	 haemorrhagic	 shock	 experiments	 in	 rodents	 by	 utilising	 a	dual	lumen	catheter	that	only	anticoagulates	the	blood	within	the	lumen	of	 the	catheter	to	guarantee	 luminal	patency	throughout	the	experiment	(Atkins	et	al.,	2013).		 4. Sato	 et	 al.	 reported	 on	 a	 novel	 rodent	 model	 of	 25%	 fixed	 volume	haemorrhagic	 shock	 model	 that	 generated	 liver	 injury	 after	 5	 hours	without	 resuscitation	 and	 a	 resultant	 low	 lethality	 (Sato	 et	 al.,	 2012).	 I	modified	 this	 model	 to	 include	 greater	 traumatic	 injury	 and	 the	development	 of	 MOF.	 Table	 2	 describes	 the	 various	 iterations	 of	 the	model	that	I	developed.			
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Haemorrhagic	shock	protocol	(Model	Iteration	2)		 During	 right-sided	 jugular	 vein	 catheterisation,	PE	25	 tubing	was	 advanced	gently	into	the	right	heart	such	that	blood	could	be	freely	aspirated.	Jugular	catheter	tip	positioning	was	confirmed	at	necropsy.	Haemorrhagic	shock	was	induced	 via	 bleeding	 from	 the	 jugular	 catheter	 to	 achieve	 a	 MAP	 of	 35+/-5mmHg	 within	 10	 minutes,	 at	 a	 rate	 no	 faster	 than	 1ml	 per	 minute.	Haemorrhage	 was	 continued	 over	 20-35	 minutes	 until	 20-30%	 of	 the	estimated	blood	volume	had	been	removed.	No	 resuscitation	was	delivered	to	the	animal	subsequently.	The	carotid	arterial	catheter	was	primed	with	a	reduced	concentration	of	heparinised	saline	(25IU/ml)	to	maintain	patency.	If	 the	MAP	signal	 indicated	a	problem	with	catheter	patency,	every	attempt	was	made	 to	 bleed	 back	 the	 catheter	 to	 remove	 any	 potential	 heparinised	saline	 before	 flushing	 with	 plain	 saline	 20μl	 (the	 dead	 space	 of	 a	 150mm	length	 of	 PE25	 tubing),	 then	 reconnecting	 to	 the	 heparinised	 saline	 system	and	 finally,	 re-priming	 with	 20μl	 heparinised	 saline.	 	 Thus,	 systemic	administration	of	heparin	was	mimimised.									
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Group	 Descriptor	 Trauma	
Phase	
Haemorrhage	
Phase	
Numbers	 Expt.	
Mortality	
Rate	(%)	
MOF	
Severity	
Start	 Finish	
1	 HS	30%	 Nil	 30%	fixed	vol	over	20	min		 8	 8	 0	 Low	
2	 T-HS	30%	 B/l	leg	fractures	+	laparotomy	 30%	fixed	vol	over	20	min	 6	 0	 100	 -	
3	 T-HS	20%	 B/l	leg	fractures	+	laparotomy	 20%	fixed	vol	over	20	min	 9	 8	 11.1	 Moderate	
4	 Severe	T-HS	25%			
B/l	leg	fractures	+	muscle	crush	+	laparotomy	
25%	fixed	vol	over	20	min	 4	 0	 100	 -	
5	 Severe	T-HS	25%	 B/l	leg	fractures	+	muscle	crush	+	laparotomy	
25%	fixed	vol	over	35	min	 13	 8	 38.4	 Severe	
	Table	2.3.	Characteristics	of	various	model	2	iterations			
Survival	Study			As	can	be	seen	 in	Table	2.3,	replication	of	 the	Sato	model	with	a	slightly	 larger	haemorrhage	(30%)	performed	over	a	mean	time	of	20	(+/-4)	minutes	resulted	in	 all	 animals	 surviving	 with	 a	 resultant	 low	 severity	 of	 MOF	 (Group	 1).	 The	addition	 of	 bilateral	 leg	 fractures	 and	 laparotomy	 resulted	 in	 100%	mortality	(Group	 2).	 Subsequently,	 haemorrhage	 was	 reduced	 to	 20%	 of	 circulating	volume	 over	 a	mean	 time	 of	 20	 (+/-4)	minutes	 (mean	 +/-SEM)	 to	 produce	 an	11%	experimental	mortality	with	moderate	severity	MOF	(Group	3).	For	the	final	iterations,	traumatic	injury	was	increased	to	include	a	10	second	bilateral	lower	limb	muscle	 crush	 injury	 in	 addition	 to	 bilateral	 leg	 fractures	 and	 laparotomy,	and	 a	 25%	 fixed	 volume	 haemorrhage	 initially	 over	 20	 (+/-4)	 minutes	 which	
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proved	 too	 severe	 with	 all	 4	 animals	 dying	 within	 3	 hours	 (Group	 4).	Subsequently,	 the	bleeding	time	was	increased	to	a	mean	of	35	(+/-4)	minutes.	This	resulted	in	an	experimental	mortality	of	38%	and	severe	MOF	(Group	5).			
Haemodynamic	Effects	–	MAP		As	can	be	seen	in	figure	2.5,	the	sham	group	experienced	a	steady	decline	in	MAP	over	 the	 course	of	 the	experiment	 from	a	baseline	of	131.6	 (+/-	3.7)	mmHg	 to	113	(+/-4.2)	mmHg	(p>0.05).	All	shock	groups	experienced	a	lower	MAP	relative	to	 shams	 through	 the	 course	 of	 the	 experiment	 (p<0.05).	 Groups	 1	 and	 3	experienced	a	similar	fall	in	MAP	and	similar	subsequent	compensation	in	MAP.	At	 10	 minutes,	 a	 nadir	 of	 42	 (+/-4)	 mmHg	 and	 37(+/-1)	 mmHg	 (p>0.05),	respectively,	 was	 achieved	 in	 both	 groups.	 Although	 group	 1	 suffered	 a	 30%	blood	loss,	the	addition	of	trauma	to	a	20%	blood	loss	in	group	3	produced	very	similar	 haemodynamic	 changes.	 Group	 5	 demonstrated	 a	 nadir	 MAP	 46(+/-3)	mmHg	 at	 25	 minutes	 to	 reflect	 a	 longer	 more	 gentle	 bleeding	 time	 in	 more	severely	 injured	animals.	There	were	no	statistical	differences	 in	MAP	between	any	of	 the	shock	groups	at	any	time	points	except	at	10	and	25	minutes	which	reflects	the	different	bleeding	protocols	between	Groups	1/3	and	5.	Final	MAPs	in	 Groups	 1,	 3	 and	 5	 were	 77	 (+/-1)	 mmHg,	 87	 (+/-4)	 mmHg	 and	 74	 (+/-3)	mmHg,	 respectively.	 The	 correlations	 between	 final	 MAP	 and	 survival	 seen	 in	Model	1	were	not	as	evident	for	this	model.	This	may	be	due	to	small	differences	in	 starting	 MAPs	 between	 the	 groups.	 However,	 these	 differences	 were	 not	statistically	 significant	 given	 the	 small	 n	 numbers	 involved	 and	 the	 highly	variable	physiological	responses	to	trauma	haemorrhage.			
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		Figure	2.5.	MAP	data	for	the	various	model	iterations.	Trauma	was	inflicted	during	-5	minutes	to	0	minutes.	Sham	group,	instrumented	animals,	n=8.	HS	30%	group,	Bleeding	of	30%	circulating	volume	over	20	minutes,	n=8.	T-HS	20%	group:	Bilateral	leg	fractures,	4cm	laparotomy,	bleeding	20%	circulating	volume	over	20	minutes,	 n=8.	 Severe	T-HS	25%	group:	Bilateral	 leg	 fractures,	4cm	laparotomy,	10	sec	bilateral	leg	muscle	crush	injury,	bleeding	25%	circulating	volume	over	35	minutes,	 n=8.	 During	 the	 haemorrhage	 and	 compensation	 phases	MAPs	 of	 all	 groups	were	significantly	lower	than	shams	at	all	time	points,	*	denotes	p<0.05,	t	test.	The	starting	MAP	of	the	HS	30%	group	was	significantly	 lower	 than	 that	of	 the	sham	and	T-HS	20%	groups,	p<0.05.	At	time	10	minutes	and	25	minutes,	the	severe	T-HS	25%	group	MAP	was	significantly	different	to	the	other	shock	groups	to	reflect	its	more	gradual	bleeding	time	of	35	minutes,	$	denotes	p<0.05,	test.	Otherwise	 there	were	no	 significant	 differences	 in	MAP	between	 the	 shock	 groups	 at	 any	time	point.	Two	way	ANOVA/Tukey’s	test	used.	Mean	values	with	SEM	bars	shown.			
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		Figure	 2.6.	 Heart	 rate	 data	 for	 all	 models.	 	 Starting	 HRs	 were	 similar	 for	 all	 groups,	 p>0.05.		Differences	 began	 to	 emerge	 at	 the	 onset	 of	 haemorrhage	 and	 again	 during	 the	 subsequent	compensation	 phases.	 	 Time	 5	 min	 (a)	 denotes	 p<0.01	 for	 T-HS	 25%	 vs	 Sham	 and	 HS	 30%	groups.	Time	10	min	(b)	denotes	p<0.05	for	Sham	vs	Severe	T-HS	25%	and	HS	30%	groups	and	p<0.0001	 for	 Severe	 T-HS	 25%	 vs	 HS	 30%	 and	 T-HS	 20%	 groups.	 At	 time	 220-250	 min	 (c)	denotes	Severe	T-HS	25%	vs	HS	30%	groups,	p<0.05.		At	time	280-370	min	(d)	denotes	p<0.001	for	Severe	T-HS	25%	vs	HS	30%	groups.	A	time	310	min	(e)	denotes	p<0.05	for	Severe	T-HS	25%	vs	 Sham.	 At	 time	 340	 min	 (f)	 denotes	 p<0.05	 for	 Severe	 T-HS	 25%	 vs	 Sham	 and	 T-HS	 20%	groups.	At	 time	370	minutes	 (g)	denotes	p<0.01	 for	 Severe	T-HS	25%	vs	Sham	and	T-HS	20%	groups.	Two	way	ANOVA/Tukey’s.	Mean	values	with	SEM	bars	shown.				
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Haemodynamic	Effects	–	Heart	Rate			As	can	be	seen	in	Figure	2.6,	the	HR	for	shams	was	relatively	unchanged	during	the	course	of	the	experiment	from	a	baseline	of	395	(+/-8.5)	bpm	to	389	(+/-15)	bpm	 (p>0.05).	 The	 starting	 HRs	 were	 similar	 at	 baseline.	 At	 the	 onset	 of	haemorrhage,	there	were	significant	drops	in	HR	in	the	two	groups	bled	over	20	minutes	 compared	 to	 the	 group	 bled	 over	 35	minutes.	 This	 is	most	 evident	 at	times	5	and	10	minutes	when	the	rate	of	bleeding	in	the	model	is	at	greatest.	At	25	minutes	through	to	180	minutes,	there	were	no	significant	differences	in	HR.	From	210	minutes	onwards,	HRs	of	each	group	began	to	separate	correlating	to	severity	 of	 injury.	 The	 overall	 severity	 of	 each	 model	 iteration	 was	 highly	correlated	with	the	final	HR	(as	with	Model	1),	r=0.99,	p=0.001.		
Organ	Dysfunction			As	 can	 be	 seen	 in	 Figure	 2.7,	 the	 development	 of	 shock	 resulted	 in	 varying	degrees	of	MOF.	The	addition	of	traumatic	injury	to	haemorrhagic	shock	resulted	in	more	severe	MOF.	Traumatic	injury	by	itself	did	not	result	in	the	development	of	MOF	 in	 these	models	 and	was	 associated	with	 100%	experimental	 survival.		Again,	 lung	 MPO	 was	 the	 most	 sensitive	 marker	 of	 organ	 injury	 related	 to	increasing	 traumatic	 injury	 and/or	 shock,	 followed	 by	 renal	 dysfunction	 and	then	liver	dysfunction.	This	correlates	with	the	progression	of	organ	dysfunction	found	 in	 clinical	 postinjury	 MOF	 (Ciesla	 et	 al.,	 2005).	 Spearman	 correlation	analysis	revealed	that	all	parameters	showed	very	high	levels	of	correlation	with	step-wise	increase	in	injury	severity,	p<0.0001	for	all	variables	(Figure	2.8).		
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								Figure	2.7.	Organ	injury	plasma	biomarkers	in	various	models	of	(trauma)	haemorrhage.		Trauma	was	 inflicted	during	-5	minutes	to	0	minutes.	Naïve	group,	uninstrumented	animals,	n=4.	Sham	group,	instrumented	animals,	n=8.	Mild	trauma	group:	Left	leg	fracture	only,	n=6.	Severe	trauma:	Bilateral	 leg	 fractures,	 4cm	 laparotomy,	 10	 sec	 bilateral	 leg	muscle	 crush	 injury,	 n=8.	HS	 30%	group:	Bleeding	of	30%	circulating	volume	over	20	minutes,	n=8.	T-HS	20%	group:	Bilateral	leg	fractures,	4cm	laparotomy,	bleeding	20%	circulating	volume	over	20	minutes,	n=8.	Severe	T-HS	25%	 group:	 Bilateral	 leg	 fractures,	 4cm	 laparotomy,	 10	 sec	 bilateral	 leg	 muscle	 crush	 injury,	bleeding	 25%	 circulating	 volume	 over	 35	minutes,	 n=8.	 *	 denotes	 p<0.05	 vs	 sham;	 **	 denotes	p<0.01	 vs	 sham;	 §	 denotes	 p<0.0001	 vs	 sham,	 all	 t	 tests.	 For	 Lung	 MPO	 symbols	 denote	significance	vs.	naïve	animals,	n=4	(uninstrumented	controls).	For	CK,	§	also	denotes	p<0.0001	for	Severe	T-HS	25%	vs	Severe	trauma	alone.	Mean	values	+/-SEM	bars	shown.		
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																											Figure	 2.8.	 Spearman	 correlation	 analysis	 of	 organ	 injury	 variables	 against	 injury	 severity	sustained.	 Injury	 scale	1=Naïve,	2=Sham,	3=Mild	 trauma,	4=Severe	 trauma,	5=HS	30%,	6=T-HS	20%,	7=Severe	T-HS	25%.	Linear	regression	 line	shown	 for	 illustrative	purposes.	p<0.0001	 for	all	 organ	 injury	 markers	 against	 injury	 severity.	 High	 overall	 correlations	 were	 seen	 for	 all	variables.	 However,	 it	 can	 be	 seen	 that	 lung	MPO	was	 the	most	 sensitive	marker	 to	 step-wise	increase	in	injury	severity;	AST	and	ALT	were	the	least	sensitive.		
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Discussion		I	 have	 developed	 a	 novel	 rodent	 model	 of	 trauma	 haemorrhage	 that	 involves	non-thoracic	trauma	and	fixed	volume	haemorrhage	without	resuscitation.	This	model	 resulted	 in	 consistent	 severe	 MOF	 and	 moderate-high	 lethality.	 It	 has	successfully	allowed	me	to	measure	a	range	of	trauma	related	DAMPs,	especially	mtDNA,	 which	 is	 otherwise	 problematic	 in	 heparinised	 animals,	 and	 correlate	their	 presence	 to	 injury	 (Chapter	 3).	 I	 have	 also	 successfully	 tested	 novel	therapeutics	in	this	model	(Chapter	4).		The	model	 generated	 progressively	 greater	 organ	 dysfunction	with	 each	 step-wise	increase	in	trauma	and	shock	applied.	It	is	clear	that	trauma	alone	does	not	cause	MOF	in	this	model,	which	mirrors	the	clinical	scenario	well.	The	presence	of	shock	is	clearly	required	for	the	development	of	MOF	in	this	model,	and	again,	this	mirrors	the	clinical	scenario.	These	results	generally	correlate	well	with	an	analysis	 of	 139	 trauma	 patients	 to	 the	 Royal	 London	 Hospital	 (unpublished	data).	 This	 study	 found	 that	 the	 patients	who	went	 on	 to	 develop	MOF	 had	 a	higher	 ISS	 (29	 vs	 12),	 lower	 systolic	 blood	 pressure	 (120	 vs	 136mmHg),	 and	worse	 base	 deficit	 (5	 vs	 2)	 on	 arrival	 to	 the	 emergency	 department	 (median	values	quoted,	p<0.01	for	all	variables).			The	correlation	analysis,	although	part	defined	on	an	arbitrary	scale,	does	allow	relative	comparison	of	the	sensitivity	of	the	organ	injury	markers	to	the	level	of	induced	injury	to	be	made.	It	can	clearly	be	seen	that	lung	MPO	levels	were	the	most	 sensitive	 to	 the	 stepwise	 increase	 in	 injury	across	 the	entire	 spectrum	of	
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injury	 followed	by	 the	 renal	markers	 and	 then	 the	 liver	markers.	 This	mirrors	the	onset	of	the	organ	dysfunction	seen	in	the	clinical	scenario	as	well.	 	Muscle	injury	 and	 systemic	 inflammation,	 as	 indicated	 by	 CK	 and	 plasma	 IL-6,	 were	intermediate	amongst	the	biomarkers	measured.			Plasma	 IL-6	 was	 found	 to	 correlate	 overall	 with	 increasing	 injury	 severity	(p<0.0001).	However,	no	detectable	levels	of	IL-1β,	TNFα,	HMGB1	or	TFAM	were	detected	in	any	group	by	ELISA	(data	not	shown).	Other	authors	have	also	found	that	IL-6	is	the	most	consistently	elevated	cytokine	in	traumatic	injury	clinically	and	experimentally	(Timmermans	et	al.,	2016b,	Frink	et	al.,	2007).	However,	 in	reality,	 complex	 temporal	 dynamic	 patterns	 of	multiple	 inflammation	markers	are	found	in	the	trauma	population,	which	may	have	prognostic	significance	for	the	development	of	MOF	and	nosocomial	infection	(Namas	et	al.,	2014).	HMGB1	and	TFAM	have	both	been	reported	in	the	early	post	trauma	period	(Namas	et	al.,	2014,	 Chaung	 et	 al.,	 2012).	 Therefore,	 the	 reasons	 for	 the	 lack	 of	 detection	 of	both	in	my	study	are	unclear.					The	severity	of	this	model	at	its	extreme	is	not	uncommon	in	the	field	of	animal	research	in	general.	The	resistance	of	the	commonly	used	animal	species	such	as	rats	and	mice	to	trauma	and	inflammation	is	well	documented	and	necessitates	a	significant,	often	near	fatal,	insult	to	enable	a	consistent	response	such	as	MOF	to	develop	(Osuchowski	et	al.,	2014).	The	6-hour	duration	of	my	model	is	common,	pragmatic	 and	 allows	 consistent	 unresuscitated	 MOF	 to	 develop.	 The	 clinical	relevance	of	my	model	is	somewhat	lessened	by	the	lack	of	a	resuscitation	phase	
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and	 critical	 care.	 However,	 clinical	 blunt	 injury	 in	 particular	 produces	 a	more	gradual	onset	of	shock	due	to	diffuse	bleeding	and	microvascular	injury,	and	the	duration	of	the	resultant	shock	is	often	prolonged	(Hauser,	2005).	My	model	also	has	 relevance	 for	 battlefield	 scenarios	 where	 blood	 and	 fluid	 resuscitation	 is	extremely	 limited	 and	 extraction	 times	 prolonged	 (Alam	 et	 al.,	 2009).	 Longer	duration	 animal	 models	 of	 trauma	 are	 inherently	 complex,	 expensive,	 and	uncommon	 in	 the	 United	 Kingdom	 and	 raise	 ethical	 concerns.	 Nonetheless,	repetition	of	 positive	 findings	 from	 small	 animal	 trauma	 studies	 is	 likely	 to	be	required	in	larger	animals	with	highly	realistic	protocols	before	clinical	testing	is	commenced.								
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CHAPTER	III	
	
MEASUREMENT	OF	CIRCULATING	
MITOCHONDRIAL	DNA	IN	TRAUMA	AND	ITS	
ASSOCIATION	WITH	INJURY	AND	ORGAN	
DYSFUNCTION	
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Introduction	
	The	polymerase	chain	reaction	(PCR)	is	a	ubiquitous	molecular	biology	tool	that	enables	the	detection	of	DNA,	theoretically	from	a	little	as	one	copy	of	the	gene	sequence	 being	 targeted.	 PCR	 requires	 the	 presence	 of	 starting	 DNA	 (to	 be	measured),	 primer	 pairs	 (short	 single	 strand	 DNA	 sequences	 designed	 to	 be	complementary	 to	 the	 target	 sequence	 in	 question),	 ample	 building	 blocks	 for	new	DNA	(nucleotides),	DNA	polymerase	and	specific	thermal	cycling	conditions	(Bartlett	and	Stirling,	2003).			After	 an	 initial	 5-10	 minute	 high	 temperature	 phase	 to	 activate	 the	 DNA	polymerase,	commonly	a	40-cycle	sequence	follows:		 1. Melting:	10-30	sec	at	95°C	causes	DNA	to	denature	and	to	split	into	single	strands	2. Annealing:	 20-40sec	 at	 a	 temperature	 3-5°C	 below	 the	 melting	temperature	 of	 the	 primers,	 allowing	 the	 primers	 to	 bind	 to	 single	stranded	DNA	3. Extension:	at	 the	optimum	temperature	 for	DNA	polymerase	 to	 function	(72°C	 for	 Thermus	 aquaticus	 (Taq)	 DNA	 polymerase)	 and	 generate	 a	complementary	 DNA	 strand	 by	 adding	 nucleotides	 that	 are	complementary	to	the	DNA	template	in	a	5’	to	3’	direction	4. Repetition	of	 this	 cycle	 results	 in	melting	of	 the	newly	 formed	DNA	and	allows	 twice	 the	 number	 of	 template	 to	 undergo	 the	 next	 step	 with	 a	doubling	of	dsDNA	at	each	cycle	
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Real	time	or	qualitative	(RT-PCR	or	qPCR)	
	The	addition	to	the	PCR	reaction	of	a	double	stranded	DNA-binding	dye,	such	as	SYBR	Green,	allows	the	cycle-by-cycle	(hence	the	term	real-time)	measurement	of	 newly	 formed	 dsDNA	 to	 be	made.	 Such	 dsDNA	 binding	 dyes	 only	 fluoresce	when	polymerisation	of	a	new	DNA	strand	has	occurred	every	cycle	 leading	 to	release	 of	 the	 fluorescent	 reporter	 (Ding	 and	 Cantor,	 2004).	 A	 compound	solution	 such	 as	 SYBR	 Green	 PCR	 Master	 Mix	 (Thermo	 Fisher	 Scientific,	 UK)	contains	all	 the	reagents	 required	 for	RT-PCR,	except	 for	 the	primers	and	DNA	template.  The	onset	of	the	exponential	phase	of	PCR	directly	extrapolates	to	the	amount	of	starting	 DNA	 template	 contained	 in	 the	 sample.	 The	 rate	 of	 PCR	 product	formation	 eventually	 slows	 and	 plateaus	 due	 to	 inhibitors	 of	 PCR	which	 form,	reagent	limitation,	accumulation	of	pyrophosphate	molecules,	and	self-annealing	of	the	accumulating	product	(Ding	and	Cantor,	2004).		
	
	
Measurement	of	cell-free	plasma	DNA	in	trauma		In	 the	 year	 2000,	 Lo	 et	 al.	 first	 reported	 the	presence	 of	 nDNA	 in	 the	 cell-free	plasma	of	trauma	patients	and	that	levels	correlated	with	severity	of	injury	and	outcome	(Lo,	2000).	More	recently,	attention	has	been	focused	on	mtDNA,	both	as	 a	 clinically	 relevant	 biomarker	 of	 trauma	 and	 mediator	 or	 DAMP	 in	 the	pathogenesis	 of	 trauma	 inflammation	 and	 organ	 dysfunction	 (Zhang	 et	 al.,	2010b).	
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	However,	 there	 is	 a	 singular	 lack	 of	 standardised	methodology	 described	with	which	 to	measure	 this	 important	molecule.	 Furthermore,	 the	mechanism	of	 its	release	 into	 the	 circulation,	 its	 degradation	 and	 association	 with	 type	 and	pattern	of	 injury	and	 resultant	de	novo	mediated	 injury	 is	not	 fully	elucidated.		The	 aim	 of	 this	 chapter	 was	 to	 develop	 a	 robust	 methodology	 for	 mtDNA	measurement	to	help	resolve	these	important	issues.			
	
Methods	
	
Plasma	preparation	
Terminal	 blood	 from	 animals	 subjected	 to	 T-HS	 was	 collected	 into	 EDTA	containing	 tubes	 (3	 x	 1.3ml,	 Sarstedt,	 UK),	 gently	 inverted	 3	 times	 and	immediately	 centrifuged	 at	 1600g	 for	 15	 minutes	 at	 4°C	 (Eppendorf	 cooled	centrifuge	Model	5417R,	UK).	The	plasma	 layer	was	 then	aspirated	 taking	care	not	 to	 disturb	 the	 cellular	 fraction	 and	 again	 centrifuged	 at	 16,000g	 for	 15	minutes	at	4°C.	200μl	aliquots	of	plasma	were	made	in	0.5ml	tubes	(Eppendorf,	UK)	and	flash	frozen	in	liquid	nitrogen	and	stored	at	-80°C	for	later	analysis.			
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Extraction	of	free	circulating	DNA	in	cell-free	plasma		DNA	was	extracted	from	cell-free	EDTA	plasma	with	the	QIAamp	Blood	Mini	kit	(Qiagen,	UK).	 Frozen	plasma	was	 thawed	over	 ice,	 vortexed	 for	 5	 seconds	 and	then	 centrifuged	 at	 1600g	 for	 5	 seconds.	Qiagen	Protease	 or	 proteinase	K	was	used.	DNA	was	eluted	into	200μl	Buffer	AE.	DNA	purity	and	yield	was	examined	with	the	spectrophotometer	(Nanodrop,	Thermo	Fisher	Scientific,	UK).			
Real	 time	 polymerase	 chain	 reaction	 (RT-PCR)	 to	 measure	 plasma	 circulating	
mtDNA	and	nDNA		Primers	 for	three	rat	mtDNA	genes	and	one	nDNA	gene	were	used	(Invitrogen,	UK):	 Cytochrome	 B	 (Cyt	 B)	 TCCACTTCATCCTCCCATTC	 (Forward)	CTGCGTCGGAGTTTAATCCT	(Reverse);	Cytochrome	C	oxidase	subunit	III	(Cyto	C	III)	 ACATACCAAGGCCACCAAC	 (Forward)	 CAGAAAAATCCGGCAAAGAA	(Reverse);	 NADH	 dehydrogenase	 CAATACCCCACCCCCTTATC	 (Forward)	GAGGCTCATCCCGATCATAG	 (Reverse);	 Glyceraldehyde	 3-phosphate	dehydrogenase	 (GAPDH)	 GAAATCCCCTGGAGCTCTGT	 (Forward)	CTGGCACCAGATGAAATGTG	 (Reverse).	 GAPDH	 is	 a	 nuclear	 gene	 that	 is	expressed	 at	 high	 levels	 in	 most	 tissues	 and	 cells,	 and	 is	 considered	 a	housekeeping	gene.	GAPDH	 is	commonly	used	as	a	 loading	control	 for	western	blot	and	as	a	control	for	RT-PCR	(Barber	et	al.,	2005).	However,	this	thesis	was	also	 concerned	 with	 nDNA	 concentrations	 per	 se.	 All	 primer	 sequences	 were	specific	 for	 their	 targets	 and	 had	 no	 similarity	 with	 bacterial	 sequences	 on	BLAST	 analysis.	 PCR	 reaction	 volumes	 varied	 according	 to	 experiment	 in	 the	
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range	 10-50μl	 (DNA	 6-15μl)	 using	 SYBR	 Green	 Mastermix	 (Life	 Technologies,	UK)	 and	 primers	 in	 a	 final	 concentration	 in	 the	 range	 0.2	 to	 1.0μM.	 The	Rotorgene	 6000	 RT-PCR	machine	was	 used	 (ex-Corbett	 Life	 Science,	 currently	Qiagen,	 UK)	 to	 perform	 40	 cycle	 PCR	 comprising	 10	 sec	 hold	 at	 95°C,	 30	 sec	annealing	at	55°C	and	30	sec	extension	at	72°C.	Data	analysis	was	performed	on	Corbett	Life	Science	proprietary	software.	Absolute	quantification	of	mtDNA	was	performed	 using	 serial	 dilutions	 of	 pure	 mtDNA	 extracted	 from	 rat	 liver	 to	generate	standard	curves.	NDNA	was	quantified	using	1/Ct	values	relative	to	the	change	in	sham	levels.		Preparation	of	pure	mtDNA	from	rat	liver		Mitochondria	 were	 isolated	 from	 rat	 liver	 either	 with	 the	 use	 of	 the	Mitochondrial	 Isolation	 Kit	 (Sigma,	 UK)	 or	 the	 Mitochondria	 Isolation	 (mouse	tissue)	kit	 (MACS	Miltenyi	Biotec,	UK).	 Liver	was	prepared	 in	 a	 sterile	manner	and	 at	 4°C.	 Liver	 was	 homogenised	 at	 4°C	 with	 a	 3ml	 volume	 electric	homogeniser	for	30	seconds.	DNA	was	extracted	using	the	QIAamp	DNA	mini	kit	(Qiagen,	 UK)	 using	 proteinase	 K.	 Yield	 and	 purity	 was	 assessed	spectrophotometrically.								
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Bacterial	16S	rRNA	PCR	screening	of	plasma	and	pure	mtDNA	fractions		In	 association	 with	 Dr	 Mark	 Wilks	 and	 Nicola	 Panton	 of	 the	 Department	 of	Microbiology,	 Barts	 Health	 NHS	 Trust,	 bacterial	 screening	 of	 animal	 cell-free	plasma	and	pure	mtDNA	fractions	was	performed	using	RT-PCR	against	bacterial	16S	rRNA.	NADK	primers	specific	for	16S	were	used	(Invitrogen,	UK)	and	NADK	probe	 modified	 with	 FAM-BHQ	 (black	 hole	 quencher)	 and	 shrimp	 nuclease	(Affymetrix,	 UK)	 to	 remove	 contaminating	 bacteria	 present	 in	 reagents.	 PCR	reaction	 volume	 was	 10μl	 comprising	 2.9μl	 molecular	 grade	 water	 (Ambion,	Thermo	Fisher	Scientific,	UK),	5μl	SSOFAST	probe	supermix	(Bio-Rad,	UK),	0.8μl	primers	(F+R)	10μM	concentration,	0.2μl	probe,	0.1μl	shrimp	nuclease.	 	CFX	96	RT-PCR	 machine	 with	 C1000	 thermal	 cycler	 (Bio-Rad,	 UK)	 used.	 40	 cycles:	 2	minutes	at	95°C,	10	sec	at	61.4°C,	5	sec	at	95°C.	Enterococcus	faecalis	standards	were	serially	diluted	1:10	from	200ng/μl	to	20fg/μl.	
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Results		
Selection	of	mtDNA	and	nDNA	primers		Table	3.1	details	the	rodent	primer	pairs	for	three	mitochondrial	genes	and	one	nuclear	gene	which	were	initially	selected	as	they	had	been	used	extensively	by	Hauser’s	 group	 (Zhang	 et	 al.,	 2010b,	 Zhang	 et	 al.,	 2010a).	 These	 primers	were	specific	to	their	gene	targets	on	BLAST	analysis.				 																	Table	3.1.		Primer	characteristics			
	
Gene	
	
Primer	Sequence	(5’	to	3’)	
	
Melting	
Temp	(Tm)	
	Cytochrome	B	 TCCACTTCATCCTCCCATTC		(F)	 59.2	CTGCGTCGGAGTTTAATCCT	(R)	 58.0	Cytochrome	C	oxidase	subunit	III	 ACATACCAAGGCCACCAAC		(F)	 59.0	CAGAAAAATCCGGCAAAGAA	(R)	 54.8	NADH	dehydrogenase		 CAATACCCCACCCCCTTATC		(F)	 60.4		GAGGCTCATCCCGATCATAG	(R)	 58.7	GAPDH	 GAAATCCCCTGGAGCTCTGT	(F)		 61.5	CTGGCACCAGATGAAATGTG	(R)	 57.5	
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These	primers	were	first	tested	against	DNA	extracted	from	EDTA-whole	blood	from	 an	 animal	 subjected	 to	 HS	 (baseline	 model).	 This	 formed	 the	 positive	control.	 Table	 3.2	 details	 the	 first	 blood	 preparation	 protocol,	 DNA	 extraction	and	 PCR	 reaction	 composition.	 DNA	 from	 whole	 blood	 was	 extracted	 using	 a	standard	spin	column	kit	from	Qiagen	and	was	eluted	into	200μL	Buffer	AE.	DNA	purity	 was	 checked	 using	 spectrophotometric	 analysis	 (Nanodrop™)	 at	 three	wavelengths,	 230nm,	 260nm	 and	 280nm.	 Pure	 DNA	 absorbs	 at	 260nm,	contaminants	 such	 as	 protein	 at	 280nm	 and	 other	 solvents	 and	 salts	 (such	 as	EDTA)	at	230nm	(Wilfinger	et	al.,	1997).		An	A260/A280	ratio	of	1.85	indicated	pure	 DNA	 	 (1.8-2.0)	 with	 no	 protein	 contamination	 evident.	 However,	A260/A230	 ratios	 were	 low	 at	 1.4	 indicating	 possible	 contamination	 with	solvent	or	salt,	such	as	EDTA.	Subsequently,	PCR	reactions	were	tested	 in	various	 total	volumes	(10-25μL)	 to	reflect	varying	amounts	of	total	starting	DNA	as	the	optimal	PCR	conditions	were	unknown.	Further	to	this,	studies	were	carried	out	on	cell-free	plasma	where	the	anticipated	 free	 DNA	 concentrations	 were	 likely	 to	 be	 very	 low.	 There	 is	 no	consensus	 on	 the	 minimum	 starting	 amount	 of	 DNA	 required	 for	 successful	amplification	with	PCR	with	ranges	quoted	as	starting	as	low	as	1pg	and	as	high	as	1μg	DNA	per	reaction,	depending	on	the	complexity	of	 the	 template	and	the	size	of	 the	genome	(New	England	Biolabs	PCR	guidelines).	However,	mtDNA	 is	small	(16.5Kb	in	 length)	and	is	contained	as	multiple	copies	in	cells,	which	will	offset	a	low	starting	overall	concentration	somewhat,	suggesting	that	extremely	low	starting	concentrations	should	be	detected	with	PCR.		The	 starting	 primer	 concentration	 was	 selected	 as	 0.2μM,	 the	 low	 end	 of	 the	range	 0.2μM	 to	 1.0μM	 suggested	 by	 Invitrogen.	 Standard	 3	 step	 PCR	 cycling	
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conditions	were	selected	to	take	into	account	the	various	melting	temperatures	of	 the	 primers	 used	 and	 the	 fact	 that	 the	 optimal	 temperature	 for	 Taq	 DNA	polymerase	is	72°C.				
Table	 3.2.	 Blood	 preparation,	 DNA	 extraction	 protocols	 and	 PCR	 reaction	 composition.	 All	terminal	 blood	 samples	 injected	 into	 1.3ml	 EDTA	 tubes.	 PBS,	 phosphate	 buffered	 saline.	A260/A280	 readings	 1.8	 -	 2.0	 indicate	 no	 contamination	 of	 DNA	 with	 protein.	 A260/A230	readings	2.0-2.2	indicate	no	other	contamination	by	salts	or	solvents.							
Table	3.3.	Thermal	cycling	parameters	for	first	PCR	run	with	positive	control		
Blood-Plasma	
	
DNA	extraction	 PCR	reaction	components	
Centrifugation	 Protease	used	 Nanodrop™	(DNA	conc)	 DNA	(μL)	 SYBR	Green	Mastermix	(μL)	
10μM	Forward	primer	(μL)	
10μM	Reverse	primer	(μL)	
Total	PCR	vol	(μL)	
Nil	(100μLWhole	EDTA-blood	+100μL	PBS)		
Proteinase	K		
A260/A280	1.85	A260/A230	1.42	(46ng/μL)	
3	 6.6		 0.2	 0.2	 10	6	 13.2		 0.4	 0.4	 20	7.5	 16.5	 0.5	(0.2μM	conc)	 0.5	 25	
Cycle	 Cycle	Point	Hold	@	95°C,	10	min	(Activates	Taq	DNA	polymerase)	 	Cycling	(40	repeats)	 Step	1	@	95°C,	hold	10	sec	(Denatures)		 Step	2	@	55°C,	hold	30	sec	(Anneals)		 Step	3	@	72°C,	hold	30	sec	(Extends)	
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Comparative	 quantitation	methodology	was	 used	 to	 calculate	 the	 takeoff	 point	(which	approximates	to	the	threshold	count,	Ct)	and	magnitude	of	amplification	for	each	PCR	reaction.			As	 can	 be	 seen	 in	 Figure	 3.1	 and	 Table	 3.4,	 there	 was	 highly	 variable	amplification	of	all	four	gene	products.	Cyt	B	amplified	the	earliest	to	a	moderate	degree,	followed	by	GAPDH	to	a	high	degree,	followed	by	NADHD	to	a	moderate	degree	 and	 then	 lastly,	 by	 Cyto	 C	 III.	 The	 far	 earlier	 amplification	 of	 Cyt	 B	compared	to	GAPDH	reflects	multiple	copies	of	mtDNA	being	present.	All	 three	mtDNA	primers	demonstrated	improved	amplification	with	greater	PCR	reaction	volumes	 at	 and	 above	 20μL.	 This	 indicated	 that	 starting	mtDNA	 concentration	was	a	critical	rate-limiting	factor.	This	did	not	apply	to	GAPDH,	which	exhibited	similar	amplification	across	all	three	volumes.	This	indicated	that	starting	nDNA	was	not	a	critical	factor	with	the	positive	controls,	which	correlates	to	the	known	expected	large	amount	of	nDNA	in	whole	blood	relative	to	mtDNA.	Melting	curve	analysis	of	the	PCR	products	confirmed	the	absence	of	non-specific	amplification	such	as	primer-dimer	and	dimer-dimer	product	formation	(Figure	3.2).	The	PCR	products	of	this	run	underwent	1%	agarose	gel	electrophoresis	(Figure	3.3).	This	confirmed	 the	 presence	 of	 product	 lengths	 of	 Cyt	 B	 and	 GAPDH	 were	approximately	105bp	and	184bp,	 respectively,	 as	 indicated	by	BLAST	analysis,	and	 the	 absence	 of	 other	 products.	 	 I	 decided	 to	 continue	 using	 these	 primer	pairs	for	the	remaining	experiments.				
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Figure	 3.1	 (Above).	 Comparative	quantification	 of	 positive	 control	 RT-PCR	using	 various	mtDNA	 primers	 and	GAPDH.		Three	 different	 PCR	 reaction	 volumes	trialled.	 	 Animal	 E1	 was	 subjected	 to	 HS	60%	for	90	min	and	resuscitated	with	50%	shed	 heparinised	 blood	 and	 20ml/kg	crystalloid.	 Expt	 terminated	 at	 6	 h.	 WB,	whole	blood;	Control,	double	distilled	water	(negative	 control).	 All	 samples	 run	 in	duplicate.	 Take-off	 values	 approximate	 to	threshold	 counts,	 Ct.	 Lack	 of	 amplification	before	 40	 cycles	 assumed	 to	 represent	 no	discernible	starting	template	DNA.	Table	 3.4	 (right).	 Take-off	 and	corresponding	amplification	values.	Cyt	 B	 and	 GAPDH	 were	 the	 most	consistently	 amplified	 PCR	 products,	followed	 by	 NADHD	 and	 then	 Cyto	 C	 III,	which	 was	 poorly	 amplified.	 	 There	 was	increased	amplification	at	and	above	a	total	PCR	 volume	 of	 20uL.	 Subsequent	 melting	curve	 analysis	 confirmed	 absence	 of	primer-dimer	products.		
	 								
					 		
No. Colour Name Take Off Amplification Rep. 
Amp. 
1 
 
WB E1 cyt B 10ul 25.7 1.18 0.80 
2 
 
WB E1 cyt B 10ul 27.2 0.41  
3 
 
WB E1 cyt B 20ul 12.3 1.55 1.55 
4 
 
WB E1 cyt B 20ul 12.2 1.55  
5 
 
WB E1 cyt B 25ul 12.8 1.53 1.54 
6 
 
WB E1 cyt B 25ul 12.6 1.56  
7 
 
Control cyt B 25ul 27.7 0.00 -0.08 
8 
 
Control cyt B 25ul 33.3 -0.15  
9 
 
WB E1 GAPDH 10ul 20.1 1.76 1.50 
10 
 
WB E1 GAPDH 10ul 20.8 1.24  
11 
 
WB E1 GAPDH 20ul 20.6 1.66 1.70 
12 
 
WB E1 GAPDH 20ul 20.4 1.73  
13 
 
WB E1 GAPDH 25ul 21.0 1.63 1.60 
14 
 
WB E1 GAPDH 25ul 21.3 1.57  
15 
 
Control GAPDH 25ul 28.9 0.06 0.03 
16 
 
Control GAPDH 25ul 13.9 0.00  
17 
 
WB E1 Cyto C III 10ul 19.5 0.07 0.04 
18 
 
WB E1 Cyto C III 10ul 34.4 0.00  
19 
 
WB E1 Cyto C III 20ul 28.8 1.57 1.54 
20 
 
WB E1 Cyto C III 20ul 31.0 1.52  
21 
 
WB E1 Cyto C III 25ul 32.9 1.73 1.80 
22 
 
WB E1 Cyto C III 25ul 32.8 1.87  
23 
 
Control Cyto C III 25ul 29.1 0.03 0.03 
24 
 
Control Cyto C III 25ul 35.4 0.04  
25 
 
WB E1 NADH 10ul 26.4 1.27 1.13 
26 
 
WB E1 NADH 10ul 33.3 0.99  
27 
 
WB E1 NADH 20ul 19.8 1.74 1.76 
28 
 
WB E1 NADH 20ul 18.5 1.77  
29 
 
WB E1 NADH 25ul 21.0 1.71 1.40 
30 
 
WB E1 NADH 25ul 26.5 1.10  
31 
 
Control NADH 25ul 12.1 0.00 0.03 
32 
 
Control NADH 25ul 33.6 0.07  
 
	
Cyt	B	
GAPDH	
NADHD	
Cyto	C	III	
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	Figure	 3.2.	 Melt	 curve	 analysis	 for	 Cyt	 B	 (left)	 and	 GAPDH	 (right).	 Note	 the	 absence	 of	 other	waveforms	suggestive	of	non-specific	amplification.					 			
	Figure	3.3.	Agarose	gel	of	PCR	products	from	first	PCR	run.	1Kb	ladder	on	left.		Cyt	B	(left)	corresponding	to	quoted	product	 length	of	105bp;	GAPDH	(right)	corresponding	to	quoted	length	of	184bp.	The	relatively	greater	signal	in	GAPDH	indicates	that	the	majority	of	the	DNA	extracted	from	whole	blood	is	nuclear	in	origin.	Red	blood	cells	contain	no	nuclei	therefore	these	 extracted	DNA	 samples	 correspond	 to	 the	DNA	of	 circulating	white	 blood	 cells,	 platelets	and	free	circulating	DNA.	
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RT-PCR	of	experimental	plasma	from	the	Baseline	HS	Model	and	Model	1			In	 parallel	 with	 the	 animal	 T-HS	 model	 development	 that	 occurred	 from	 the	Baseline	model	 to	Model	1	 (Chapter	2),	RT-PCR	was	attempted	on	animal	 cell-free	plasma	with	singular	 lack	of	amplification	despite	numerous	modifications	to	 plasma	 preparation,	 DNA	 extraction	 and	 PCR	 reaction	 composition	 (Table	3.5).			Modifications	that	were	undertaken	to	improve	PCR	amplification	included:		 1. Use	of	Qiagen	proteinase	K	or	Qiagen	protease	during	DNA	extraction.	2. Decreasing	 the	 final	 volume	 of	 DNA	 eluate	 post	 spin	 column	 extraction	from	 200μL	 to	 50-60μL	 in	 an	 attempt	 to	 increase	 the	 starting	concentration	of	DNA	for	PCR.	3. Increasing	PCR	reaction	volumes	to	50μL.	4. Increasing	the	primer	concentration	to	1.0μM	(0.2μM	previously).	5. Minimising	heparin	administration	during	T-HS	experiments	by	reducing	the	added	heparin	to	shed	blood	from	100IU/ml	to	50IU/mL	and	then	to	10IU/mL.		Despite	 these	 modifications,	 PCR	 amplification	 of	 Cyt	 B	 and	 GAPDH	 occurred	only	sporadically	and	at	cycles	32-35	at	best.				
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Table	3.5.	Modified	plasma	preparation,	DNA	extraction	protocols	and	PCR	reaction	composition	for	 first	 run	 of	 PCR	 on	 6	 h	 plasma	 from	 sham,	 trauma,	 HS	 and	 T-HS	 animals.	 Despite	 various	modifications	 to	 the	 plasma	 preparation,	 DNA	 extraction	 method	 and	 PCR	 reaction	 volume	composition,	 there	was	 almost	 total	 lack	 of	 amplification	 of	 both	mtDNA	 and	 nDNA	within	 35	cycles.	 No	 difference	 was	 found	 in	 type	 of	 protease	 used,	 increasing	 primer	 concentration	 to	1.0μM,	 or	 increasing	 PCR	 reaction	 volumes.	 Of	 note,	 spectrophotometer	 readings	 consistently	recorded	 low	 A260/A230	 readings	 for	 all	 animals,	 particularly	 in	 those	 animals	 exposed	 to	greater	 amounts	 of	 heparin.	 Reducing	 the	 heparin	 added	 to	 shed	 blood	 did	 not	 improve	 PCR	amplification.					
	
	
	
Blood-Plasma	 DNA	extraction	
	
PCR	reaction	components	
Centrifugation	 Protease	used		 Nanodrop™			(DNA	conc)	 DNA	(μL)	 Mastermix	(μL)	 10uM	Forward	primer	(μL)	
10uM	Reverse	primer	(μL)	
Total	PCR	vol	(μL)	
EDTA-plasma	1600g	x		15	min,	16,000g	x	15min	at	4’C		
Proteinase	K	or	Qiagen	protease		
A260/A280	1.7-1.9	A260/A230	1.0	-	1.4	(0-10ng/μL)	
6	 10		 2	 2	 20	7.5	 12.5		 2.5	 2.5	 25	15	 25	 5	(1.0μM	conc)	 5	 50	
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Plasma	spin	protocols		EDTA-plasma	 was	 doubly	 centrifuged	 at	 1600g	 then	 16,000g.	 A	 number	 of	authors	 have	 suggested	 that	 the	 lack	 of	 a	 high-speed	 step	 fails	 to	 remove	 a	significant	 proportion	 of	 platelets,	 leukocytes,	 and	 other	 cell	 fragments	 that	could	also	contain	mtDNA	(Chiu	et	al.,	2003,	Swinkels	et	al.,	2003,	Yamanouchi	et	al.,	2013).	These	authors	have	also	all	successfully	used	EDTA-blood	to	perform	RT-PCR	for	the	measurement	of	mtDNA	in	cell-free	plasma.		However,	 at	 this	 point,	 I	 decided	 to	modify	 the	 plasma	 centrifugation	 protocol	and	follow	the	same	protocol	as	advised	to	me	by	Dr	Kiyoshi	Itagaki,	of	Prof	Carl	Hauser’s	 laboratory	 at	 Harvard	 (personal	 communication).	 They	 recently	 had	finished	 PCR	 testing	 for	 mtDNA	 in	 plasma	 from	 150	 patients	 from	 the	 Royal	London	Hospital	using	a	spin	protocol	consisting	of	200g	for	10	minutes	at	room	temperature,	then	3000g	at	15	minutes	at	4	°C	and	then	a	further	3000g	spin	for	15	minutes	at	4	°C.	Other	research	groups	investigating	mtDNA	concentrations	in	cell-free	 plasma	 have	 found	 that	 the	 addition	 of	 a	 second	 spin	 was	 critical	 in	reducing	contaminating	mtDNA	(presumably	 from	cell	 fragments,	platelets	and	platelet	 derived	microparticles)	 but	 that	 the	 speed	 of	 the	 second	 spin	was	 not	critical,	 with	 similar	 levels	 of	 mtDNA	 present	 irrespective	 of	 the	 speed	 of	 the	second	 spin	 (Mehra	 et	 al.,	 2007,	Mehra,	 2007).	 Interestingly,	 this	 type	 of	 spin	protocol	 has	 also	 been	 used	 for	 analyses	 of	 microparticles	 where	 researchers	have	 faced	 similar	 uncertainties	 regarding	 the	 optimum	 spin	protocol	 (Dignat-
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George	 et	 al.,	 2009).	 The	 problem	 of	 contaminating	 platelets	 in	 supposed	 cell-free	plasma	has	been	cited	as	a	major	issue	in	methodology	(Mehra,	2007).		As	can	be	seen	in	Table	3.6,	the	more	gentle	spin	protocol	resulted	in	an	almost	10	times	greater	concentration	of	mtDNA	and	more	consistent	amplification	with	PCR.	I	decided	to	continue	with	this	spin	protocol	for	the	remaining	experiments	to	 achieve	 workable	 PCR	 results.	 However,	 PCR	 amplification	 was	 still	 most	consistent	 in	 the	 groups	 that	 had	 been	 exposed	 to	 isolated	 traumatic	 injury;	plasma	 from	severely	 trauma-shocked	animals	at	6	h	still	 failed	 to	consistently	amplify	more	than	sham	animal	plasma.			Further	optimisation	was	 carried	out,	 repeating	much	of	 the	work	prior	 to	 the	change	 in	 plasma	 spin	 protocol.	 Again,	 the	 type	 of	 protease	 used	 during	 DNA	extraction	 (Qiagen	 Protease	 or	 proteinase	 K)	 was	 not	 found	 to	 impact	 PCR	amplification	(data	not	shown).			The	type	of	solvent	used	to	elute	DNA	post	spin	column	protocol	was	also	found	not	 to	 impact	 PCR	 amplification	 (Table	 3.7).	 However,	 I	 decided	 to	 continue	using	water	 due	 to	 the	 reported	 theoretical	 inhibition	 of	 the	 EDTA	 content	 in	Buffer	 AE	 causing	 inhibition	 of	 PCR	 (Dr	 Kiyoshi	 Itagaki,	 personal	communication).	Furthermore,	I	generally	used	the	entire	available	DNA	sample	for	 multiple	 PCR	 runs	 on	 the	 day	 of	 extraction	 and	 therefore	 did	 not	 have	 to	contend	with	the	issue	of	long-term	storage	and	DNA	degradation	over	time.		Subsequently,	 I	 investigated	 the	 impact	 of	 age	 of	 primers	 against	 PCR	amplification	 (Table	 3.8).	 Aliquots	 of	 primers	 at	 100μM	 concentration	 were	
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prepared	 and	 stored	 at	 -20°C	 until	 use.	 The	 results	 of	 this	 study	 indicated	 a	significant	impairment	of	performance	of	the	GAPDH	primers,	but	not	Cyt	B,	over	12	months.	 Therefore,	 primers	were	 not	 used	 after	 6	months	 storage	 at	 -20°C	from	this	point	onwards.				
		Table	 3.6.	 Effect	 of	 variable	 spin	 protocol	 during	 plasma	 preparation	 from	 100ul	whole	 blood	from	a	rodent	subjected	to	HS	for	6	h.	‘Slow’,	1x	200g	spin	at	room	temperature	for	10	minutes,	then	 1x	 3000g	 spin	 at	 4°C	 for	 15	minutes	 and	 then	 1x	 3000g	 at	 4°C	 for	 15	minutes.	 ‘Fast’,	 1x	1600g	spin	at	4°C	 for	15	minutes,	 then	1x	16,000g	at	4°C	 for	15	minutes.	DNA	extracted	using	spin	column	protocol	and	eluted	 into	50μL	Buffer	AE.	Total	PCR	reaction	volume	20μL.	mtDNA	measured	using	RT-PCR	with	Cyt	B	as	the	target	gene.	There	was	a	mean	difference	in	Ct	of	3.66	between	the	‘slow’	and	‘fast’	samples	indicating	that	the	‘slow’	prepared	plasma	contained	23.066	times	 (=9.4	 times)	more	mtDNA	 than	 the	 ‘fast’	prepared	plasma.	PCR	reactions	which	 failed	 to	amplify	were	assigned	a	Ct	of	40.	
No. Colour Name Take Off Amplification 
1 
 
E1 Slow AE 20ul Cyt B 21.5 1.69 
2 
 
E1 Slow AE 20ul CytB 20.9 1.75 
3 
 
E2 Slow AE 20ul Cyt B 24.0 1.73 
4 
 
E2 Slow AE 20ul Cyt B 24.6 1.61 
5 
 
E3 Slow AE 20ul Cyt B 29.3 1.61 
6 
 
E3 Slow AE 20ul Cyt B 28.1 1.55 
21 
 
Control WB E1 Cyt B 13.8 1.52 
22 
 
Control WB E1 Cyt B 15.4 1.17 
23 
 
Water Cyt B 29.7 -0.02 
24 
 
Water Cyt B 25.0 0.00 
25 
 
E1 Fast AE 20ul Cyt B 25.3 -0.02 
26 
 
E1 Fast AE 20ul Cyt B 17.6 0.00 
27 
 
E2 Fast AE 20ul Cyt B 30.8 1.56 
28 
 
E2 Fast AE 20ul Cyt B 32.2 1.10 
29 
 
E3 Fast AE 20ul Cyt B 32.7 1.64 
30 
 
E3 Fast AE 20ul Cyt B 29.1 1.48 
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	 			Table	 3.7.	RT-PCR	 results	 for	 6	 h	 plasma	 from	animals	 subjected	 to	T-HS	 (group	G)	 and	 Sham	controls	(group	H)	tested	for	mtDNA	using	Cyt	B	as	the	target	gene.	DNA	has	been	extracted	from	plasma	 and	 eluted	 into	 50μL	 of	 either	 double	 distilled	water	 or	 Buffer	 AE.	 All	 samples	 run	 in	duplicate.	Take-off	 values	 approximate	 to	 threshold	 counts,	 Ct.	 Lack	of	 amplification	before	40	cycles	 assumed	 to	 represent	 no	 discernable	 starting	 template	 DNA.	 There	 was	 no	 statistical	difference	overall,	p=0.50,	t	test,	between	the	two	solvents.	However,	water	was	used	from	this	point	onwards	due	 to	 its	purported	superior	performance	with	DNA	when	present	 in	very	 low	concentrations.					
Name Take Off Amplification 
G1 Slow Water 20ul Cyt B 23.0 1.60 
G1 Slow Water 20ul Cyt B 23.6 1.77 
G2 Slow Water 20ul Cyt B 25.6 1.72 
G2 Slow Water 20ul Cyt B 24.3 1.77 
G3 Slow Water 20ul Cyt B 22.1 1.49 
G3 Slow Water 20ul Cyt B 30.4 1.25 
H1 Slow Water 20ul Cyt B 35.3 0.07 
H1 Slow Water 20ul Cyt B 33.5 1.78 
H2 Slow Water 20ul Cyt B 29.8 1.49 
H2 Slow Water 20ul Cyt B 27.5 1.65 
 
Name Take Off Amplification 
G1 Slow AE 20ul Cyt B 26.3 1.50 
G1 Slow AE 20ul Cyt B 22.4 1.58 
G2 Slow AE 20ul Cyt B 23.7 1.73 
G2 Slow AE 20ul Cyt B 23.8 1.71 
G3 Slow AE 20ul Cyt B 33.2 0.43 
G3 Slow AE 20ul Cyt B 33.1 1.00 
H1 Slow AE 20ul Cyt B 31.6 1.75 
H1 Slow AE 20ul Cyt B 26.7 1.61 
H2 Slow AE 20ul Cyt B 33.1 1.26 
H2 Slow AE 20ul Cyt B 33.5 0.88 
+ve Control WB E1 Cyt B 13.8 1.52 
+ve Control WB E1 Cyt B 15.4 1.17 
Water Cyt B 29.7 -0.02 
Water Cyt B 25.0 0.00 
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				 														Table	3.8.	 	RT-PCR	results	 for	positive	controls	(DNA	extracted	 from	whole	blood)	against	new	and	12-month	old	primers	for	mtDNA	(Cyt	B)	and	nDNA	(GAPDH).		There	was	no	degradation	of	performance	 of	 Cyt	 B	 primers	 evident	 over	 time	 but	 there	 was	 significant	 degradation	 in	performance	of	old	GAPDH	primer	compared	to	freshly	prepared	primer,	p<0.01,	t	test	used.					
No. Colour Name Take Off Amplification 
1 
 
E3 +ve control old Cyt B 11.7 1.70 
2 
 
E3 +ve control old Cyt B 11.2 1.67 
3 
 
G2 +ve control old Cyt B 17.7 1.74 
4 
 
G2 +ve control old Cyt B 16.9 1.75 
5 
 
Water -ve control old Cyt B 31.1 -0.01 
6 
 
Water -ve control old Cyt B 32.2 1.77 
9 
 
E3 +ve control New Cyt B 11.9 1.72 
10 
 
E3 +ve control New Cyt B 11.9 1.46 
11 
 
G2 +ve control New Cyt B 16.8 1.71 
12 
 
G2 +ve control New Cyt B 16.9 1.73 
13 
 
Water -ve control New Cyt B 9.7 0.00 
14 
 
Water -ve control New Cyt B 12.1 0.02 
17 
 
E3 +ve control old GAPDH 21.2 1.63 
18 
 
E3 +ve control old GAPDH 21.3 1.72 
19 
 
G2 +ve control old GAPDH 27.1 1.75 
20 
 
G2 +ve control old GAPDH 27.3 1.63 
21 
 
Water -ve control old GAPDH 14.1 0.00 
22 
 
Water -ve control old GAPDH 6.0 0.00 
25 
 
E3 +ve control new GAPDH 19.1 1.63 
26 
 
E3 +ve control new GAPDH  18.9 1.65 
27 
 
G2 +ve control New GAPDH 25.7 1.71 
28 
 
G2 +ve control New GAPDH 25.4 1.83 
29 
 
Water -ve control New GAPDH 14.1 -0.18 
30 
 
Water -ve control New GAPDH 31.2 0.14 
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RT-PCR	time	course	study	of	mtDNA			Next,	I	carried	out	a	combined	time	course	study	and	PCR	reaction	volume	study	with	 the	 above	modifications	 to	 the	protocol.	Due	 to	 the	 relatively	 large	blood	volumes	required	to	prepare	1mL	cell-free	plasma,	I	found	that	animals	had	to	be	euthanased	at	each	of	the	1	h,	2	h,	4	h,	and	6	h	time	points	to	provide	sufficient	samples	without	 the	extra	confounder	of	gradually	 increased	shock	 induced	by	serial	blood	draws	from	one	animal.	Figure	3.4	demonstrates	the	results	of	this	study	with	a	PCR	reaction	volume	of	20μL	(containing	6μL	DNA).	Overall,	it	can	be	seen	that	 the	most	consistent	amplification	of	mtDNA	was	seen	 in	 the	sham	and	trauma	groups.	There	was	a	peak	of	mtDNA	concentration	at	2	h	relative	to	sham	which	decreased	over	 the	 course	of	 the	experiment.	However,	 there	was	total	lack	of	amplification	of	the	shocked	groups	at	2	h	and	4	h	and	amplification	equivalent	to	sham	levels	at	6	h.	Figure	3.5	shows	the	same	study	except	with	a	total	PCR	reaction	volume	of	30μL	(DNA	9μL)	and	the	addition	of	1	h	data.	The	sham	group,	 in	particular,	 showed	 increased	amplification	above	 that	expected	for	a	50%	increase	in	starting	DNA,	i.e.	Ct	increased	by	>2	indicating	inadequate	starting	DNA	amounts	in	the	20μL	PCR	reactions	previously.	Both	the	1	h	sham	and	 trauma	 groups	 demonstrated	 a	 rise	 in	 mtDNA	 concentrations.	 	 These	elevations	were	sustained	over	the	course	of	the	experiment	in	proportion	to	the	degree	 of	 trauma	 sustained	 (assuming	 sham	 instrumentation	 is	 in	 fact	 a	mild/moderate	 degree	 of	 trauma	 per	 se).	 The	 1	 h	 shocked	 group	 data	demonstrated	 partial	 suppression	 of	 mtDNA	 amplification,	 as	 opposed	 to	 the	total	suppression	seen	previously	at	2	h.	This	can	be	explained	by	the	 fact	 that	these	 animals	have	not	 yet	 received	 resuscitation	with	 shed	heparinised	blood	
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but	 they	have	still	 likely	been	exposed	 to	small	amounts	of	heparin	via	carotid	arterial	 line	 flushes	 after	 volumes	 of	 blood	 were	 intermittently	 withdrawn	during	the	bleeding	phase.	The	subsequent	2	h,	4	h	and	6	h	data	were	similar	to	the	previous	20μL	PCR	volume	time	study.	At	6	h	in	both	studies,	there	was	no	significant	difference	 in	mtDNA	concentration	between	any	of	 the	 four	 groups.	This	pointed	to	the	presence	of	a	PCR	inhibitor,	most	likely	to	be	heparin.	30μL	PCR	reactions	were	used	for	all	subsequent	experiments.																				
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		Figure	3.4.	RT-PCR	measurement	of	mtDNA	using	Cyt	B	as	the	target	gene.	Time	course	study	–	Plasma	sampled	from	animals	at	specified	time	subjected	to	instrumentation	only	(Sham),	lower	limb	fractures	and	laparotomy	(Trauma),	bleeding	60%	of	EBV	and	then	resuscitation	with	100%	shed	heparinised	blood	(HS)	and	combined	trauma	and	HS	(T-HS).	First	1.3ml	blood	from	carotid	catheter	not	used	for	analysis.	Animals	were	euthanased	at	each	time	point.	At	2	h,	there	was	a	significant	 increase	 in	 mtDNA	 in	 trauma	 animals	 compared	 to	 sham,	 HS	 and	 T-HS	 animals;	 §	denotes	 p<0.0001.	 2	 h	HS	 and	T-HS	 animals	 failed	 to	 amplify	mtDNA,	 hence	were	 assigned	 Ct	values	of	40.	These	represent	mtDNA	levels	many	times	lower	than	that	found	in	sham	animals	at	the	 same	 time,	 which	 is	 nonsensical.	 Trauma	 animal	 mtDNA	 decreased	 over	 6	 h,	 §	 denotes	p<0.0001	for	2	h	vs	4	h	and	6	h	trauma.	Similar	but	less	significant	changes	were	seen	within	the	4	 h	 group.	 	 Again,	 both	 4	 h	 HS	 and	 T-HS	 animals’	 plasma	 failed	 to	 amplify	mtDNA,	 *	 denotes	p<0.05	 vs	 2	 h	 sham.	 At	 6	 h,	 there	 was	 greater	 amplification	 of	mtDNA	 for	 both	 HS	 and	 T-HS	compared	to	their	2h	counterparts,	p<0.001	for	2h	HS	vs	6h	HS	and	p<0.01	for	2h	T-HS	vs	6h	T-HS.	However,	these	levels	were	close	to	sham	levels,	which	again	is	nonsensical	given	these	were	the	most	 severely	 injured	 animals.	 A	PCR	 inhibitor	was	 likely	 the	 cause,	most	 likely	 heparin.	 t	tests	used.	20uL	PCR	reaction	volumes	used.	Samples	run	in	duplicate.	Reciprocal	of	Ct	values	are	given	on	y-axis.	Mean	values	with	SEM	bars	shown.	n=5	animals	per	group.				
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Figure	3.5.	RT-PCR	measurement	of	mtDNA	using	Cyt	B	as	the	target	gene.	Time	course	study	–	Plasma	sampled	from	animals	at	specified	time	subjected	to	instrumentation	only	(Sham),	lower	limb	fractures	and	laparotomy	(Trauma),	bleeding	60%	of	EBV	and	then	resuscitation	with	100%	shed	heparinised	blood	(HS)	and	combined	trauma	and	HS	(T-HS).	Animals	were	euthanased	at	each	time	point.		First	1.3ml	blood	from	carotid	catheter	not	used	for	analysis.	Experiment	as	per	Figure	3	except	additional	1	h	samples	taken	and	starting	DNA	template	amount	increased	from	6μL	 to	 9μL	 (total	 volume	 30μL)	 to	 fully	 exclude	 low	 starting	 amount	 as	 cause	 for	 lack	 of	amplification.	 In	 general,	 samples	 not	 given	 heparin	 (sham	 and	 trauma	 animals)	 showed	increased	mtDNA	 levels	compared	 to	 the	previous	experiment	 in	excess	of	 that	predicted	 for	a	50%	increase	in	starting	DNA.	Sham	and	trauma	animals	showed	a	decline	in	mtDNA	levels	over	the	experiment,	§	denotes	p<0.0001	for	1	h	trauma	vs	both	4	h	and	6	h	trauma	animals.	*	denotes	p<0.05	 for	1	h	sham	vs	2	h	sham;	‡	denotes	p<0.001	for	1	h	sham	vs	4	h	sham,.	As	previously,	there	 was	 very	 poor,	 but	 not	 absent,	 amplification	 of	 mtDNA	 in	 1	 h	 HS	 and	 T-HS	 animals,	 †	denotes	p<0.01	vs	1	h	sham.	This	sample	was	taken	at	1	h	at	the	end	of	haemorrhage	but	before	resuscitation	with	heparinised	shed	blood	at	90min;	however,	these	animals	were	still	subject	to	very	 small	 volumes	 of	 heparinised	 daline	 via	 the	 arterial	 carotid	 cannula	 during	 the	 bleeding	phase	 to	maintain	 patency.	 2	 h	HS	 and	T-HS	 animals	 showed	 total	 absence	 of	 amplification	 as	before,	 §	denotes	p<0.0001	vs	2	h	 sham.	Amplification	was	 less	 suppressed	at	6	h	but	 still	not	greater	than	sham	at	6	h.	t	tests	used.	30μL	PCR	reaction	volumes	used.	Samples	run	in	duplicate.	Reciprocal	of	Ct	values	are	given	on	y-axis.	Mean	values	with	SEM	bars	shown.	n=5	animals	per	group.			
1 h
 Sh
am
1 h
 Tr
au
ma
1 h
 H
S
1 h
 T-
HS
2 h
 Sh
am
2 h
 Tr
au
ma
2 h
 H
S
2 h
 T-
HS
4 h
 Sh
am
4 h
 Tr
au
ma
4 h
 H
S
4 h
 T-
HS
6 h
 Sh
am
6 h
 Tr
au
ma
6 h
 H
S
6 h
 T-
HS
0.00
0.02
0.04
0.06
1/
Ct
 v
al
ue
s  
mtDNA	30μL	PCR	reac1on	volume	
§	
§	
†	 †	
*	
‡	
§	 §	
	 141	
														Figure	3.6.	Route	of	blood	withdrawal	and	its	effect	on	subsequent	plasma	mtDNA	concentration.	Blood	was	taken	at	1	h	time	points	from	(left	to	right	columns):		(a)	sham	(instrumented)	animals	without	aspirating	 the	dead	space	volume	of	 the	carotid	catheter,	 i.e.	 the	 first	1.3ml	blood	was	used	for	analysis	(b)	the	second	1.3ml	blood	was	used	for	subsequent	analysis	as	in	experiments	depicted	 in	 figures	3	and	4	 (c)	 trauma	animals	1	h	2nd	1.3ml	aspirated	and	analysed	 (d)	Naïve	(uninstrumented)	animals	with	terminal	cardiac	puncture	blood	for	analysis.		All	 three	 groups	 demonstrated	 significantly	 higher	 mtDNA	 concentrations	 as	 shown	 by	 1/Ct	values	 compared	 to	 sham	 1	 h	 animal	 blood	 that	 had	 not	 been	 cleared	 of	 dead	 space	 volume	(containing	 heparinised	 saline),	 §	 denotes	 p<0.0001.	 Interestingly,	 blood	 from	 naïve	 animals	sampled	via	cardiac	puncture	also	showed	significantly	higher	mtDNA	concentrations	compared	to	 sham	1	h	animals,	 even	when	 the	 first	1.3ml	had	been	discarded,	p<0.001	vs	Sham	1h.	This	suggests	 that	 contamination	 with	 heparin	 and	 site	 of	 sampling	 are	 important	 factors.	 Direct	cardiac	sampling	was	shown	to	liberate	mtDNA	from	the	organ	with	the	highest	concentration	of	mitochondria	of	all	organs.	t	tests	used,	n=4-5	per	group.	Mean	values	with	SEM	bars	shown.	
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Route	 of	 blood	 withdrawal	 and	 its	 effect	 on	 subsequent	 plasma	 mtDNA	
concentration		The	 final	 experiment	 in	 this	 series	 consisted	 of	 an	 analysis	 of	 the	 route	 and	composition	of	blood	withdrawal	 (Figure	3.6).	 	 Sequential	blood	 samples	were	taken	 from	 sham	 animals	 via	 their	 carotid	 artery	 catheters,	 i.e.	 the	 first	 1.3ml	blood	 was	 compared	 to	 the	 next	 1.3ml.	 Blood	 was	 also	 taken	 from	 naïve	(uninstrumented)	 anaesthetised	 animals	 via	 a	 terminal	 cardiac	 puncture.	 The	results	showed	that	there	was	very	significant	inhibition	of	PCR	amplification	of	mtDNA	in	samples	originating	from	the	first	1.3ml	blood	taken	from	the	arterial	catheter	compared	to	the	second	1.3ml	(p<0.0001).	Direct	cardiac	puncture	from	naïve	animals	also	resulted	in	the	highest	measured	levels	of	mtDNA	of	the	four	groups	studied	(p<0.001	vs	1h	sham,	2nd	1.3	ml	blood).	 	This	further	suggested	the	 role	 of	 heparin	 as	 the	 inhibitor	 and	 that	 cardiac	 sampling	 was	 not	appropriate	 for	 these	 studies.	 The	 heart	 contains	 the	 some	 of	 the	 highest	concentrations	 of	 mitochondria	 of	 all	 mammalian	 organs	 and	 this	 route	 of	sampling	reflected	this	fact.	Myocardial	cells	can	contain	up	to	100	mitochondria	(Marín-García	 and	 Goldenthal,	 2002).	 Interestingly,	 other	 animal	 studies	 of	mtDNA	 in	 trauma	 have	 utilised	 cardiac	 sampling	 methodology	 (Zhang	 et	 al.,	2010a).	In	light	of	these	findings,	their	results	should	be	challenged.							
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Optimising	PCR	amplification	with	a	‘clean	up’	step	to	remove	PCR	inhibitors		A	‘clean	up’	step	was	suggested	by	the	technical	team	at	Qiagen	which	comprised	of	 a	 repetition	 of	 the	 spin	 column	 protocol	 without	 use	 of	 protease,	 as	A260/A280	 ratios	 were	 above	 1.8	 for	 all	 DNA	 samples,	 indicating	 pure	 DNA	without	protein	contamination.	Figure	3.7	illustrates	the	PCR	inhibition	that	was	present	in	the	shocked	animal	groups	and	subsequent	drastic	improvement	post	‘clean	 up’.	 Heparin	 was	 further	 confirmed	 as	 the	 direct	 inhibitor	 in	 a	 further	experiment	 where	 terminal	 animal	 blood	 was	 either	 injected	 into	 heparin	containing	tubes	(30IU	per	3ml	tube)	or	EDTA	containing	tubes	(the	standard).	There	 was	 complete	 inhibition	 of	 PCR	 amplification	 from	 heparinised	 plasma,	normal	 PCR	 amplification	 with	 Sham	 and	 Trauma	 EDTA-plasma	 and	 variably	inhibited	amplification	from	HS	and	T-HS	EDTA-plasma,	n=4	per	group	(data	not	shown).	However,	the	consistent	requirement	to	perform	a	second	processing	step	on	all	plasma	 samples	was	 not	 thought	 to	 be	 an	 efficient	 use	 of	 time	 and	 resources.	Furthermore,	there	was	likely	to	be	a	loss	of	DNA	amount	with	each	subsequent	processing	step.									
	 144	
Figure	 3.7.	 PCR	 normalised	 fluorescence	 curves	 for	 mtDNA	 (Cyt	 B,	 top)	 and	 nDNA	 (GAPDH,	middle)	 in	 Sham,	 Trauma,	 HS	 and	 T-HS	 groups	 as	 detailed	 previously.	 Generally,	 Sham	 and	Trauma	groups	demonstrated	 full	and	normal	amplification	of	mtDNA	and	nDNA.	HS	and	T-HS	groups	demonstrated	moderately	severe	to	complete	inhibition	of	amplification	as	shown	above.	These	groups	have	been	exposed	to	variable	amounts	of	heparin,	the	likely	inhibitor.	Therefore,	these	groups’	 fluorescence	 readings	do	not	 reach	a	predetermined	 threshold,	 commonly	 in	 the	range	 of	 10-1	 to	 10-1.5	 in	 my	 experiments	 and	 PCR	 conditions.	 Further	 processing	 of	 the	 DNA	using	 a	 ‘clean	up’	 step	 improved	but	 did	 not	 fully	 normalise	 amplification	 (bottom,	 Cyt	B	 only	
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shown).	Persistent	‘S-shaped’	curves	were	evident	in	lieu	of	smooth	curves.	Heparin	was	further	confirmed	as	the	direct	inhibitor	in	a	further	experiment	where	animal	blood	was	either	injected	into	 heparin	 containing	 blood	 tubes	 or	 EDTA	 tubes	 (the	 standard).	 There	 was	 complete	inhibition	 of	 PCR	 amplification	 from	heparinised	plasma,	 normal	 PCR	 amplification	with	 Sham	and	Trauma	EDTA-plasma	and	variably	inhibited	amplification	from	HS	and	T-HS	EDTA-plasma,	n=4	per	group	(data	not	shown).																						
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Optimising	PCR	amplification	by	minimising	systemic	heparin	use		Ultimately,	 I	 developed	 a	 new	 heparin-free	 fixed	 volume	 haemorrhage	unresuscitated	 trauma	 shock	 model	 (Model	 2).	 The	 haemorrhage	 phase	consisted	 of	 bleeding	 the	 animal	 via	 the	 jugular	 catheter	 rather	 than	 the	heparinised	carotid	arterial	catheter.	Thus,	 flushes	of	saline	(20μL)	rather	 than	heparinised	 saline	were	 required.	 The	 alternatives	 to	 a	 completely	 new	model	were	considered,	such	as	the	use	of	heparinase	to	treat	animal	plasma	and	use	of	an	extra	clean	up	step	for	every	DNA	sample.	These,	however,	were	considered	to	 be	 too	 cumbersome	 and	would	 likely	 introduce	 other	 confounders	 into	 the	experiment.		The	revised	model	successfully	yielded	amplification	of	mtDNA	that	was	proportional	to	the	degree	of	trauma	and	shock	sustained	at	6	h	(Figure	3.11	details	the	fully	quantified	results	rather	than	unquantified	Ct	data).		
Absolute	Quantification	of	mtDNA	PCR			I	 used	 two	 different	 mitochondria	 isolation	 kits	 to	 obtain	 pure	 mitochondria	from	fresh	rat	liver:	1. The	 kit	 from	 Sigma,	 based	 on	 serial	 differential	 centrifugation,	 used	extensively	by	Hauser’s	group	(Zhang	et	al.,	2010b).			2. 	The	kit	 from	Miltenyi	Biotec	which	utilised	 the	MACS	method	whereby	paramagnetic	 microbeads	 conjugated	 with	 antibody	 to	 mouse	 anti-TOM22	 antibodies	 bind	 to	 the	 translocase	 of	 outer	 mitochondrial	membrane	22	(TOM22)	of	mouse	mitochondria	(Hornig-Do	et	al.,	2009).	I	was	advised	by	the	manufacturer	that	although	a	rat	specific	kit	was	not	
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yet	 commercially	 available,	 there	 was	 a	 degree	 of	 cross	 reactivity	between	 the	 species	 (personal	 communication,	 unpublished	observations).			‘Pure’	 mtDNA	 was	 then	 extracted	 from	 these	 mitochondrial	 fractions	 and	examined	for	purity	with	the	spectrophotometer.	Both	samples	yielded	pure	DNA	 with	 A260/280	 and	 A260/A230	 ratios	 of	 1.8-2.0	 and	 1.6-2.0,	respectively.	Table	3.9	depicts	 the	RT-PCR	results	 for	both	sample	 types	of	mtDNA	against	Cyt	B	and	GAPDH.	Sigma-derived	mtDNA	demonstrated	a	far	greater	difference	 in	Ct	values	between	Cyt	B	and	GAPDH	than	that	 for	 the	MACS-derived	 sample	 (equating	 to	 a	 26.3=80-fold	 relative	 increase	 in	composition	of	nDNA	 in	 the	MACS	derived	 compared	 to	 the	 Sigma-derived	sample).	This	equates	 to	a	 theoretical	purity	of	mtDNA	of	Sigma-mtDNA	of	98.75%.	 	The	Sigma-derived	samples	were	assumed	to	be	pure	mtDNA	and	used	as	standards	in	the	subsequent	mtDNA	quantification	in	PCR.			Serial	 1:10	 dilutions	 of	 these	 standards	 were	 then	 performed	 and	 these	standards	were	placed	in	every	PCR	run.	A	straight	line	was	then	calculated	on	 the	 axes	 of	 threshold	 count	 and	 log10	 concentration	 from	 which	experimental	 sample	mtDNA	concentrations	were	derived	 (Figures	3.8	and	3.9).	 I	 then	 performed	 further	 dilutions	 of	 the	 standards	 to	 assess	 the	sensitivity	 of	 the	 system,	 which	 revealed	 that	 starting	mtDNA	 amounts	 as	small	as	1pg	per	reaction	could	be	amplified.			
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PCR	for	bacterial	16S	rRNA		Cell-free	 plasma	 from	 all	 animals	 was	 tested	 against	 primers	 for	 the	 bacterial	gene	 encoding	 for	 16S	 ribosomal	 RNA	 (rRNA).	 This	 gene	 is	 also	 present	 in	mitochondria	 hence	 the	 primers	 were	 designed	 to	 only	 target	 the	 common	bacterial	component	of	the	gene.	There	was	universal	absence	of	amplification	in	all	 PCR	 runs	 suggesting	 lack	 of	 bacterial	 contamination	 in	 my	models	 (Figure	3.10).								
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	times	
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	derive
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le.	This
	equate
s	to	mt
DNA	pu
rity		
of	at	le
ast	98.
75%	fo
r	the	Si
gma	de
rived	s
ample.
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Standard	Curve	Generation	
		Figure	 3.8.	 	 Standard	 curve	 generation	 from	 mtDNA	 extracted	 from	 rat	 liver	 (Miltenyi	 MACS	method	 derived	 sample	 shown	 from	 table	 7).	 Serial	 10	 fold	 dilutions	were	made	 and	 RT-PCR	performed	against	mtDNA	(Cyt	B,	top	left	graph)	and	nDNA	(GAPDH,	top	right	graph)						
	 	
	
Cyt	B	 GAPDH	
Standard	Curve	
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			Figure	 3.9.	 Example	 of	 fully	 quantified	 RT-PCR	 for	 mtDNA	 with	 Sigma-derived	 standards.	 A	straight	 line	of	Ct	vs	 log10	concentration	was	then	generated,	described	by	the	gradient,	m,	and	the	 x=1	 (100)	 intercept,	 b,	 given	 here	 as	 -3.57	 and	 17.67,	 respectively.	 Note:	 a	 perfect	 10-fold	dilution	of	the	known	standards	and	error-free	PCR	should	generate	an	m	value	of	-3.33		(i.e.	23.3	=10).	The	R2	value	or	coefficient	of	determination	is	almost	1	indicating	an	almost	perfect	fit	of	the	 data	 with	 the	 regression	 line.	 	 As	 can	 be	 seen	 from	 this	 real	 example,	 picogram	 range	amounts	of	DNA	have	been	successfully	measured	with	this	setup.	The	sensitivity	is	down	to	at	least	1pg	mtDNA	per	reaction	(Cyt	B).								
	
	
Standard	curve	with	experimental	samples	
No. Colour Name Ct Calc Conc (ng/reaction) Rep. Ct Rep. Ct Std. Dev. 
1 
 
B2A 21.97 .06275765 21.96 0.01 
2 
 
B2A 21.96 .06316230   
3 
 
B2B 21.80 .07000323 21.80 0.00 
4 
 
B2B 21.81 .06977528   
5 
 
B2C 23.20 .02831992 23.20 0.00 
6 
 
B2C 23.20 .02837431   
 
Threshold 0.100 
Left Threshold 1.000 
Standard Curve Imported No 
Standard Curve (1) conc= 10^(-0.280*CT + 4.950) 
Standard Curve (2) CT = -3.571*log(conc) + 17.676 
Reaction efficiency (*) 0.90558 (* = 10^(-1/m) - 1)  
M -3.57108 
B 17.67581 
R Value 0.99979 
R^2 Value 0.99957 
 
Quan%ta%on	informa%on	
Quan%ﬁed	PCR	readout	
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					Figure	3.10.	RT-PCR	for	Bacterial	16S	rRNA	of	Model	2	Sham,	Trauma,	HS	and	T-HS	groups.	There	was	 no	 amplification	 of	 DNA	 extracted	 from	 cell-free	 plasma	 from	 animals	 subjected	 to	interventions	indicating	absence	of	bacterial	contamination.	Similar	runs	were	performed	for	all	subsequent	samples	including	pure	mtDNA	used	for	injection	into	healthy	animals	(Chapter	4).	Positive	control	shown	is	enterococcus	faecalis	DNA	20ng/μL.	This	PCR	setup	had	reliable	sensitivity	for	bacterial	16S	rRNA	down	to	at	least	0.2pg.				
	
	
	
	
	
	
	 153	
Plasma	mtDNA	levels	vs	degree	of	trauma	and	shock		As	 can	 be	 seen	 in	 Figure	 3.11,	 both	mtDNA	 and	 nDNA	 concentrations	 broadly	increased	 with	 increasing	 severity	 of	 injury	 as	 reflected	 by	 the	 moderate	correlation	between	mtDNA	and	nDNA	(p<0.01).	However,	important	differences	were	evident.	MtDNA	levels	exhibited	a	dose	dependent	increase	with	increasing	isolated	traumatic	injury,	whereas	nDNA	did	not.	These	findings	complement	the	time	 course	 study	 findings	 from	 earlier	 (Figures	 3.4	 and	 3.5).	 Plasma	 nDNA	concentration	 was	 increased	 significantly	 with	 moderate	 pure	 HS,	 whereas	mtDNA	 concentration	was	 not.	With	 severe	 combined	 trauma	 and	 shock	 both	concentrations	were	significantly	raised	with	respect	to	sham	levels:	10	fold	and	50	 fold	 for	mtDNA	and	nDNA,	 respectively.	 Interestingly,	 the	 0-10ng/ml	 range	for	mtDNA	concentration	 found	 in	my	study	correlates	well	with	other	 studies	(Gu	et	al.,	2013,	Zhang	et	al.,	2014a,	Lam	et	al.,	2004a)	and	the	 fold	 increase	 in	nDNA	levels	has	also	been	reported	in	this	range	by	others	(Timmermans	et	al.,	2016b).		A	 further	 large	 correlation	 analysis	 including	 all	 measured	 parameters	 of	inflammation,	 organ	 dysfunction	 and	 DNA	 concentrations	 from	 all	 Model	 2	animals	 was	 then	 carried	 out	 (Table	 3.10).	 MtDNA	 and	 nDNA	 were	 only	moderately	 correlated	 to	 each	 other	 (p<0.01),	 which	 lead	 to	 some	 divergent	findings	in	this	analysis.	Interestingly,	of	all	the	variables	measured	(except	lung	IL-6),	 mtDNA	 was	 the	 most	 highly	 correlated	 to	 lung	 MPO	 levels	 (p<0.001).	NDNA,	 by	 contrast,	was	not	 correlated	with	 lung	MPO	 	 (p=0.051).	MtDNA	was	highly	 correlated	 with	 urea	 concentrations	 (p<0.0001)	 and	 moderately	correlated	 with	 plasma	 IL-6	 and	 the	 other	 organ	 function	 scores	 (p<0.05	 to	
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p<0.01).	NDNA,	on	 the	other	hand,	was	highly	correlated	with	plasma	IL-6	and	the	non-lung	organ	 injury	markers	 (p<0.0001).	Although	 this	does	not	 confirm	causation,	it	supports	a	large	body	of	work	suggesting	lung	injury	is	particularly	driven	 by	 mtDNA	 concentrations	 (Zhang	 et	 al.,	 2010b,	 Zhang	 et	 al.,	 2010a,	Hauser	 et	 al.,	 2010,	 Zhang	 et	 al.,	 2014a).	 Similarly	 for	 nDNA,	 causation	 is	 not	proven.	 However,	 there	 is	 no	 published	 evidence	 to	 support	 any	 direct	inflammatory	injury	with	nDNA;	these	strong	associations	are	likely	a	marker	of	general	illness	severity.													
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	 								Figure	 3.11.	 Plasma	mtDNA	 and	 nDNA	 concentrations	 taken	 at	 6	 h	 from	 rodents	 subjected	 to	increasing	degrees	of	traumatic	injury	and	shock	(Model	2,	unresuscitated	fixed	volume	shock).	Top	panel,	 fully	 quantified	mtDNA	 concentrations	 from	RT-PCR	 (Cyt	B).	 Bottom	panels,	 nDNA,	1/Ct	 (GAPDH)	 and	 fold	 increases	 relative	 to	 sham	concentrations	displayed.	There	was	 a	dose	dependent	increase	in	mtDNA	with	increasing	trauma	severity	as	opposed	to	pure	HS;			†	denotes	p<0.01	for	severe	trauma	vs	naïve	animals.	With	increasing	severity	of	concomitant	shock	there	again	was	a	dose	dependent	increase	in	mtDNA,	‡	denotes	p<0.001	and	§	denotes	p<0.0001	for	T-HS	20%	and	Severe	T-HS	25%,	respectively,	vs	naïve	animals.	There	was	moderate	correlation	between	changes	in	mtDNA	and	nDNA	concentration	overall	(p<0.01)	but	important	differences	emerged.	There	was	no	rise	in	nDNA	with	increasing	traumatic	injury	but	pure	HS	30%	induced	a	small	 but	 significant	 rise	 in	nDNA,	†	denotes	p<0.01	vs	naive	 animals.	 Severe	T-HS	 resulted	 in	a	large	rise	 in	nDNA,	§	denotes	p<0.0001	vs	naïve	animals.	 t	 tests	used.	Mean	values	with	SEM	bars	shown.		
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	Table	 3.10.	 Pearson	 Correlation	 table	 of	 all	 measured	 variables	 relating	 to	 Model	 2.	 Top	 grid	indicates	correlation	significance,	*	denotes	p<0.05,	****	denotes	p<0.0001.	Bottom	grid	indicates	correlation	coefficients.	
	
	
	
LUNG	
MPO	
	
	
LUNG	
IL-6	
PLASMA	
IL-6	 UREA	 CREAT	 ALT	 AST	 CK	 nDNA	
	
mtDNA	
	
***	0.0001	 *	0.0436	 **	0.00756	 ****	3.251	x10-05	 *	0.0312	 **	0.0097	 **	0.0097	 *	0.0197	 **	0.003	
	
Lung	
MPO	
	
	 ****	1.515	x10-07	 ns	0.071	 *	0.017	 ns	0.206	 ns	0.348	 ns	0.105	 *	0.032	 ns	0.051	
	
Lung	
IL-6	
	
1.515	x10-07	 	 ****	3.969	x10-06	 ns	0.92	 ns	0.15	 ns	0.565	 ns	0.329	 *	0.049	 *	0.011	
	
Plasma	
IL-6	
	
0.0706	 3.97	x10-06	 	 **	0.0019	 ****	3.182	x10-08	 ****	9.282	x10-05	 ****	2.794	x10-06	 ****	1.668	x10-10	 ****	3.054	x10-08	
	
	
Urea	
	
0.0169	 0.920	 0.0018	 	 ****	6.770	x10-13	 ****	1.607	x10-06	 ****	2.799	x10-06	 ****	6.199	x10-05	 ****	4.703	x10-05	
	
	
Creat	
	
0.206	 0.1508	 3.182	x10-08	 6.770	x10-13	 	 ****	3.729	x10-12	 ****	1.001	x10-13	 ****	4.017	x10-10	 ****	2.168	x10-08	
	
	
ALT	
	
0.348	 0.565	 9.282	x10-05	 1.607	x10-06	 3.729	x10-12	 	 ****	2.792	x10-37	 ****	3.034	x10-08	 ****	1.181	x10-06	
	
	
AST	
	
0.105	 0.3287	 2.794	x10-06	 2.799	x10-06	 1.0014	x10-13	 2.792	x10-37	 	 ****	2.889	x10-17	 ****	2.181	x10-10	
	
	
CK	
	
	
0.032	 0.048	 1.669	x10-10	 6.199	x10-05	 4.017	x10-10	 3.0346	x10-08	 2.889	x10-17	 	 ****	2.071	x10-08	
	
	
	
LUNG	
MPO	
	
	
LUNG	
IL-6	
PLASMA	
IL-6	 UREA	 CREAT	 ALT	 AST	 CK	 nDNA	
	
mtDNA	
	
0.54	 0.41	 0.33	 0.47	 0.25	 0.30	 0.32	 0.28	 0.34	
	
Lung	
MPO	
	
	 0.86	 0.28	 0.35	 0.19	 0.14	 0.24	 0.32	 0.30	
	
Lung	
IL-6	
	
0.86	 	 0.84	 -0.02	 0.31	 -0.13	 0.21	 0.42	 0.52	
	
Plasma	
IL-6	
	
0.28	 0.84	 	 0.36	 0.60	 0.45	 0.55	 0.67	 0.62	
	
	
Urea	
	
0.35	 -0.02	 0.36	 	 0.69	 0.50	 0.51	 0.43	 0.45	
	
	
Creat	
	
0.19	 0.31	 0.60	 0.69	 	 0.67	 0.73	 0.63	 0.59	
	
	
ALT	
	
0.14	 -0.13	 0.45	 0.50	 0.67	 	 0.95	 0.57	 0.53	
	
	
AST	
	
0.24	 0.21	 0.55	 0.51	 0.73	 0.95	 	 0.79	 0.68	
	
	
CK	
	
	
0.32	 0.42	 0.67	 0.43	 0.63	 0.57	 0.79	 	 0.60	
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Discussion		I	have	successfully	developed	and	optimised	a	RT-PCR	system	to	measure	both	mtDNA	and	nDNA	in	cell-free	plasma	from	rodents.			The	 separation	 of	 trauma	 from	 shock-induced	 rises	 in	 mtDNA	 has	 not	 been	studied	 before.	 I	 have	 found	 that	 over	 a	 6	 h	 period,	 isolated	 traumatic	 injury	caused	 a	 rise	 in	 plasma	 mtDNA	 concentration	 which	 was	 proportional	 to	 the	magnitude	of	the	insult.	The	most	severe	degree	of	trauma	inflicted	in	my	study	resulted	 in	 levels	 of	mtDNA	 that	 peaked	 and	 then	 began	 to	 fall	within	 the	 6	 h	timeframe.	 This	 broadly	 concurs	 with	 the	 clinical	 data	 which	 shows	 that	admission	mtDNA	 is	 correlated	 to	 ISS	per	 se.	The	 combined	 trauma	and	 shock	data	 is	 more	 difficult	 to	 interpret	 due	 to	 the	 heparin	 inhibition	 in	 the	 earlier	experiments	impacting	the	T-HS	data	to	the	greatest	degree.	Thus,	a	time	course	over	the	first	6	h	cannot	be	definitely	commented	on.	However,	at	6	h,	there	was	a	dose	dependent	 increase	 in	mtDNA	with	 respect	 to	 severity	 of	T-HS	 applied.	This	confirms	mtDNA	to	be	a	useful	biomarker	for	both	trauma	and	combined	T-HS	per	se.		Plasma	 mtDNA	 levels	 have	 only	 been	 studied	 in	 small	 numbers	 of	 trauma	patients	and	also	in	a	small	number	of	animal	studies.	The	peak	of	mtDNA	post	mixed	 trauma	clinically	has	been	 found	 to	occur	within	 the	 first	24	h	of	 injury	and	levels	remained	elevated	for	a	week	(Yamanouchi	et	al.,	2013,	Timmermans	et	al.,	2016b).	This	concurs	with	an	animal	study	which	showed	that	resuscitated	T-HS	resulted	in	a	peak	of	mtDNA	at	around	24	h	as	well	(Zhang	et	al.,	2010a).	
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		The	 finding	 that	 direct	 cardiac	 sampling	 yields	 a	 marked	 rise	 in	 mtDNA	 as	 a	result	of	 the	sampling	process	 itself	 is	 interesting.	 It	raises	questions	regarding	other	 published	work	 and	 their	methodologies.	 It	 also	 raises	 the	 possibility	 of	using	mtDNA	to	assess	degree	of	localised	trauma	severity,	e.g.	direct	thoracic	or	myocardial	injury.			With	regards	to	nDNA	concentrations,	I	found	a	40-50	fold	increase	at	6	h	with	severe	T-HS	compared	to	sham	animals.	Timmermans	et	al.	(2016)	also	reported	a	similar	magnitude	of	nDNA	rise	within	a	few	hours	of	injury	clinically.	This	rise	in	 nDNA	 appears	 to	 be	 disproportionate	 relative	 to	 mtDNA.	 There	 is	 poor	understanding	of	the	mechanisms	of	release	of	nucleic	acids	into	the	circulation	in	 trauma	 and	 also	 of	 their	 subsequent	 degradation,	 such	 that	 many	 possible	hypotheses	 can	 be	 put	 forward	 to	 explain	 this	 differential	 rise	 in	 mtDNA	 and	nDNA.		Empirically,	there	is	a	far	greater	amount	of	nDNA	than	mtDNA	in	a	cell.	However,	up	to	10	copies	of	the	mtDNA	genome	can	exist	in	each	mitochondrion	and	 each	 cell	 can	 contain	 hundreds	 of	 mitochondria.	 MtDNA	 contains	 a	preponderance	 of	 highly	 immunogenic	 CpG	 repeats.	 Taken	 together,	mtDNA	 is	and	 has	 been	 reported	 to	 be	 a	much	more	 potent	 inflammatory	 stimulus	 than	nDNA	 (see	 Chapter	 One).	 	 Thus,	 recent	 reports	 focusing	 on	 the	 magnitude	 of	nDNA	in	trauma	and	ascribing	association/	causation	of	adverse	outcomes	to	the	magnitude	 of	 this	 rise	 in	 nDNA	 in	 particular,	 may	 be	misguided	 based	 on	 the	current	evidence	(Timmermans	et	al.,	2016b).	If	blunt	trauma	is	thought	to	result	in	 physical	 cellular	 disruption,	 the	 increased	 nDNA	 relative	 to	 mtDNA	 is	
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nonsensical.		If	necrosis	occurs,	again,	a	large	leak	of	nDNA	into	the	extracellular	space	 relative	 to	 mtDNA	 also	 does	 not	 appear	 credible.	 	 An	 active	 secretory	mechanism	 causing	 the	 release	 of	 nDNA	 in	 quantities	 in	 excess	 of	 mtDNA	 is	theoretically	 sound,	 but	 no	 evidence	 exists	 for	 such	 a	mechanism	 in	 the	 early	post	 trauma	phase.	NETosis	 could	explain	 this	phenomenon,	however,	 this	has	been	recorded	in	trauma	patients	several	days	later	and	resulted	in	a	measured	increase	 in	 mtDNA,	 not	 nDNA,	 plasma	 concentrations	 (McIlroy	 et	 al.,	 2015,	Itagaki	et	al.,	2015a).	Another	reason	for	this	discrepancy	may	well	be	explained	by	methodological	failings	related	to	the	measurement	of	cell-free	plasma	DNA,	in	particular	of	mtDNA,	given	 its	very	 small	 size	and	possibility	of	being	easily	degraded	and	lost	in	subsequent	processing	steps,	well	before	PCR	analysis	(see	later	 in	 section).	 Further	 work	 is	 clearly	 required	 to	 investigate	 these	hypotheses.		A	 particularly	 strong	 correlation	 between	 mtDNA	 and	 lung	 injury	 was	demonstrated	in	my	study.	The	poor	correlation	between	nDNA	and	lung	injury	was	also	striking.	These	contrasting	 findings	have	not	yet	been	reported	 to	my	knowledge.	However,	they	concur	with	a	broad	body	of	work	that	suggests	that	acute	 lung	 injury	 is	 particularly	 driven	 by	 elevated	 plasma	 mtDNA	concentrations	 (see	 Chapter	 One).	 The	 extremely	 high	 correlations	 between	nDNA	 and	 plasma	 IL-6	 and	 the	 other	 non-lung	 organ	 injury	 scores	 were	 also	noted.	Timmermans	et	al.	(2016)	reported	similarly	high	correlations	in	trauma	patients	between	nDNA	on	arrival	and	IL-6,	IL-8	and	IL-10.	Obviously,	causation	cannot	 be	 inferred.	 A	 number	 of	 different	 hypotheses	 can	 explain	 this	 finding.	However,	 on	 the	 strength	 of	 current	 evidence,	 there	 is	 no	 basis	 for	 direct	
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causation	 between	 nDNA	 and	 organ	 injury.	 High	 nDNA	 levels	 may	 simply	 be	reflective	 of	 general	 severity	 of	 illness,	 or	 be	 a	marker	 of	 the	 release	 of	 other	DAMPs	(Timmermans	et	al.,	2016b).		Several	problems	became	evident	during	the	course	of	 this	study.	The	 lack	of	a	standardised	approach	to	anticoagulant	use,	plasma	preparation,	centrifugation	protocol,	 DNA	 extraction	 and	 PCR	 setup	 has	 resulted	 in	 a	 wide	 range	 of	techniques	and	methods	being	utilised	and	reported	in	the	literature.	This	makes	direct	comparison	of	my	results	with	others	problematic.			In	general,	I	have	utilised	methodologies	that	are	widely	used	and	reported.	For	example,	I	have	used	EDTA	as	the	anticoagulant	for	plasma	generation	and	used	Qiagen	 spin	 columns	 because	 they	 have	 been	 extensively	 reported	 for	 the	measurement	of	mtDNA	(Chiu	et	al.,	2003,	Lam	et	al.,	2004a,	Zhang	et	al.,	2010a,	Zhang	et	al.,	2010b,	Raoof	et	al.,	2010,	Kung	et	al.,	2012,	Puskarich	et	al.,	2012,	Khubutia,	 2013,	 Gu	 et	 al.,	 2013,	 Yamanouchi	 et	 al.,	 2013,	McIlroy	 et	 al.,	 2014).	However,	 one	 group	 has	 reported	 that	 EDTA	 was	 only	 superior	 to	 other	anticoagulants	 if	 processing	 was	 delayed	 by	 more	 than	 6	 hours	 at	 room	temperature	 (which	 was	 not	 the	 case	 in	 my	 experiments;	 all	 samples	 were	processed	 immediately	 and	 stored	 at	 -80°C)(Lam	 et	 al.,	 2004b).	 Notably,	Hauser’s	 group	 has	 used	 heparin	 extensively	 (verbal	 communication)	 and	seemingly	 did	 not	 encounter	 problems	 with	 PCR	 inhibition	 in	 their	 setup.	Similarly,	Qiagen’s	own	 instructions	(QIAGEN,	2015)	 for	 the	QIAamp	Mini	DNA	extraction	kit	state	that	the	resultant	eluted	DNA	optimally	predominates	around	the	20-30kb	 range	 in	 size.	Therefore,	 this	may	not	be	 the	most	 suitable	kit	 for	
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small	 lengths	 of	 DNA	 such	 as	 mtDNA	whose	 genome	 is	 16.5kb	 in	 length,	 and	furthermore,	smaller	fragments	of	mtDNA	would	be	expected	in	cell-free	plasma.	This	 is	 supported	by	a	 study	which	 found	 that	of	 three	different	DNA	 isolation	methods	 tested	 against	 cell-free	plasma,	Qiagen’s	 spin	 columns	had	 the	 lowest	yield	 (Fleischhacker	et	al.,	 2011).	Further	experiments	 should	 ideally	 include	a	quality	 control	 step	 to	 measure	 the	 efficiency	 of	 DNA	 extraction,	 perhaps	 by	spiking	a	known	amount	of	plasmid	DNA	into	the	cell-free	plasma	sample.			Spin	 protocols	 for	 the	 generation	 of	 cell-free	 plasma	 are	 either	 often	 not	reported	or	are	highly	variable	between	groups.	This	variable	is	likely	to	explain	in	 large	 part	 the	 wide	 range	 in	 reported	 mtDNA	 concentrations	 in	 trauma,	ranging	from	865	(IQR	251-2565)	pg/ml	(900g	spin,	followed	by	9600g	spin,	(Gu	et	al.,	2013)	to	2.74+/-0.94μg/ml	(single	1600g	spin,	(Zhang	et	al.,	2010b).	The	balance	of	evidence	suggests	a	second	spin	is	necessary.		MtDNA	associated	with	fragments	 of	 mitochondria,	 platelets	 or	 NETs	 have	 been	 speculated	 to	 be	 the	source	 of	 some	 of	 the	 cell-free	 plasma	 DNA	 that	 is	 not	 truly	 freely	 circulating	(Chiu	 et	 al.,	 2003,	 Mehra,	 2007,	 McIlroy	 et	 al.,	 2014).	 Much	 further	 work	 is	needed	 to	 further	 elucidate	 the	 optimum	 protocol	 with	 regard	 to	 the	preservation	 of	 bona	 fide	 cell-free	 DNA	 and	 to	 identify	 other	 important	constituents	of	the	microparticular	milieu.			Further	improvements	could	also	be	made	to	the	area	of	quantification	of	mtDNA	PCR.	 Although	 it	 is	 likely	 that	 a	 relatively	 pure	 set	 of	 mtDNA	 standards	 was	generated,	 further	 corroboration	 of	 this	 purity	 could	 be	 obtained	 with	 the	simultaneous	absolute	quantification	of	nDNA	PCR	with	nDNA	standards.		
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Further	 experiments	 to	 be	 considered	 for	 the	 future	 should	 also	 include	 a	detailed	investigation	of	the	type	and	size	of	mtDNA	(and	indeed	nDNA)	found	in	the	 circulation	 of	 trauma	 shock	 subjects.	 This	 is	 currently	 unknown	 and	 may	reveal	 important	 associations	 and	 causation	 with	 pattern	 of	 cell	 death,	 organ	dysfunction	and	mortality	in	trauma	patients.														
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CHAPTER	IV	
	
SCAVENGING	CIRCULATING	MTDNA	AS	A	
POTENTIAL	THERAPEUTIC	OPTION	FOR	
ORGAN	DYSFUNCTION	IN	TRAUMA	
HAEMORRHAGE	
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Introduction	
	In	 the	 previous	 chapters,	 I	 have	 reported	 clear	 rises	 in	 circulating	 mtDNA	 in	trauma	haemorrhage	which	were	associated	with	acute	lung	injury	and	MOF	in	the	animal	model.	This	correlates	with	the	results	of	the	analysis	of	139	trauma	patients	 performed	 by	 our	 group	 (Centre	 for	 Trauma	 Science,	 Royal	 London	Hospital,	unpublished	data).	 I	have	shown	that	mtDNA,	as	opposed	to	nDNA,	 is	particularly	associated	with	lung	injury.	This	is	important	because	lung	injury	is	invariably	 the	 first	 organ	 to	 fail	 in	 the	 critically	 ill	 and	 therefore	 arresting	 its	development	 and	 progression	 is	 a	 research	 priority.	 Currently,	 there	 are	 no	therapeutic	options	to	prevent	organ	dysfunction	in	severe	trauma	hemorrhage.	Tranexamic	acid	is	the	only	agent	proven	to	improve	mortality	by	reducing	death	from	 bleeding	 but	 an	 associated	 immuno-modulatory	 effect	 may	 underlie	 this	effect	(Lord	et	al.,	2014).		Conceptually,	 mtDNA	 could	 be	 targeted	 with	 pharmacological	 agents	 in	 a	number	of	ways:		 1. The	 administration	 of	 nucleases	 to	 enhance	 degradation	 of	 circulating	
nucleic	 acid	 prior	 to	 their	 access	 to	 PRRs	 of	 the	 innate	 immune	 system.		Endogenous	 nucleases	 (DNases)	 act	 to	 degrade	 intra-	 and	 extracellular	nucleic	 acids	but	 can	be	overwhelmed	by	acutely	 increased	nucleic	 acid	producing	 pathologies,	 such	 as	 acute	 trauma	 (Zhang	 et	 al.,	 2010b),	 or	chronically	 by	 autoimmune	 diseases	 where	 DNases	 have	 become	dysfunctional	 or	 mutations	 to	 DNase	 genes	 have	 occurred	 (Magna	 and	
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Pisetsky,	 2016).	 	 The	 importance	 of	 DNase	 in	 the	 degradation	 of	intracellular	 mtDNA	 resulting	 from	 cell	 stress	 and	 mitochondrial	breakdown	and	 in	 the	maintenance	of	mitochondrial	quality	control	has	been	 confirmed	 (Oka	 et	 al.,	 2012).	 	 	 The	 use	 of	 DNase	 immobilized	 on	microspheres	 and	 delivered	 into	 a	 canine	 extracorporeal	 model	confirmed	 that	 the	 degradation	 of	 circulating	DNA	 could	 be	 accelerated	with	no	evidence	of	harm	to	the	host	(Terman	et	al.,	1976).	More	recently,	this	approach	has	also	been	successfully	used	in	a	rodent	extracorporeal	model	 (Trofimenko	 et	 al.,	 2015)	 but	 clinical	 application	 has	 yet	 to	 be	achieved.	However,	the	use	of	recombinant	nuclease	to	treat	patients	with	systemic	 lupus	 erythematosus	 (a	 prototypical	 autoimmune	 disease	whereby	 antibodies	 are	 generated	 against	 the	 patient’s	 own	nDNA)	 has	been	trialled,	unfortunately	without	success	(Davis	et	al.,	1999).		2. The	use	of	antibodies	targeting	mtDNA	or	its	primary	receptor,	TLR9.	This	approach	 has	 not	 been	 attempted	 clinically	 but	 one	 can	 predict	 several	likely	 hurdles.	 Firstly,	 there	 is	 great	 redundancy	 and	 complexity	 of	signalling	within	the	immune	system,	which	means	that	targeting	a	single	receptor	 is	 unlikely	 to	 realise	 the	 gains	 anticipated.	 The	 trauma	 and	critical	care	literature	is	replete	with	examples	of	this	type	of	failed	anti-inflammatory	 intervention	 (Lord	 et	 al.,	 2014).	 In	 addition,	 harm	 might	arise	as	a	result	of	the	suppression	of	normal	immune	functioning	(Lee	et	al.,	 2011).	Another	hurdle	one	could	envisage	would	be	 collateral	 tissue	damage	 from	 an	 antibody	 treatment	 to	 mtDNA,	 for	 example,	 unless	significant	 improvements	 in	 precision	 drug	 delivery	 were	 to	 be	 made.	
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This	 is	 currently	 the	 major	 challenge	 of	 nanomedicine:	 to	 deliver	 a	therapeutic	drug	at	a	specific	point	in	time	and	space.			3. Recently,	a	number	of	diverse	nucleic	acid	scavenging	polymers	have	been	
recognised	in	vitro	and	in	vivo	(Oney	et	al.,	2009).	A	number	of	these	agents	were	subsequently	shown	to	prevent	the	activation	of	endosomal	TLRs	in	a	 CpG	 dependent	 murine	 model	 of	 toxic	 shock	 (Lee	 et	 al.,	 2011).	Furthermore,	 this	 class	 of	 agent	 appears	 to	 allow	 normal	 immune	responses	to	occur,	alleviating	much	of	the	concern	with	the	use	of	anti-inflammatory	agents	in	general	(Holl	et	al.,	2013).	I	have	focused	on	this	therapeutic	 approach	 in	 the	 treatment	 of	 trauma	 haemorrhage	 induced	organ	dysfunction.				
The	emergence	of	nucleic	acid	scavenging	polymers	to	treat	nucleic	acid	from	dead	
and	dying	cells		Naturally	 occurring	 polyphosphates	 including	 the	 nucleic	 acid	molecules,	 DNA	and	RNA,	as	well	as	inorganic	polyphosphates,	have	recently	been	discovered	to	trigger	 coagulation.	 These	 compounds	 exhibit	 negative	 charge	 chemistry	 as	 a	result	 of	 their	 polyphosphate	 composition.	 This	 knowledge	was	 exploited	 by	 a	group	 led	 by	 Sullenger	 from	 Duke	 University	 which	 confirmed	 the	 ability	 of	various	 nucleic	 acid	 scavenging	 polymers	 to	 inhibit	 thrombosis	 without	increasing	bleeding	in	vivo	(Jain	et	al.,	2012).	These	NASPs	have	been	previously	extensively	 studied	 for	 their	 ability	 to	 form	nanocomplexes	with	DNA,	 various	drugs	 and	 small	 molecules	 for	 targeted	 delivery	 into	 cells.	 Subsequent	
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experiments	showed	that	of	the	many	polycationic	NASPs	initially	studied,	only	two,	 hexadimethrine	 bromide	 (HDMBr,	 trade	 name	 Polybrene)	 and	polyamidoamine	 dendrimer,	 1,4-diaminobutane	 core-PAMAM–G3	 (PAMAM-G3)	were	 found	 to	 inhibit	 multiple	 types	 of	 nucleic	 acid-mediated	 activation	 of	endosomal	 TLRs	 in	 a	 wide	 variety	 of	 cell	 types	 (Lee	 et	 al.,	 2011).	 The	 exact	mechanism	of	 action	of	 these	 two	agents	has	not	 yet	 been	 fully	 elucidated	but	has	been	found	to	involve	(Lee	et	al.,	2011):		 1. Neutralisation	 of	 extracellular	 nucleic	 acids	 due	 to	 charge	 chemistry	interactions.	2. Neutralisation	 of	 accessible	 nucleic	 acid;	 not	 those	 contained	 within	membranes	or	encapsulated	within	viral	pathogens.	3. Lack	of	direct	inhibition	of	nucleic	acid-sensing	endosomal	TLR	activity	4. Lack	 of	 inhibition	 at	 non-nucleic	 acid	 sensing	 TLRs,	 e.g.	 bacterial	 LPS	acting	at	TLR4.	5. Decreased	uptake	of	CpG	nucleic	acids	into	cells.	6. Alteration	 of	 the	 intracellular	 distribution	 of	 CpG	 nucleic	 acids	 largely	towards	 the	 nucleus	 and	 away	 from	 the	 endosomes	 where	 it	 would	otherwise	co-localise	with	TLR	9.	7. Rescue	from	CpG	challenge	in	D-galactosamine	(D-GalN)	sensitised	mice,	a	 model	 of	 acute	 toxic	 shock,	 whereby	 animals	 otherwise	 die	 from	overwhelming	TNF-alpha	mediated	liver	injury.			Interestingly,	 both	 HDMBr	 and	 PAMAM-G3	 both	 failed	 to	 inhibit	 heparan	sulphate	related		(normally	strongly	negatively	charged)	mediated	inflammation	
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in	 vitro	which	normally	 results	 from	stressed	 cells	 shearing	off	 components	of	their	glycocalyx	to	act	via	TLR4/RAGE.	This	suggested	that	NASP	activity	was	not	merely	a	function	of	charge	chemistry	(Lee	et	al.,	2011).		I	decided	to	further	investigate	the	potential	role	of	HDMBr	as	a	protective	agent	in	 trauma	 haemorrhage	 due	 to	 a	 number	 of	 factors.	 Namely,	HDMBr	 has	 been	used	 previously	 in	 humans	 in	 the	 1950’s	 and	 1960’s	 as	 an	 alternative	 to	protamine	and	thus	a	safety	profile	exists	clinically.	HDMBr	is	also	approximately	100	times	cheaper.		HDMBr	is	a	basic	non-protein	polycationic	compound	that	was	discovered	as	an	alternative	 to	protamine	(PRESTON,	1952).	HDMBr	 is	a	quaternary	ammonium	salt	polymer	with	the	empirical	formula	(C13H30Br2N2)x.	Similar	to	protamine,	it	neutralises	heparin	in	vitro	and	in	vivo	and	is	itself	an	anticoagulant.	HDMBr	was	introduced	to	clinical	practice	 in	1956	 for	 the	reversal	of	heparin	at	 the	end	of	cardiopulmonary	bypass	surgery	(HOHF	et	al.,	1956).	HDMBr	was	not	shown	to	induce	precipitously	low	blood	pressure	(which	was	common	with	protamine)	in	humans	 if	 administered	 at	 the	 correct	 dilution	 and	 rate	 (WEISS	 et	 al.,	 1958).	There	are	numerous	reports	of	 it	being	used	in	hundreds	of	patients	 in	centers	where	 it	 replaced	 protamine	 use	 routinely	 (WEISS	 et	 al.,	 1958,	 KEATS	 et	 al.,	1959,	 LILLEHEI	 et	 al.,	 1960,	 BLUMBERG	 et	 al.,	 1960,	 PATE	 and	 LEE,	 1963).	 In	1962,	 concerns	 surfaced	 about	 renal	 toxicity	 in	 association	with	 administered	doses	in	excess	of	5mg/kg	of	the	drug,	as	was	sometimes	required	for	prolonged	bypass	times	(Haller	et	al.,	1962,	PATE	and	LEE,	1963,	Yasargil	et	al.,	1965).	Its	manufacture	 for	 clinical	 use	 was	 discontinued	 at	 this	 time.	 However,	 toxicity	
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with	doses	of	Polybrene	<5mg/kg	has	not	been	conclusively	 shown	 in	humans	(Haller	et	al.,	1962,	Yasargil	et	al.,	1965,	RANSDELL	et	al.,	1965)	and	the	drug	has	been	 safely	 used	 at	 a	 dose	 of	 5mg/kg	 relatively	 recently	 in	 patients	with	 true	protamine	 allergy	 undergoing	 cardiopulmonary	 bypass	 surgery	 (Cooney	 and	Mann,	1999).	As	a	result	of	 this	knowledge,	 I	have	experimented	with	doses	 in	this	range	in	my	animal	model	of	trauma	haemorrhage.			The	 charge	 chemistry	 of	 HDMBr	 has	 continued	 to	 be	 utilised	 in	 gene	 delivery	using	 viral	 transduction	 techniques	 (Toyoshima	 and	 Vogt,	 1969,	 Kawai	 and	Nishizawa,	1984).		HDMBr	is	thought	to	help	overcome	the	natural	repulsion	that	exists	 between	 the	negatively	 charged	 viral	membrane	 and	negatively	 charged	plasma	cell	membrane,	thus	facilitating	viral	absorption	and	transduction.			
Animal	evidence	for	effects	on	coagulation		HDMBr	in	doses	up	to	5mg/kg	administered	to	heparinised	dogs	has	been	shown	to	 restore	 the	 clotting	 time	 to	normal,	 usually	within	5	minutes	 for	 the	 lowest	end	of	 this	dose	range,	and	within	30	minutes	 for	 the	highest	doses	(PRESTON	and	 PARKER,	 1953,	 WEISS	 et	 al.,	 1958,	 EGERTON	 and	 ROBINSON,	 1961,	KARLSON	 and	 LERNER,	 1962).	 There	 was	 a	 dose	 dependent	 prolongation	 of	clotting	time	as	the	anticoagulant	effect	of	HDMBr	itself	became	more	prominent.	In	unheparinised	dogs,	HDMBr	administered	at	a	dose	of	1mg/kg	prolonged	the	clotting	 time	 for	 15-20	 minutes	 before	 normalising	 again	 (EGERTON	 and	ROBINSON,	1961).			
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Interestingly,	recent	 in	vitro	studies	have	shown	that	HDMBr	was	able	to	block	tissue	factor	mediated	extrinsic	blood	coagulation	which	is	associated	with	pro-inflammatory	 states	 such	as	 sepsis	 and	 trauma	haemorrhage	 (Chu	et	 al.,	 2002,	Chu,	 2011).	 Other	 evidence	 of	 the	 anti-inflammatory	 effects	 of	 HDMBr	 has	appeared	over	the	previous	decades.	The	intravenous	administration	of	HDMBr	in	a	dose	range	of	4-20mg/kg	in	a	rat	paw	heat	injury	model	showed	a	reduction	of	both	oedema	formation	and	plasma	extravasation	(Leme	et	al.,	1970,	Leme	et	al.,	 1973).	 HDMBr	 has	 also	 been	 shown	 to	 inhibit	 calcium	 leak	 in	 cultured	 rat	cardiac	 cells	 subjected	 to	 injury	 by	 free	 radical	 exposure	 and	 metabolic	inhibition	to	model	ischaemia	reperfusion	injury	(Clague	et	al.,	1993).	The	non-heparin	 related	 nucleic	 acid	 scavenging	 effect	 of	 this	 class	 of	 drugs	 might	potentially	explain	these	older	findings.	However,	the	breadth	and	complexity	of	drug	 interactions	 for	HDMBr	 appear	 to	 be	 large.	 As	 supporting	 evidence	 for	 a	potential	pro-thrombogenic	role,	HDMBr	has	been	shown	to	increase	thrombus	formation	on	intact	endothelium	in	a	hamster	cheek	in	vivo	model	(Shanberge	et	al.,	 1990).	 The	 authors	 have	 speculated	 that	 this	 effect	 may	 be	 related	 to	HDMBr’s	 ability	 to	 bind	 to	 glycosaminoglycan	 (GAG)	 components	 such	 as	chrondroitin	sulphate	C	(Landázuri	and	Le	Doux,	2005)	and	dermatan	sulphate	(Landázuri	 and	 Le	 Doux,	 2005,	 Sié	 et	 al.,	 1989)	 rather	 than	 heparan	 sulphate	(Lee	et	al.,	2011)	of	the	endothelium	or	to	its	ability	to	potentiate	antithrombin	III	activity	(Shanberge	et	al.,	1990).	Both	of	these	mechanisms	normally	serve	to	provide	anticoagulation	at	the	endothelium.				
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Animal	evidence	of	renal	toxicity		Generally,	high	doses	of	HDMBr	are	required	to	 induce	renal	 injury.	Lutterbeck	demonstrated	 renal	 dysfunction	 and	 histological	 lesions	 (tubular	 necrosis)	 in	rats	at	8mg/kg	doses	and	above	(Lutterbeck	et	al.,	1967);	Ransdell	showed	the	same	with	doses	greater	than	5mg/kg	in	dogs	(RANSDELL	et	al.,	1965).	HDMBr	has	been	shown	to	induce	heavy	reversible	proteinuria	at	high	doses	(equivalent	to	9-10mg/kg	total	dose)	purportedly	via	interaction	with	the	negatively	charged	components	of	the	glomerular	basement	membrane	and	epithelial	cell	glycocalyx	(probably	 to	 carboxyl	 groups	 and	 not	 to	 heparan	 sulphate)	 thus	 altering	 its	charge	dependent	permselectivity	to	increase	barrier	pore	size	(Hunsicker	et	al.,	1981,	 Vehaskari	 et	 al.,	 1984,	 Bertolatus	 et	 al.,	 1984,	Hunsicker	 and	Bertolatus,	1987,	Bridges	et	 al.,	 1991).	 It	 is	 clear	 from	most	of	 the	animals	 studies	quoted	here	that	the	prior	use	of	heparin	allows	higher	doses	of	HDMBr	to	be	safely	used	and	that	the	administration	of	heparin	post	HDMBr	can	reverse	some	of	the	toxic	effects.			
Animal	evidence	of	lung	toxicity		The	 rapid	 injection	 of	 HDMBr	 into	 heparinised	 animals	 or	 humans	 on	cardiopulmonary	 bypass	 resulted	 in	 marked	 increases	 in	 pulmonary	 vascular	resistance	 and	 systemic	 hypotension,	 which	 invariably	 returned	 to	 baseline	within	minutes	(Weiss	et	al.,	1958,	Mackenzie	et	al.,	1961,	Egerton	and	Robinson,	1961).	These	haemodynamic	changes	were	much	less	marked	when	HDMBr	was	given	to	unheparinised	dogs	(Egerton	and	Robinson,	1961).		
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Polycationic	 compounds	 in	 general	 have	 been	 shown	 to	 cause	 increased	 cell	membrane	 porosity	 in	 a	 charge-density	 dependent	 manner	 (Prevette	 et	 al.,	2010).	 For	 example,	 generation	 7	 PAMAM	 dendrimers	 have	 been	 shown	 to	induce	nanoscale	disruption	in	plasma	membranes	resulting	in	pores	up	to	40nm	across,	 allowing	 leakage	 of	 molecules	 up	 to	 140kDa	 in	 size.	 There	 have	 been	several	 publications	 to	 suggest	 HDMBr	 has	 direct	 lung	 toxic	 effects	 via	 such	membrane	 destabilising	 mechanisms.	 An	 explanted	 rat	 lung	 model	demonstrated	 that	 HDMBr	 increased	 the	 rate	 of	 leeching	 of	 GAG	 components	(mostly	 heparan	 sulphate)	 and	 lung	 proteins	 from	 lung	 tissue	 (Gleisner	 and	Martin,	 1986).	 Increased	 lung	 vascular	 permeability	 was	 also	 shown	 with	HDMBr	 in	 an	 isolated	 perfused	 rat	 lung	 model	 (Chang	 et	 al.,	 1987)	 and	 in	conscious	 sheep	 at	 a	 very	 low	 dose	 of	 0.1mg/kg	 (Toyofuku	 et	 al.,	 1989).	However,	the	preponderance	of	pulmonary	macrophages	in	certain	species	such	as	 sheep,	 pigs	 and	 cows,	 but	 not	 humans,	 has	 lead	 some	 to	 speculate	 that	 the	sensitivity	 and	 response	 of	 sheep	 lungs	 might	 not	 be	 comparable	 to	 humans	(Schapira	and	Christman,	1990).											
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Methods	
	
Trauma-haemorrhagic	shock	(Model	Iteration	2)		As	 described	 previously,	 severe	 trauma	 (in	 the	 form	 of	 bilateral	 lower	 limb	fractures,	 laparotomy	 and	 bilateral	 lower	 limb	muscle	 crush	 injury)	 and	 25%	EBV	unresuscitated	haemorrhagic	shock	was	applied	to	the	animal.			
Therapeutic	agent	administration		At	 15	minutes	 after	 the	 haemorrhage	 phase	 was	 completed,	 animals	 received	either	an	 intravenous	bolus	of	saline	250μl	(0.9%	NaCl,	Baxter	Healthcare,	UK)	or	 the	 Nucleic	 Acid	 Scavenging	 Polymer	 (NASP)	 study	 drug	 (Hexadimethrine	bromide,	Sigma,	UK)	at	a	concentration	of	1-4mg/kg,	dissolved	 in	saline	250μl,	both	administered	over	10	minutes.		
Plasma	preparation	
Terminal	 blood	was	 collected	 into	EDTA	 containing	 tubes	 (3	 x	 1.3ml,	 Sarstedt,	UK),	gently	inverted	3	times	and	immediately	centrifuged	at	200g	for	10	minutes	at	room	temperature	to	remove	the	platelet	rich	fraction.	The	plasma	layer	was	then	 aspirated	 taking	 care	 not	 to	 disturb	 the	 cellular	 fraction	 and	 again	centrifuged	 at	 3000g	 for	 15	 minutes	 at	 4°C,	 and	 then	 again	 at	 3000g	 for	 15	minutes	at	4°C.	
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	200μl	 aliquots	 of	 plasma	were	made	 in	0.5ml	 tubes	 (Eppendorf,	UK)	 and	 flash	frozen	in	liquid	nitrogen	and	stored	at	-80°C	for	later	analysis.		Plasma	and	whole	blood	 was	 tested	 for	 lactate	 (POC,	 Roche,	 UK)	 and	 routine	 biochemistry,	respectively	(Vetlab,	UK)		
Plasma	and	lung	cytokine	analysis		Commercial	colorimetric	rat	ELISA	kits	for	the	measurement	of	plasma	IL-1β,	IL-6	and	TNF-α	were	used	(R&D	Systems,	UK).	Rat	HMGB1	(MyBioSource,	USA)	and	TFAM	 (Cusabio,	 Japan)	ELISA	kits	were	 also	used.	 Plasma	dilutions	were	none	(neat)	 for	 all	 ELISA	 kits	 except	 IL-6	 (1:2	 dilution).	 Lung	 homogenates	 were	tested	for	IL-6	concentration	using	a	rat	ELISA	kit	(Sigma,	UK).			
DNA	extraction	and	PCR	for	mtDNA,	nDNA	and	bacterial	16S	rRNA	
	DNA	was	extracted	from	cell-free	plasma	as	before	and	eluted	into	60μL	water.	PCR	performed	as	described	in	Chapter	3.		
NASP	toxicity	experiments		Healthy	controls	were	anaesthetised	and	instrumented	as	described	previously.	NASP	2mg/kg	or	4mg/kg	in	250μL	saline	0.9%	total	volume	was	intravenously	injected	into	animals	over	10	minutes.	Plasma	and	organs	were	sampled	at	6	h.	
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Pure	mtDNA	Challenge	in	Healthy	Animals		Healthy	controls	were	anaesthetised	and	instrumented	as	described	previously.	Pretreatment	with	NASP	2mg/kg	was	followed	by	intravenous	injection	of	pure	mtDNA	from	5%	liver	by	weight	(Sigma,	UK).	Pure	mtDNA	from	either	3%	liver	or	 5%	 liver	 was	 also	 intravenously	 injected	 alone	 into	 healthy	 instrumented	animals.		Plasma	and	organs	were	sampled	at	6	h.		
Lung	Myeloperoxidase	(MPO)	Activity	
	Performed	 in	 association	 with	 Prof.	 Massimo	 Collino,	 Department	 of	 Drug	Science	 and	 Technology,	 Turin	 University,	 Italy.	 MPO	 activity,	 used	 as	 an	indicator	of	leukocyte	accumulation	into	the	lung,	was	determined	as	previously	described	(Collino	et	al.,	2011).			
Lung	Tissue	Western	Blot	Analysis	
 Performed	 in	 association	 with	 Prof.	 Massimo	 Collino,	 Department	 of	 Drug	Science	and	Technology,	Turin	University,	Italy.	Western	blots	were	carried	out	as	 previously	 described	 (Collino	 et	 al.,	 2013).	 Proteins	 were	 separated	 by	 8%	sodium	dodecyl	sulphate-polyacrylamide	gel	electrophoresis	and	transferred	to	polyvinyldenedifluoride	 membrane,	 which	 was	 then	 incubated	 with	 primary	antibodies	(rabbit	anti-NF-κB	p65,	rabbit	anti-STAT-3	and	rabbit	anti-phospho-
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STAT-3).	Blots	were	then	incubated	with	a	secondary	antibody	conjugated	with	horseradish	 peroxidase	 (dilution	 1:10000)	 and	 developed	 using	 the	 ECL	detection	 system.	 The	 immunoreactive	 bands	 were	 visualized	 by	autoradiography	and	 the	density	of	 the	bands	was	 evaluated	densitometrically	using	 Gel	 Pro®Analyzer	 4.5,	 2000	 software	 (Media	 Cybernetics,	 Silver	 Spring,	MD,	USA).	The	membranes	were	stripped	and	incubated	with	β-actin	monoclonal	antibody	 (dilution	 1:5000)	 and	 subsequently	 with	 an	 anti-mouse	 antibody	(dilution	1:10000)	 to	 assess	 gel-loading	homogeneity.	Unless	 otherwise	 stated,	all	compounds	were	purchased	from	the	Sigma-Aldrich,	Missouri,	USA.	The	BCA	Protein	 Assay	 kit	 and	 SuperBlock	 blocking	 buffer	 were	 from	 Pierce	Biotechnology	 (Illinois,	 USA).	 Antibodies	were	 from	New	 England	 Biolabs,	 UK.		Luminol	ECL	was	from	Amersham	(Buckinghamshire,	UK).			
Lung	Histological	Analysis			
Performed	in	association	with	Prof.	Fred	Wong	and	Dr	Winston	Liao	Wupeng,	Department	of	Pharmacology	and	Immunology	Program,	National	University	Health	System,	Singapore.	
The	 rat	 lung	 was	 fixed	 in	 10	 %	 formalin	 (Sigma)	 for	 24	 hr,	 followed	 by	embedment	 and	 6µm	 sectioning	 for	 haematoxylin	 and	 eosin	 staining.	 Samples	were	dehydrated	using	graded	ethanol,	embedded	in	paraffin	wax,	and	cut	 into	sections	 using	 a	 Leica	 rotary	 microtome	 (thickness,	 6μm).	 Sections	 were	deparaffinized	 with	 xylene,	 stained	 with	 Gills	 haematoxylin,	 and	 washed.	 Sec-	tions	were	 then	 subsequently	 counterstained	with	 1%	 eosin,	 dehydrated	with	
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ethanol,	 and	 cleared	 with	 Neo-Clear	 (Darmstadt,	 Germany)	 before	 mounting	using	 HistoMount	 (Atlanta,	 Ga,	 USA).	 Sections	 were	 analyzed	 using	 a	 Leica	DM2000	 upright	 microscope	 (Wetzlar,	 Germany).	 The	 entire	 H&E-stained	section	was	evaluated	at	low	magnification	(5	x	objective)	for	inflammatory	cell	infiltration.	A	4-point	scoring	scale	of	cell	infiltration	was	used	to	determine	the	grade	of	 lung	 inflammation:	0	=	normal;	1	=	mild;	2	=	 intermediate;	3	=	severe	(Downing	 et	 al.,	 2010).	 Features	 examined	were	 inflammatory	 cell	 infiltration,	pulmonary	congestion,	and	thickening	of	 the	alveolar	septa.	A	 total	of	10	 fields	were	 evaluated	 randomly	 for	 each	 sample.	 The	 score	 for	 each	 group	 was	 the	average	score	for	all	samples	in	the	group.	Quantitative	analysis	was	performed	in	a	blinded	way.		
	
Lung	immunohistochemistry	analysis		Performed	 in	 association	with	 Prof.	 Fred	Wong	 and	Dr	Winston	 Liao	Wupeng,	Department	 of	 Pharmacology	 and	 Immunology	 Program,	 National	 University	Health	System,	Singapore.	
Paraffin-embedded	 sections	 were	 deparaffinized	 with	 histo-clear/ethanol	 and	rehydrated.	Antigen	retrieval	was	made	in	sodium	citrate	buffer	(10	mM,	pH	6.0)	at	 a	 sub-boiling	 temperature	 for	10	min,	 followed	by	30	min	 cooling	on	bench	top.	 After	 incubation	 with	 3	 %	 hydrogen	 peroxide	 to	 remove	 endogenous	peroxidase	 activity,	 the	 slides	 were	 washed	 with	 PBS	 and	 blocked	 with	 5	 %	normal	serum	for	1	hr.	The	sections	were	immunostained	with	anti-rat	cleaved	caspase-3	 (1:1000,	 Cell	 Signaling	 Technology,	 Danvers,	 MA,	 USA)	 and	 anti-rat	
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nitrotyrosine	 (1:1000,	 EMD	 Millipore,	 Temecula,	 CA,	 USA)	 at	 4	 °C	 overnight.	After	 washing	 with	 PBST,	 the	 slides	 were	 incubated	 with	 a	 biotinylated	secondary	 antibody	 (Vector	 labs,	 Burlingame,	 CA,	 USA),	 followed	 by	streptavidin-HRP	 (Vector	 labs).	 The	 bound	 antibodies	 were	 developed	 by	ImmPACTTM	DAB	peroxidase	substrate	kit	(Vector	labs).	The	cleaved	caspase-3+	cell	number	was	quantified	by	counting	positively	stained	cells	 in	20	randomly	selected	fields	under	60	x	objective.	
	
Results		
Survival	study			Table	4.1	describes	the	characteristics	of	the	different	study	groups,	which	were	the	combination	of	two	independent	experiments.		The	untreated	group	showed	a	 slightly	 higher	 6-hour	 experimental	 mortality	 than	 in	 the	 same	 model	described	in	Chapter	2	at	44.8%	compared	to	38.4%.		Animals	treated	with	any	dose	of	NASP	approximately	15	minutes	after	the	end	the	trauma	haemorrhage	phase	showed	improved	survival	but	this	failed	to	reach	statistical	significance.	When	all	the	NASP	treated	animals	were	combined	(doses	1,2	and	4mg/kg)	there	was	 a	 statistically	 significant	 improvement	 in	 survival	 compared	 to	 controls,	p<0.05,	Chi-square	 test.	Bleeding	 times	of	 all	 groups	were	well	matched.	NASP	dosing	 occurred	 15	 minutes	 post	 injury,	 range	 45-60	 minutes	 into	 the	experiment.	 In	 those	 that	 did	 not	 survive	 6	 hours,	 there	was	 a	 non-significant	trend	 towards	 increased	 survival	 with	 lower	 doses	 of	 the	 drug,	 but	 the	 small	
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numbers	 precluded	 meaningful	 interpretation	 of	 this	 data.	 Overall,	 this	 study	was	 significantly	 underpowered	 to	 detect	 meaningful	 differences	 in	 survival;	therefore	caution	must	be	used	here.	Approximately	50%	more	animals	would	be	required	 to	demonstrate	statistical	differences	 in	survival	between	different	doses	of	NASP	used	assuming	the	previous	trends	in	survival	were	maintained.	Of	note,	animals	in	the	NASP	1mg/kg	group	were	significantly	lighter	than	those	in	the	other	groups.	This	may	have	some	bearing	on	the	interpretation	of	some	organ	 injury	 scores	 and	 parameters,	 e.g.	 plasma	 creatinine,	 where	 a	 result	indexed	for	body	weight	may	result	in	small	but	significantly	altered	differences		occurring	between	groups.	
Table	 4.1.	 Characteristics	 of	 study	 groups	 involving	 NASP	 (Hexadimethrine	 bromide).	 ns,	 not	significant.	a	denotes	p<0.05	for	all	NASP	groups	combined	vs	untreated	T-HS	group,	Chi-square.	Mean	values	with	SEM	given.	
	 Severe	T-HS	25%	
	
NASP	
1mg/kg	
NASP	
2mg/kg	
NASP	
4mg/kg	 p	value	
Starting	
(N)	
	
29	 14	 20	 23	 -	
Surviving	
(n)	
	
16	 12	 14	 18	 -	
Mortality	
(%)	
	
44.8	 16.7	 30	 21.7	 ns	a	
Bleeding	
time	
(min)	
	
35	(+/-4)	 33	(+/-2)	 37	(+/-4)	 35	(+/-2)	 ns	
Survival	
time	of	
non-
survivors	
(h)	
2.794	(+/-0.28)	 4.625	(+/-0.13)	 3.643	(+/-0.45)	 2.848	(+/-0.27)	 ns	
Weight	
(g)	
	
	
351	(+/-7)	 320	**	(+/-4)	 354	(+/-6)	 356	(+/-5)	 <0.01	
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	Figure	4.1.	Haemodynamic	data.	Sham	group,	 instrumented	animals,	n=5.	Trauma	occurred	at	 -15	 to	 -5	minutes.	 Severe	T-HS	25%	group,	Bilateral	 lower	 limb	 fractures,	 laparotomy,	bilateral	lower	limb	muscle	crush,	25%	EBV	bleed,	250μl	bolus	Normal	Saline	at	time	45-60	minutes,	n=16	(combination	 of	 two	 experiments).	 NASP	 (Hexadimethrine	 bromide)	 1mg/kg	 group,	 As	 per	Severe	T-HS	25%	group	except	bolus	NASP	1mg/kg	in	250μL	saline	0.9%	at	time	45-60	minutes,	n=12	(combination	of	two	experiments).	NASP	2mg/kg	group,	as	per	Severe	T-HS	25%	+	NASP	2mg/kg	 bolus	 in	 250μl	Normal	 Saline,	 n=14	 (combination	 of	 two	 experiments).	 NASP	 4mg/kg	group,	As	per	Severe	T-HS	25%	+	NASP	4mg/kg	bolus	in	250μl	Normal	Saline,	n=18	(combination	of	two	experiments).	*	denotes	p<0.0001	vs	Sham	from	time	0	onwards.	Baseline	-15min	MAP	of	NASP	1mg/kg	group	significantly	lower	than	all	other	groups,	p<0.05.	Otherwise	no	differences	in	MAPs	between	any	shocked	groups	throughout.	Two	way	ANOVA/Tukey’s.	Mean	values	with	SEM	bars	shown.				
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Figure	 4.2.	 Heart	 rate	 data.	 Baseline	 HR	 data	 was	 similar	 in	 all	 groups,	 p>0.05.	 During	haemorrhage	 there	 was	 no	 significant	 difference	 in	 HR	 between	 all	 groups,	 p>0.05.	 Absolute	changes	in	HR	may	be	a	result	of	small	non-significant	differences	in	baseline	HR.	From	t=30	min	to	180	min,	NASP	 (Hexadimethrine	bromide)	1mg/kg	had	a	 significantly	higher	HR	 than	NASP	2mg/kg	and	4mg/kg	groups,	*	denotes	p<0.05.	From	t=210	to	300	min,	NASP	1mg/kg	group	had	a	significantly	higher	HR	than	the	NASP	4mg/kg,	*	denotes	p<0.05.	Two	way	ANOVA/Dunnett’s	vs	NASP	1mg/kg.	Mean	values	with	SEM	bars	shown.					
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Haemodynamic	studies	–	MAP		As	can	be	seen	 in	Figure	4.1,	all	 shocked	groups	were	well	matched	at	all	 time	points,	p>0.05,	Two	way	ANOVA,	Tukey’s.	The	exception	to	this	was	the	baseline	MAP	of	 the	NASP	1mg/kg	group	which	had	a	 significantly	 lower	MAP	 than	 the	other	 groups,	 110(+/-4)	 mmHg	 vs.	 125(+/-2)	 mmHg	 for	 controls,	 p<0.05.	Overall,	 this	 indicates	 that	 all	 groups	were	 haemorrhaged	 in	 a	 similar	 fashion.	The	 lowest	 MAPs	 were	 achieved	 at	 15	 minutes,	 range	 47(+/-3)	 to	 52(+/-3)	mmHg.	MAPs	recovered	spontaneously	by	120	minutes	to	a	range	of	73(+/-1)	to	79(+/-4)	 mmHg	 and	 were	 generally	 maintained	 at	 these	 levels	 until	 the	termination	 of	 the	 experiment.	 As	 with	 the	 previous	 experiments,	 final	 MAPs	were	 not	 significantly	 different,	 although	 small	 differences	 emerged	 that	correlated	with	severity	of	MOF	and	survival	(p<0.01).		
Haemodynamic	studies	–	Heart	Rate		Baseline	 HRs	 and	 HRs	 during	 the	 haemorrhage	 phases	 of	 all	 groups	were	 not	significantly	different	(Figure	4.2).	However,	there	was	a	trend	towards	a	higher	HR	 at	 baseline	 for	 the	 NASP	 1mg/kg	 group,	 (p=0.10)	 and	 there	 was	 a	significantly	 higher	 HR	 at	 30	 minutes	 to	 300	 minutes	 for	 the	 NASP	 1mg/kg	compared	to	the	other	NASP	treated	groups,	p<0.05,	Two	way	ANOVA,	Dunnett’s.	The	 lowest	 HRs	 achieved	were	 at	 30	minutes,	 range	 362(+/-7)	 to	 401(+/-12)	bpm.	 	 HRs	 gradually	 rose	 to	 a	 peak	 at	 300-330	minutes,	 range	 426	 (+/-9)	 to	
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463(+/-13)	bpm.	The	final	HRs	of	all	groups	were	similar.	Overall,	the	MAP	and	HR	 data	 indicates	 that	 all	 shocked	 groups	 were	 subjected	 to	 similar	haemorrhage.	However,	small	differences	in	baseline	data	for	the	NASP	1mg/kg	group	may	have	had	a	bearing	on	their	subsequent	haemodynamic	profiles.			
		Figure	4.3.	6-hour	plasma	mtDNA,	lung	inflammation	scores	and	systemic	IL-6.	Cell-free	mtDNA	was	measured	with	RT-PCR	using	Cytochrome	B	as	the	target	gene:	Severe	T-HS	25%	resulted	in	an	approximately	8	fold	increase	in	mtDNA	compared	to	sham,	0.57(+/-0.1)	to	4.1(+/-0.6)	ng/ml,	p<0.0001,	t	test.		The	addition	of	NASP	(Hexadimethrine	bromide)	1mg/kg	post	injury	resulted	in	a	 non-significant	 trend	 towards	 reduced	 mtDNA,	 mean	 2.46(+/-0.46)	 ng/ml,	 p=0.06.	 NASP	2mg/kg	 reduced	 circulating	 plasma	 mtDNA	 by	 half	 to	 2.2(+/-0.36)	 ng/ml,	 *	 denotes	 p<0.05.		NASP	4mg/kg	resulted	in	an	increased	mean	mtDNA	5.09(+/-0.9)	ng/ml	relative	to	untreated	T-HS	 25%,	 p>0.05.	 Lung	 MPO:	 Untreated	 T-HS	 25%	 showed	 a	 marked	 increased	 in	 lung	 MPO	compared	 to	 shams,	 140(+/-0.5)	 vs	 25.8(+/-0.8)	 uU	 MPO/g,	 p<0.0001.	 There	 was	 significant	attenuation	of	lung	MPO	in	the	NASP	1mg/kg	and	2mg/kg	groups,	49.4(+/-0.4)	and	61.9(+/-0.9)	
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uU	 MPO/g	 respectively,	 §	 denotes	 p<0.0001,	 but	 not	 in	 the	 NASP	 4mg/kg	 group.	 Lung	 IL-6	concentration	was	measured	by	ELISA:	Untreated	T-HS	25%	resulted	in	a	significant	increase	in	Lung	 IL-6	 from	sham	 levels,	74.9(+/-6.5)	vs	23.7	 (+/-1.1)	pg/mg	protein,	p<0.0001.	There	was	significant	 attenuation	 in	 lung	 IL-6	with	 all	 three	 doses	 used,	 24.7(+/-0.76),	 34.2	 (+/-5.5)	 and	41.3	(+/-2.3)	pg/mg	protein	respectively,	§	denotes	p<0.0001	vs	untreated	T-HS	25%.	Systemic	IL-6	concentration	was	measured	by	ELISA:	There	was	a	marked	in	increased	in	plasma	IL-6	in	untreated	T-HS	compared	to	controls,	2999(+/-782)	pg/ml	vs	186(+/-2)	pg/ml,	p<0.0001.	There	was	significant	attenuation	of	IL-6	release	with	all	three	doses	used:	373(+/-51)	pg/ml,	1299(+/-298)	 pg/ml	 and	 738(+/-69)	 pg/ml	 respectively,	 †	 denotes	 p<0.01	 and	 §	 denotes	 p<0.0001	 vs	untreated	T-HS	25%,	t	tests	throughout.	Mean	values	with	SEM	bars	shown.						
		Figure	4.4.	6-hour	plasma	nuclear	DNA	concentrations.	Cell-free	plasma	nDNA	was	measured	by	RT-PCR	 using	 GAPDH	 as	 the	 target	 gene.	 Y-axis	 is	 denoted	 as	 the	 reciprocal	 of	 the	 threshold	count,	 Ct,	 the	 PCR	 cycle	 at	 which	 the	 rate	 of	 PCR	 product	 starts	 to	 rise	 exponentially,	 which	corresponds	 to	 the	 amount	 of	 starting	 template.	 The	 right	 hand	 graph	 illustrates	 the	corresponding	 fold	 increase	 in	 nDNA	 relative	 to	 sham.	 There	was	 a	 45-fold	 increase	 in	 nDNA	concentration	relative	to	sham,	p<0.0001.	NASP	(Hexadimethrine	bromide)	1mg/kg	resulted	 in	significant	 attenuation	 of	 this	 rise	 to	 5	 fold	 sham	 levels;	 ‡	 denotes	 p<0.001.	 NASP	 2mg/kg	resulted	in	lesser	but	significant	attenuation	to	17	fold	sham	levels,	*	denotes	p<0.05.	Attenuation	with	 NASP	 4mg/kg	was	 not	 significant	 statistically.	 	 t	 tests	 used.	 Mean	 values	 with	 SEM	 bars	shown.		
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Circulating	nucleic	acid	concentration	is	decreased	with	NASP	treatment	in	T-HS		As	can	be	seen	 in	Figure	4.3,	 circulating	plasma	mtDNA	at	6	hours	 increased	8	fold	 in	 untreated	 trauma	haemorrhage	 compared	 to	 sham	 controls.	 The	use	 of	NASP	 1mg/kg	 post	 injury	 resulted	 in	 a	 non-significant	 reduction	 in	 mtDNA	(p=0.06);	NASP	2mg/kg	caused	a	significant	reduction	in	mtDNA	by	about	50%	(p=0.015).	 Interestingly,	 NASP	 4mg/kg	 showed	 an	 approximately	 unchanged	mtDNA	 concentration	 compared	 to	 controls.	 Figure	 4.4	 illustrates	 the	corresponding	changes	in	nDNA.	Untreated	severe	trauma	haemorrhage	resulted	in	a	45-fold	rise	in	nDNA.	NASP	1mg/kg	resulted	in	attenuation	in	nDNA	levels	to	approximately	 5	 fold	 sham	 levels,	 followed	 by	 a	 17	 and	 22	 fold	 rise	 for	 NASP	2mg/kg	 and	NASP	4mg/kg	 groups,	 respectively.	 	 Similar	magnitudes	 of	 rise	 of	mtDNA	and	nDNA	levels	in	trauma	haemorrhage	have	been	reported	previously	in	 trauma	 patients	 (Timmermans	 et	 al.,	 2016b).	 There	 has	 been	 an	 extensive	body	of	work	published	which	confirms,	however,	that	nDNA,	at	 least	in	a	pure	or	 unmodified	 form,	 is	 immunologically	 inert	 (Magna	 and	 Pisetsky,	2016)(Chapter	1).	Numerous	studies	of	purified	nDNA	and	mtDNA	challenge	into	healthy	 animals	 have	 resulted	 in	 inflammation	 and	 organ	 injury	 from	mtDNA,	but	not	nDNA.	The	extensive	correlation	analysis	of	my	animal	data	(Chapter	3)	further	corroborates	this	by	confirming	very	high	levels	of	correlation	between	circulating	mtDNA	and	 the	development	of	 acute	 lung	 injury	 in	particular,	 and	conversely,	 non-correlation	 between	 nDNA	 levels	 and	 acute	 lung	 injury.	Contrastingly,	 nDNA	 levels	 appear	 to	 be	 much	 more	 highly	 correlated	 with	systemic	 IL-6	 release	 and	 the	 development	 of	 non-lung	 organ	 injury.	Furthermore,	lung	MPO	appears	to	be	a	very	sensitive	marker	of	lung	injury	that	
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is	responsive	to	higher	doses	of	NASP	per	se,	probably	reflecting	toxicity	and	cell	necrosis	 (Figure	 4.9).	 MtDNA	 release	 may	 be	 a	 result	 of	 this	 toxicity	 itself	reflecting	 cellular	oxidative	 stress	 and	damage.	 Similar	 toxicity	has	been	noted	with	other	cationic	agents	(Prevette	et	al.,	2010,	Hunter	and	Moghimi,	2010,	Wei	et	al.,	2015).			IL-6	is	known	to	be	presynthesised	in	white	blood	cells	and	released	as	early	as	1	h	after	trauma	injury	in	mice	but	subsequent	release	is	likely	to	require	a	longer	period	for	new	synthesis	(Abrams	et	al.,	2013).	Therefore,	subsequent	systemic	release	of	 IL-6	 is	 likely	to	be	delayed	and	 local	release	of	 IL-6	may	not	develop	into	systemic	release	within	the	duration	of	these	experiments.	NDNA	release	in	trauma	may	be	associated	with	other	DAMPs	to	explain	the	high	concentrations	and	systemic	release	of	IL-6.	Of	note,	other	cytokines	and	DAMPs	were	measured	at	 6	 hours	 in	 this	 experiment	 including	 IL-1β,	 TNFα,	 HMGB1	 and	 TFAM	 but	extremely	low	or	undetectable	levels	were	found	in	all	groups	(data	not	shown).			
NASP	 treatment	 produces	 broad	 anti-inflammatory	 action	 at	 the	 transcriptional	
level	in	T-HS	
 IL-6	was	 the	most	 consistently	 elevated	 cytokine	measured	 in	 this	 study.	 IL-6	exerts	its	action	via	the	signal	transducer	gp130	leading	to	the	activation	of	the	STAT	 (Signal	 transducer	 and	 activator	 of	 transcription)	 and	 MAPK	 cascades	(Heinrich	et	al.,	2003).	TLR-9	is	known	to	signal	via	Myd88	which	then	activates	NF-κB	signalling	to	produce	a	broad	inflammatory	phenotype	(Wei	et	al.,	2015).	
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NF-κB	is	also	a	strong	inducer	of	IL-6	(Keller	et	al.,	1996).		Therefore,	we	decided	to	 focus	 on	 these	 two	 proteins	 in	 lung	 tissue.	 Western	 Blot	 analysis	 of	 lung	homogenates	for	phosphorylation	of	NF-κB	and	STAT-3	was	performed	(Figure	4.5).	There	was	marked	attenuation	of	phosphorylation	of	NF-κB	to	sham	levels	with	 both	 NASP	 2mg/kg	 and	 NASP	 4mg/kg.	 With	 regards	 to	 STAT-3,	 NASP	2mg/kg	produced	attenuation	of	phosphorylation	to	sham	levels;	NASP	4mg/kg	produced	 less	 but	 still	 significant	 attenuation.	 No	 loss	 of	 anti-inflammatory	action	was	noted	at	the	higher	dose	of	NASP	used.			
NASP	treatment	improves	lung	histological	appearance	in	T-HS		Trauma	 haemorrhagic	 shock	 leads	 to	 cellular	 stress,	 failure	 of	 mitophagy	 and	autophagy,	increasing	degrees	of	oxidative	stress,	translocation	of	mtDNA	to	the	cytosol,	and	activation	of	apoptotic	cell	death	pathways	(Kepp	et	al.,	Oka	et	al.,	2012).	When	the	ischaemia	is	prolonged	and/or	reperfusion	injury	supervenes,	cellular	 necrosis	 occurs	 with	 resultant	 movement	 of	 mtDNA	 into	 the	extracellular	 space.	 Apoptosis	 is	 known	 to	 be	 associated	 with	 the	 release	 of	oxidised	mtDNA	 into	 the	 cytosol,	 where	 it	 binds	 to	 the	 NLRP3	 inflammasome	causing	local	and	systemic	inflammation	(Shimada	et	al.,	2012).			Immune	cell	 infiltration,	apoptotic	cell	death	and	oxidative	injury	in	lung	tissue	was	 assessed	 by	 the	 use	 of	 H&E,	 cleaved	 caspase-3	 and	 3-NT	 staining,	respectively	(Figures	4.6-4.8).	There	was	a	broad	protective	effect	evident	with	all	 three	 stains	 with	 NASP	 use	 and	 evidence	 of	 a	 dose-dependent	 protective	effect.	Again,	no	loss	of	protection	was	noted	at	the	highest	dose	of	NASP	used.			
	 188	
			
					Figure	 4.5.	 Western	 blot	 analysis	 of	 lung	 homogenates.	 Phosphorylated	 NF-κB	 levels	 were	markedly	 increased	 at	 6	 hours	 post	 T-HS	 with	 attenuation	 to	 sham	 levels	 with	 NASP	(Hexadimethrine	 bromide)	 2mg/kg	 and	 4mg/kg	 dosing,	 †	 denotes	 p<0.01	 vs.	 untreated	 T-HS	25%.	 Phosphorylated	 STAT-3	 levels	 were	 similarly	 attenuated	 by	 NASP	 2mg/kg,	 ‡	 denotes	p<0.001	vs	untreated	T-HS	25%,	less	so	with	NASP	4mg/kg,	†	denotes	p<0.01	vs.	untreated	T-HS	25%.	 n=3-4	 animals	 per	 group.	 ANOVA/Tukey’s.	 Bar	 graphs	 indicate	 mean	 values	 with	 SEM.	NASP	1mg/kg	data	not	available.				
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NASP	toxicity	study		De	 novo	 toxicity	 was	 evaluated	 by	 the	 injection	 of	 NASP	 2mg/kg	 and	 NASP	4mg/kg	into	healthy	animals	(Figure	4.9).	Significant	increases	in	lung	MPO	were	noted	 with	 increasing	 doses	 of	 NASP	 compared	 to	 naïve	 animals.	 This	 is	 in	keeping	with	the	known	and	predicted	side	effects	of	this	agent	given	its	charge	chemistry	 and	 likely	 affinity	 for	 binding	 to	 pulmonary	 vascular	 endothelium.	There	 were	 non-significant	 trends	 towards	 increased	 liver	 and	 muscle	 injury	with	the	higher	NASP	4mg/kg	dose	(p=0.10,	p=0.14,	respectively,	n=4	per	group,	data	not	illustrated)	and	no	deterioration	in	renal	function	markers.	The	kidney	has	 been	 noted	 to	 be	 particularly	 resistant	 to	 the	 inflammatory	 potential	 of	mtDNA	 challenge	 in	 a	previous	 study	 in	mice	 and	 rats	 (He	 et	 al.,	 2015).	 There	was	a	non-significant	trend	towards	increased	mtDNA	concentrations	with	NASP	4mg/kg	 (p=0.06)	 and	 no	 significant	 increase	 in	 nDNA	 concentrations.	 This	further	 suggests	 cytotoxicity	with	 this	 dose	 of	NASP	 and	potentially	 leads	 to	 a	feed-forward	cycle	of	mtDNA	propagated	inflammation.			
MtDNA	challenge	in	healthy	animals		Pure	mtDNA	extracted	 from	rodent	 liver	was	 injected	 into	healthy	animals	and	plasma	and	organs	were	sampled	at	6	hours	(Figure	4.9).	Two	doses	of	mtDNA	were	 chosen,	 3%	 and	 5%	 of	 liver	 by	 weight,	 because	 they	 had	 been	 used	extensively	 by	 Hauser’s	 group	 and	 produced	 clinical	 range	 plasma	 mtDNA	concentrations	with	subsequent	organ	 injury	 (Zhang	et	al.,	2010b,	Zhang	et	al.,	
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2010a).	The	pure	mtDNA	extracts	were	proven	to	be	infection-free	with	the	use	of	PCR	 for	bacterial	16S	rRNA	(data	not	shown).	A	dose	dependent	 increase	 in	lung	MPO	was	detected	with	 increasing	dosage	of	mtDNA	 compared	 to	 shams.	However,	post	treatment	with	NASP	2mg/kg	30	minutes	after	mtDNA	challenge	failed	to	attenuate	this	rise	 in	MPO.	Similarly,	pretreatment	with	NASP	2mg/kg	15	 minutes	 before	 mtDNA	 challenge	 failed	 to	 attenuate	 the	 lung	 injury	 as	measured	 by	 MPO.	 The	 reasons	 for	 the	 inability	 to	 rescue	 MPO	 induced	 lung	injury	 are	 not	 clear	 but	 include	 extreme	 sensitivity	 of	 the	 lung	 MPO	 test	 to	measure	inflammation,	crude	modeling	of	the	clinical/in	vivo	injury	with	a	single	bolus	 of	 mtDNA	 and	 susceptibility	 of	 the	 animal	 lung	 to	 the	 toxicity	 of	 the	treatment	itself.			A	small	but	significant	rise	in	plasma	IL-6	and	lung	IL-6	was	evident	with	the	5%	liver	 mtDNA	 dose	 (Figure	 4.9).	 Other	 plasma	 organ	 injury	 markers	 were	 not	elevated.	However,	pre-treatment	with	NASP	2mg/kg	attenuated	the	rise	in	lung	and	plasma	IL-6	to	sham	levels.			Further	 histological	 examination	 of	 lungs	 from	 this	 experiment	 using	 H&E,	cleaved	caspase-3	and	3-NT	stains	 further	 confirmed	 that	 the	 injection	of	pure	mtDNA	 into	 healthy	 animals	 caused	 moderately	 severe	 acute	 lung	 injury	 on	histological	 appearances.	 	 NASP	 pre-treatment	 was	 able	 to	 attenuate	inflammatory	 cellular	 infiltration,	 apoptotic	 cell	 death	 and	 oxidative	 cellular	injury	in	lung	tissue	in	a	dose	dependent	manner	(Figure	4.10).			
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Other	plasma	organ	injury	markers		The	results	of	this	array	of	tests	were	more	mixed	(Figure	4.14).	All	three	doses	produced	a	similarly	statistically	reduced	6-hour	lactate	compared	to	untreated	T-HS	 animals.	 As	 the	 bleeding	 phase,	 injury	 phase	 and	 post	 mortem	examinations	(to	exclude	large	limb	haematomas	or	intraperitoneal	bleeding,	for	example)	 were	 similar	 in	 all	 groups,	 this	 improvement	 in	 lactate	 supports	 a	broad	 cellular	 protective	mechanism	with	 NASP	 treatment.	 However,	 multiple	organ	protection	was	most	consistently	shown	with	NASP	2mg/kg.														
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												Figure	4.6.	NASP	(Hexadimethrine	bromide)	treatment	of	rodent	T-HS	improved	lung	histological	appearances.	Haematoxylin	&	Eosin	(H&E)	staining	 to	measure	cell	 infiltration	 into	 the	airway,	an	 indicator	of	 airway	 inflammation.	NASP	 treatment	 showed	a	dose-dependent	attenuation	of	cellular	 infiltration.	 †	denotes	p<0.01	vs	untreated	Severe	T-HS	25%,	 t	 test.	 n=4-7	animals	per	group.	Mean	values	with	SEM	bars	shown.	Scale	bars	represent	50μm.	
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	Figure	4.7.	NASP	(Hexadimethrine	bromide)	treatment	of	rodent	T-HS	improved	lung	histological	appearances.	 Cleaved	 caspase-3	 staining	 was	 used	 to	 evaluate	 apoptotic	 cell	 death.	 NASP	treatment	 showed	 a	 dose	 dependent	 reduction	 of	 apoptotic	 cell	 death.	 †	 denotes	 p<0.01	 vs	untreated	 Severe	 T-HS	 25%,	 t	 test.	 n=4-8	 animals	 per	 group.	 Dark	 arrows	 indicate	 cleaved	caspase-3	cells.	Scale	bar	represents	50μm.	
Cleaved	caspase-3	staining						(40	×)	
T-HS	25%	Naive	
NASP	
2mg/kg	
NASP	
4mg/kg	
Na
ive
Se
ve
re 
T-
HS
NA
SP
 1m
g/k
g
NA
SP
 2m
g/k
g
NA
SP
 4m
g/k
g
0
100
200
300
C
as
pa
se
-3
+  c
el
ls
Naive	
Severe	
T-HS	25%	
NASP		
1mg/kg	
NASP		
2mg/kg	
NASP		
4mg/kg	
†	
†	
†	
	 194	
									
	Figure	4.8.	NASP	(Hexadimethrine	bromide)	treatment	of	rodent	T-HS	improved	lung	histological	appearances.	 Staining	 for	 3-Nitrotyrosine	 (3-NT),	 a	 marker	 of	 peroxynitrite	 production	 and	hence	 oxidative	 stress,	 was	 used	 to	 evaluate	 oxidative	 injury.	 There	 was	 a	 dose	 dependent	improvement	 in	 lung	 histological	 appearance	 with	 increasing	 doses	 of	 NASP	 (not	 quantified).	Black	arrows	indicate	3-NT	positive	stained	cell.	Red	scale	bar	represents	50μm.	
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						Figure	 4.9.	 Lung	 MPO,	 lung	 and	 plasma	 IL-6.	 Lung	 MPO	 (Top):	 Injection	 of	 NASP	(Hexadimethrine	 bromide)	 2mg/kg	 and	 4mg/kg	 into	 naïve	 rats.	 Lungs	 sampled	 at	 6	 h.	 There	were	 significant	 increases	 in	MPO	with	 both	 doses	 compared	 to	 naive	 animals	 indicating	 lung	toxicity	 at	 the	 higher	 dose	 especially,	 *	 denotes	 p<0.05,	 §	 denotes	 p<0.0001.	 Pure	 mtDNA	extracted	 from	3%	and	5%	rat	 liver	by	 total	weight	was	 injected	 into	 sham	animals	with	dose	dependent	 increases	 in	 lung	 MPO	 compared	 to	 sham	 animals,	 *	 denotes	 p<0.05,	 	 †	 denotes	p<0.01.	Then,	pure	mtDNA	extracted	 from	5%	 liver	was	 injected	 into	shams	 followed	by	NASP	2mg/kg	 30	minutes	 later;	 there	was	 no	 significant	 change	 in	MPO	 found.	 Finally,	 shams	were	injected	with	 NASP	 2mg/kg	 followed	 by	 5%	 liver	 pure	mtDNA	 injection	 15	minutes	 later.	 No	significant	 alteration	 in	 lung	 MPO	 was	 found.	 t	 tests	throughout.	 n=3-5	 animals	 per	 group.	
Plasma	 and	 Lung	 IL-6	 (Bottom)	 were	 both	 measured	 by	 ELISA:	 Injection	 of	 pure	 mtDNA	extracted	 from	 5%	 liver	 resulted	 in	 a	significant	 rise	 in	 both	 Plasma	 and	 Lung	 IL-6	concentrations,	p<0.01.	Pre-treatment	of	sham	animals	with	NASP	2mg/kg	followed	by	injection	of	pure	mtDNA	extracted	from	5%	liver	15	minutes	later	resulted	in	attenuation	of	both	values	to	sham	levels,	‡	denotes	p<0.001,	§	denotes	p<0.0001	vs	pure	mtDNA,	 t	 tests.	n=3-5	animals	per	group.	 	Overall,	MPO	appears	 to	 be	 a	 very	 sensitive	marker	 of	 lung	 injury.	 Pre-treatment	with	NASP	attenuated	other	inflammatory	marker	increases	with	pure	mtDNA	injections.	Mean	values	with	SEM	shown.	
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																Figure	4.10.	NASP	(Hexadimethrine	bromide)	2mg/kg	pre-treatment	followed	by	5%	liver	pure	mtDNA	 injections	 into	 sham	 animals	 attenuated	 lung	 injury	 on	 histological	 examination	 with	H&E,	 caspase-3	 and	 3-NT	 staining.	 *	 denotes	 p<0.05,	 †	 denotes	 p<0.01,	 both	 vs.	 Pure	mtDNA	injection	alone,	t	tests.	n=3-5	animals	per	group.	Mean	values	with	SEM	bars	shown.			
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																													Figure	4.11.		Further	toxicity	study.	NASP	(Hexadimethrine	bromide)	2mg/kg	and	NASP	4mg/kg	was	injected	into	controls;	plasma	and	organs	were	sampled	at	6	hours.	mtDNA	and	nDNA	were	measured	using	RT-PCR	using	Cytochrome	B	and	GAPDH	as	the	target	genes,	respectively.	There	was	 a	non-significant	 trend	 towards	 increased	 mtDNA	 plasma	 concentrations	 (p=0.06)	 with	NASP	4mg/kg	and	no	significant	rise	in	nDNA	concentration	with	either	dose	of	NASP	(p=0.50).	Mean	values	with	SEM	bars	shown,		n=3-4	anaimals	per	group				
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		Figure	4.12.	RT-PCR	for	Bacterial	16S	rRNA	in	cell-free	plasma	taken	from	animals	subjected	to	T-HS	with	and	without	NASP	(Hexadimethrine	bromide)	treatment.		There	was	no	amplification	of	 DNA	 indicating	 absence	 of	 bacterial	 contamination.	 Similar	 runs	 were	 performed	 for	 pure	mtDNA	used	for	injection	into	healthy	animals	which	also	showed	absence	of	contamination	(not	shown).	 Positive	 control	 shown	 is	 enterococcus	 faecalis	 DNA	 200pg/μL.	 This	 PCR	 setup	 had	reliable	sensitivity	for	bacterial	16S	rRNA	down	to	at	least	0.2pg.									
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		Figure	4.13.	Standard	curves	generated	for	PCR	mtDNA	quantification	(using	CytB	as	the	target	gene)	and	for	PCR	quantification	of	bacterial	contamination	(using	16S	rRNA	as	the	target	gene).	5-6	 serial	 10	 fold	 dilutions	 of	 known	 pure	 mtDNA	 or	 enterococcus	 faecalis	 were	 used,	respectively.	The	top	graph	depicts	experimental	samples	superimposed	on	the	standard	curve.	The	detailed	quantitation	information	is	also	indicated	for	this	standard	curve	on	the	top	right.	
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		Figure	4.14.	Other	organ	injury	markers	at	6	hours.	Urea:	There	was	no	detectable	difference	in	urea	concentration	with	increasing	dose	of	NASP	(Hexadimethrine	bromide)	used	in	severe	T-HS	25%.	Creatinine:	Renal	protection	was	evident	with	NASP	2mg/kg	and	4mg/kg	doses.	ALT	and	AST:	 There	 was	 significant	 attenuation	 of	 liver	 injury	 evident	 with	 NASP	 2mg/kg	 dosing.	 CK:	There	was	significant	attenuation	of	muscle	 injury	with	both	NASP	1mg/kg	and	2mg/kg	doses.		Lactate:	There	was	significant	reduction	in	6h	lactate	with	all	three	doses	NASP	used.	*	denotes	p<0.05,	 †	 denotes	 p<0.01	 vas	 untreated	 severe	T-HS	25%,	 t	 tests.	 n=12-18	 animals	 per	 group.	Mean	 values	 with	 SEM	 bars	 shown.	 Overall,	 the	 NASP	 2mg/kg	 group	 produced	 the	 most	consistent	multiple	 organ	 protection	 in	 severe	 T-HS	 25%.	 	 Indexing	 biochemistry	markers	 by	weight	of	animals	made	no	difference	to	significance	levels.			
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			Figure	 4.15.	 Standard	 curves	 generated	 for	 various	 ELISAs.	 Undetectable	 or	 barely	 detectable	concentrations	 of	 IL-1β,	 TNFα,	 TFAM	 and	 HMGB1	 were	 found	 in	 plasma	 samples	 taken	 from	rodent	models	 at	multiple	 time	points	during	 the	 first	 6	hours.	 IL-6	was	 the	most	 consistently	measured	cytokine	across	all	the	studies	undertaken.				
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TNFα	 Lung	IL-6	
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Discussion		To	 the	 best	 of	 my	 knowledge,	 this	 study	 is	 the	 first	 to	 report	 a	 reduction	 in	circulating	 mtDNA	 (and	 nDNA)	 in	 an	 in	 vivo	 model	 of	 trauma	 haemorrhage	induced	by	the	NASP,	Hexadimethrine	bromide,	that	is	associated	with	multiple	organ	 protection	 and	 increased	 survival.	 Notably,	 the	 therapeutic	 agent	 was	administered	at	a	clinically	relevant	time	point.		Overall,	 the	results	pertaining	to	acute	lung	injury	and	the	use	of	NASP	in	T-HS	suggest	 that	NASP	has	definite	 lung	protective	properties,	most	convincingly	at	1mg/kg	and	2mg/kg	doses.	Higher	doses	appear	to	elicit	toxicity	as	evidenced	by	increased	 lung	MPO	 concentrations	 and	 possibly	 higher	 plasma	mtDNA	 levels.	Polycationic	 compounds	 in	 general	 have	 been	 shown	 to	 accumulate	 in	 lung	tissue	 in	 particular	 (Wei	 et	 al.,	 2015).	 However,	 this	 toxicity	 is	 neither	demonstrated	 in	 the	 cytokine	 profile	 nor	 on	 histological	 examination	 of	 lungs	from	 rats	 subjected	 to	 T-HS	 and	 treated	 with	 NASP.	 The	 expected	 toxicity	 of	cationic	agents	such	as	HDMBr	would	include	plasma	membrane	destabilisation	and	apoptotic	cell	death	signalling.	These	features	have	not	been	demonstrated	in	 this	 study	 in	 the	 context	of	 rescue	 from	severe	 trauma	hemorrhage	 induced	injury.	 Clearly,	 there	 is	 a	 risk-benefit	 profile	 and	 therapeutic	 index	 to	 be	established	 in	 further	 studies.	 The	 mechanistic	 mtDNA	 challenge	 experiments	confirm	 that	 mtDNA	 is	 an	 important	 mediator	 in	 the	 pathogenesis	 of	 T-HS	induced	lung	injury	and	that	mtDNA	can	be	targeted	by	a	NASP	such	as	that	used	
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here.	 However,	 circulating	 nDNA	 is	 also	 reduced	 in	 these	 experiments,	 so	 an	effect	from	nDNA	cannot	be	fully	excluded.			The	 exact	 nature	 of	 HDMBr-DNA	 interactions	 and	 their	 subsequent	 cellular	trafficking	 remains	 poorly	 elucidated.	 Much	 of	 the	 recent	 evidence	 of	polycationic	charge	interactions	relates	to	more	modern	compounds	such	as	the	PAMAM	dendrimers.	Thus,	 references	 to	 these	studies	will	be	made	 to	support	reasonable	hypotheses	as	to	the	mechanism	of	HDMBr-DNA	interactions	and	its	subsequent	trafficking.	HDMBr,	like	other	polycationic	compounds	used	as	drug	and	 molecular	 delivery	 platforms,	 is	 a	 nanoscale	 compound.	 It	 has	 a	 well-recognised	ability	 to	 condense	DNA	 into	nanocomplexes	 for	delivery	 into	 cells.	Its	ability	to	disrupt	plasma	membranes	and	increase	membrane	permeability	to	itself	 and	 other	 molecules	 probably	 also	 plays	 a	 part	 in	 its	 cellular	 uptake	(Carmona-Ribeiro	 and	 de	Melo	 Carrasco,	 2013).	 The	 degree	 of	 absorption	 and	penetration	of	DNA	has	been	shown	to	depend	on	pH,	size	of	polycation,	charge	density	and	length	of	DNA.	Deeper	penetration	of	DNA	inside	the	polycation	may	result	 in	 subsequent	 difficulty	 with	 DNA	 release.	 This	 is	 problematic	 in	 gene	delivery	 technology	 but	may	be	 less	 so	 in	 the	 context	 of	 treatment	 for	 trauma	haemorrhage.	Interestingly,	proteinase	K	has	been	shown	to	successfully	disrupt	cationic	peptide-nanoparticle	complexes	to	enable	measurement	of	DNA	loading	(Jain	et	al.,	2014).	Whether	this	applies	to	HDMBr	is	unknown.			Smaller	lengths	of	DNA	(less	than	150	base	pairs	or	50nm	in	length)	have	been	shown	to	be	less	flexible	and	less	able	to	bend	around	polycationic	vehicles	than	longer	lengths	(Nandy	et	al.,	2012).	Differences	in	DNA	length	found	in	necrosis	
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and	apoptosis	have	been	well	described.	NDNA	fragmentation	is	a	key	feature	of	apoptosis	 and	 results	 in	 fragments	 of	 nDNA	 in	 multiples	 of	 180bp	 lengths	whereas	 necrosis	 results	 in	 random	 sized	nDNA	 lengths	 (Jahr	 et	 al.,	 2001).	 An	analysis	 of	 DNA	 length,	 in	 particular	 of	 mtDNA	 length,	 released	 in	 trauma	haemorrhage	has	not	yet	been	carried	out.	Given	the	length	of	the	human	mtDNA	molecule	 is	 only	 16kbp,	 one	 would	 expect	 small	 fragments	 to	 be	 liberated	 in	trauma	haemorrhage.	This	may	have	relevance	 to	polycation-DNA	 interactions.		Despite	being	positively	charged	and	still	retaining	most	of	this	charge	with	the	addition	 of	 cargo	 such	 as	 DNA,	 these	 nanomolecules	 are	 small	 enough	 to	penetrate	within	cells.	HDMBr	has	one	of	the	smallest	molecular	weights	in	this	class	which	probably	aids	its	cellular	entry,	although	no	direct	evidence	exists	for	the	internalisation	of	HDMBr	itself.			Other	than	entry	via	the	(disrupted)	plasma	membrane,	 polycation-DNA	 complexes	have	been	 shown	 to	be	 internalised	via	endocytic	 and	 phagocytic	 routes	 into	 vesicles	 where	 they	 then	 destabilize	endosomal	 membranes	 or	 act	 as	 proton	 sponges,	 which	 then	 releases	 the	complexes	 into	 the	 cytoplasm	(Hunter	and	Moghimi,	2010).	These	effects	have	been	 indirectly	 measured	 in	 the	 case	 of	 HDMBr-CpG	 interactions;	 CpG,	 in	 the	presence	 of	 HDMBr	 treated	 cells,	 was	 seen	 to	 localise	 in	 the	 cytoplasm	 and	towards	 the	 nucleus	 rather	 than	 co-localise	 at	 the	 endosomal	 compartment	where	TLR9	is	located	(Lee	et	al.,	2011).	Once	internalised,	polycations	have	the	potential	 to	 cause	 cytotoxicity	 by	 inducing	 endosomal	 destabilization	 and	rupture,	 lysosome	 perforation	 with	 lysosomal	 enzyme	 leakage,	 and	mitochondrial	 permeabilisation	 and	 mitochondrially	 mediated	 apoptosis	 with	resultant	cytochrome	c	 leakage	 (Hunter	and	Moghimi,	2010,	Fang	et	al.,	2015).	Recent	 work	 has	 documented	 direct	 polycationic	 toxicity	 due	 to	 its	 direct	
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binding	with	Na+/K+-ATPase	and	 its	 resultant	 impairment.	This	 resulted	 in	cell	necrosis	 with	 leakage	 of	 mtDNA	 and	 canonical	 TLR9/MyD88	 dependent	inflammation	 (Wei	 et	 al.,	 2015).	 A	 trend	 towards	 increased	 mtDNA	concentrations	was	 found	 in	my	NASP	 4mg/kg	T-HS	 and	 toxicity	 experiments.	Other	more	recently	described	forms	of	cell	death,	such	as	necroptosis,	NETosis	and	pyroptosis	can	also	liberate	mtDNA	(Magna	and	Pisetsky,	2016).	Thus,	 it	 is	likely	that	NASP	4mg/kg	caused	a	degree	of	pulmonary	cellular	necrosis,	without	evidence	 of	 lung	 apoptosis,	 lung	 oxidative	 stress,	 immune	 cell	 infiltration	 into	lung	 tissue	 or	 systemic	 inflammation	 at	 the	 6	 hour	 time	 point.	 This	 partially	correlates	with	the	findings	of	Wei	et	al.			Important	 limitations	 of	 this	 study	 should	 be	 noted.	 It	 was	 underpowered	 to	detect	 differences	 in	 survival	 and	 caution	must	 therefore	 be	 used	 to	 interpret	this	 data.	 The	 study	 was	 not	 blinded	 although	 every	 effort	 was	 made	 to	standardise	 the	 trauma	 and	 haemorrhage	 phases	 of	 each	 animal.	 Surgery	was	not	 carried	 out	 in	 a	 fully	 sterile	 manner,	 although	 great	 effort	 was	 used	 to	maintain	cleanliness	with	regular	alcohol	cleaning	of	instruments.	No	evidence	of	bacterial	 contamination	 was	 detected	 using	 extremely	 sensitive	 PCR	 assays.	Inspection	of	laparotomy	wounds	showed	them	all	to	be	dry	at	the	termination	of	 the	 experiments,	 and	 post	 mortem	 examinations	 of	 all	 animals	 excluded	intraperitoneal	 bleeding	 and	 limb	 haematomas	 related	 to	 fracture	 sites.	However,	 an	 analysis	 of	 coagulation	was	 not	 carried	 out;	 this	would	 be	 useful	given	 the	 unknown	 effects	 of	HDMBr	 on	 the	 coagulation	 system	when	 used	 in	severe	trauma	haemorrhage.			
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Finally,	 HDMBr	 was	 not	 engineered	 to	 be	 used	 in	 this	 context	 but	 this	 study	clearly	 has	 translational	 potential	 and	 offers	 a	 proof	 of	 concept	 that	 can	 be	developed	 further.	 Clearly,	 further	 experiments	 need	 to	 be	 carried	 out	 with	HDMBr	and	also	with	other	modern	polycationic	or	non-charged	agents	which	can	potentially	be	modified	to	induce	less	cytotoxicity	and	therefore	more	likely	to	be	used	in	man.																					
	 207	
					
	
	
	
CHAPTER	V	
	
	
GENERAL	DISCUSSION	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 208	
In	Chapter	 II,	 I	developed	a	rodent	model	of	 trauma	haemorrhage	that	allowed	the	application	of	varying	degrees	of	traumatic	injury	and	haemorrhagic	shock	to	determine	 association	 with	 organ	 injury	 and	 release	 of	 DAMPs	 into	 the	circulation.	 Over	 the	 course	 of	 6	 h,	 consistent	 MOF	 resulted	 from	 the	combination	 of	 trauma	 and	 haemorrhagic	 shock,	 which	 closely	 mirrors	 the	clinical	scenario.	However,	the	model	 lacks	medium	and	long-term	components	such	as	the	post	injury	phase	of	critical	care	support.	We	know	that	patients	who	survive	 the	 initial	 severe	 traumatic	 insult	 can	 go	 on	 to	 develop	 MOF	 in	 25%	cases,	and	this	can	occur	over	the	following	days	and	weeks.	Clearly,	animal	data	derived	 from	 this	 type	 of	model	 needs	 to	 be	 repeated	 in	 a	 larger	 animal	with	recovery	over	a	longer	time	scale	before	clinical	trials.				In	Chapter	III,	I	developed	a	robust	PCR	methodology	for	measuring	mtDNA	and	nDNA	in	cell-free	plasma	from	the	unheparinised	model	of	T-HS	discussed	above.	This	 methodology	 may	 be	 of	 benefit	 to	 future	 researchers	 investigating	 T-HS	using	PCR,	as	heparin	is	a	major	confounder	in	many	animal	models	of	T-HS.			I	have	demonstrated	a	dose	dependent	release	of	mtDNA	from	isolated	trauma	and	combined	T-HS	with	two	likely	different	time	courses.	There	was	a	very	high	degree	of	correlation	between	circulating	mtDNA	and	the	development	of	acute	lung	injury	and	other	organ	injury	to	a	lesser	extent.	The	pattern	of	nDNA	release	into	the	circulation	was,	unsurprisingly,	moderately	correlated	to	that	of	mtDNA.	Remarkably,	 however,	 there	 was	 non-correlation	 with	 acute	 lung	 injury,	 and	high	correlations	with	plasma	IL-6	and	other	non-lung	organ	injury.		This	adds	to	the	 growing	 evidence	 base	 for	 the	 importance	 of	 circulating	 mtDNA,	 in	
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particular,	 as	 a	 driver	 of	 acute	 lung	 injury	 in	 T-HS.	 Overall,	 I	 have	 shown	 that	there	 is	 utility	 in	 using	 mtDNA	 as	 a	 biomarker	 in	 trauma	 with	 6	 h	 levels	correlating	 to	 the	 development	 of	MOF	 and	 survival.	 This	 parallels	 the	 clinical	findings	from	our	unpublished	data	of	150	trauma	patients.			In	Chapter	 IV,	 I	 successfully	 introduced	an	old	 therapeutic	agent,	HDMBr,	 for	a	novel	use	as	a	NASP	to	reduce	circulating	mtDNA	(and	nDNA),	improve	MOF	and	possibly	also	 improve	survival	 in	my	model	of	T-HS.	 	This	 is	 the	 first	 recorded	successful	 modulation	 of	 mtDNA	 in	 vivo	 with	 a	 therapeutic	 agent	 leading	 to	improved	 outcomes	 in	 T-HS.	 Furthermore,	 it	 was	 administered	 at	 a	 clinically	relevant	 time	 point,	 shortly	 after	 the	 injury	 had	 occurred.	 Unlike	 many	therapeutics	administered	experimentally,	there	is	a	wealth	of	clinical	data	about	HDMBr	 that	has	accrued	due	 to	 its	 extensive	use	as	a	protamine	alternative	 in	the	1950’s	and	1960’s.	Doses	up	to	5mg/kg	delivered	to	heparinised	patients	on	cardiopulmonary	bypass	are	 safe	 (Cooney	and	Mann,	1999).	However,	 the	 safe	dose	without	heparin	is	likely	to	be	lower	than	this.	 	The	charge	chemistry	side	effect	profile	is	likely	to	be	diminished	in	the	presence	of	heparin	(Chapter	IV).			I	 have	 shown	 that	 the	 administration	 of	 HDMBr	 at	 a	 dose	 of	 2mg/kg	 in	 T-HS	rescued	 rats	 from	 severe	 MOF.	 Interestingly,	 the	 4mg/kg	 dose	 continued	 to	exhibit	anti-inflammatory	effects	as	evidenced	by	profoundly	reduced	plasma	IL-6	 levels,	 marked	 attenuation	 of	 NF-κB	 and	 STAT3	 phosphorylation	 to	 sham	levels	 and	 the	 most	 improved	 histological	 scores	 of	 all	 three	 doses	 used.	 No	organ	protection	was	evident	biochemically,	but	 there	was	also	no	evidence	of	induced	harm	at	this	dose	in	the	T-HS	study	either.	There	is	a	possibility	that	a	
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benefit	at	this	dose	may	manifest	over	a	longer	timeframe	study.	Clearly,	further	experiments	are	warranted	to	explore	this	interesting	drug.				Finally,	 I	 have	 also	 shown	 definite	 evidence	 of	 acute	 lung	 injury	 with	 mtDNA	challenges	 into	 healthy	 animals.	 The	 inflammogenic	 potential	 of	 truly	 pure	mtDNA	has	been	disputed	by	a	minority	 in	 the	 field	 (Prikhodko	et	 al.,	 2015).	 I	have	 also	 demonstrated	 partial	 rescue	 of	 lung	 injury	 with	 HDMBr	 at	 2mg/kg	given	preemptively.	Failure	to	show	these	results	with	a	post	mtDNA	inoculation	dose	 of	 HDMBr,	 does	 not	 temper	 the	 original	 in	 vivo	 findings.	 Rather,	 this	experiment	 probably	 poorly	 recreates	 the	 clinical	 traumatic	 insult.	 Further	experiments	altering	the	duration	of	infusion	of	mtDNA	inoculation	and/or	NASP	into	 the	 animal	 may	 deliver	 these	 results.	 Of	 course,	 the	 charge	 chemistry	 of	HDMBr,	 like	 other	 polycationic	 compounds,	 allows	 for	 a	 large	 number	 of	theoretical	 interactions	with	other	molecules.	It	 is	conceivable,	that	HDMBr	has	an	 effect	 on	 another	 hitherto	 unrecognised	 DAMP	 molecule	 to	 explain	 its	protection	in	severe	T-HS.	There	is	some	evidence	to	suggest,	 for	example,	 that	there	 is	 synergistic	 inflammatory	 activity	with	 a	 combination	 of	mitochondrial	molecules,	such	as	mtDNA	and	FPs,	that	are	likely	to	be	present	in	clinical	trauma	(Sun	et	al.,	2013,	Crouser	et	al.,	2009).		The	mechanism	of	action	of	HDMBr	in	T-HS	is	not	fully	understood	and	requires	further	 investigation.	 	 Its	 utility	 as	 a	 NASP	 per	 se	 has	 been	 well	 documented	(Oney	 et	 al.,	 2009,	 Lee	 et	 al.,	 2011)	 but	 to	 what	 extent	 this	 effect	 occurs	intravascularly	 or	 intracellularly	 is	 unclear.	 I	 have	 demonstrated	 a	 clear	reduction	in	circulating	DNA	with	HDMBr.	Its	ability	to	bind	free	plasma	mtDNA	
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appears	 to	 be	 a	 large	part	 of	 its	 protective	mechanism.	This	 is	 supported	by	 a	recent	study	from	Duke	University	in	which	an	unnamed	NASP	was	immobilised	on	the	surface	of	6μm	microspheres	to	allow	the	development	of	higher	charge	density	 and	 less	 cellular	 toxicity.	 Incubation	 of	 the	 NASP-coated	microspheres	with	cells	resulted	in	subsequent	inhibition	of	uptake	of	CpG	DNA	into	cells,	and	inhibition	of	endosomal	TLR	activity	by	CpG	and	CpG-antibody	complex,	as	well	as	from	the	supernatant	of	dying	cells	(Zhang	et	al.,	2015).			Polycationic	 compounds	 such	 as	 the	 quaternary	 ammonium	 compounds	 (of	which	HDMBr	is	a	member)	have	the	potential	to	be	used	as	novel	antimicrobials	(Carmona-Ribeiro	 and	 de	 Melo	 Carrasco,	 2013).	 The	 proposed	 antimicrobial	mechanisms	generally	involve	direct	bacterial	membrane	disruption	but	nucleic	acid	 scavenging	 effects	 are	 unstudied.	 NASPs	 such	 as	 HDMBr	 and	 PAMAM-G3	have	 been	 shown	 not	 to	 inhibit	 activity	 at	 TLR	 1,	 TLR	 2	 and	 TLR	 4,	 which	recognise	 non-nucleic	 acid	 TLR	 agonists	 such	 as	 bacterial	 lipoprotein	 and	 LPS	(Lee	et	al.,	2011).	However,	there	is	likely	to	be	secondary	injury	from	the	septic	insult	 itself	 leading	to	mtDNA	release	 from	injured	cells	as	a	result	of	 the	 feed-forward	 mechanisms	 described	 in	 Chapter	 I	 (Kuck	 et	 al.,	 2015).	 Elevations	 of	plasma	mtDNA	levels	have	been	well	documented	in	clinical	sepsis	and	correlate	strongly	 with	 worse	 outcomes	 (Hsiao	 et	 al.,	 2012,	 Nakahira	 et	 al.,	 2013,	Yamanouchi	et	al.,	2013).					
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Further	exploration	of	HDMBr	and	other	members	of	this	class	of	therapeutic	is	required	 in	T-HS	 to	 build	 on	 the	 proof	 of	 concept	 as	 explored	 in	 this	 thesis.	 If	successful,	this	could	potentially	provide	a	much	needed	treatment	in	the	field	of	T-HS	research,	and	potentially	in	other	field	such	as	sepsis,	too.										
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